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 Abstract 
Kaposi's Sarcoma-associated Herpesvirus (KSHV), is a necessary cause of Kaposi's 
sarcoma (KS), the risk of which increases among people with immune suppression, such as 
that caused by infection with HIV. KS incidence varies, being highest in places with a high 
prevalence of KSHV. Controlling KSHV transmission is key in reducing KS incidence. 
Documented KSHV prevalence is reported to be higher in rural Uganda than has been found 
elsewhere. This PhD research focused on investigating environmental and immunological 
factors associated with KSHV antibody responses and viral detection/shedding in blood and 
in saliva as well as KSHV specific cell-mediated immune responses in Uganda. 
 
ELISA and Luminex were used for antibody measurements, real-time PCR for viral detection 
and quantification and an ELISPOT assay for cell-mediated IFN- response measurement. 
Infections such as malaria and helminths were the main environmental risk factors analysed.  
 
The factors associated with higher KSHV antibody responses included early age of infection, 
malaria parasitaemia, low haemoglobin levels and Schistosoma mansoni infection. Malaria 
infection was also associated with higher levels of KSHV DNA in blood while male sex was 
associated with increased viral shedding in saliva. Children had the highest proportion of 
individuals with detectable KSHV DNA in blood and in saliva. In relation to IFN- production, 
individuals responded to a wide variety of KSHV peptides without any immune dominance.  
 
In conclusion, KSHV transmission in endemic areas occurs mainly in childhood; this may 
play a role in the failure to control the virus, leading to increased viral shedding and 
increased viral transmission. Parasite infections such as malaria and worms may play a 
significant role in rendering children susceptible to KSHV infection as well as in enhancing 
reactivation of the virus, increasing lytic replication and, thereby increasing transmission and 
3
 pathogenesis.The cell-mediated immune response to KSHV is complex due to the lack of 
immunodominance. 
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 Chapter One: Background 
Human Herpesviruses  
Organisms from the family herpesviridae are among the oldest animal viruses. They infect a 
wide variety of vertebrates including mammals, reptiles, birds and fish as well as a few 
invertebrates. Inclusion in this family was originally dependant on the virion morphology 
(spherical with four major components: the core, capsid, tegument and envelope as well as 
linear double-stranded DNA). These viruses are known for the establishment of both lifelong 
latency and lytic replication by modulating the host immune response [1].  
 
The herpesviridae family is divided into three subfamilies according to the international 
committee on taxonomy of viruses (ICTV). These include herpesvirinae, herpesvirinae 
and herpesvirinae [1]. This subfamily classification was originally based on biological 
criteria such as cell tropism during latency and clinical manifestation of the virus [2]; 
herpesvirinae establish latency in neurons, herpesvirinae in monocyte lineage cells and 
herpesvirinae in lymphocytes [1]. These subfamilies have been divided into genera and 
species based on genomic characteristics including size and structure. Currently, there are 
nine herpesvirus species that infect humans. HHV-1 (herpes simplex virus -HSV-1), HHV-2 
(herpes simplex virus-HSV-2) and HHV-3 (varicella-zoster virus-VZV), the herpesvirinae; 
HHV-5 (human cytomegalovirus-HCMV), HHV-6A, HHV-6B and HHV-7, the herpesvirinae; 
and HHV-4 (Epstein-Barr virus -EBV) and HHV-8 (Kaposi's sarcoma-associated 
herpesvirus-KSHV), the herpesvirinae. EBV belongs to the Lymphocryptovirus genus and 
KSHV belongs to the Rhadinovirus genus.  
 
Within the family, only herpesvirinae (EBV and KSHV) are linked to cancer aetiology in 
humans [3]. EBV was the first infectious agent to be linked directly to cancer (Burkitt’s 
lymphoma). Initial EBV infection is generally asymptomatic, although it can manifest 
15
 infectious mononucleosis if infection is delayed into teenage years. Subsequent lifelong 
infection is usually asymptomatic, but it can be associated with a number of clinical 
manifestations both in immune competent and immunocompromised individuals. These 
include non-Hodgkin’s lymphomas such as Burkitt's lymphoma and diffuse large B-cell 
lymphomas, Hodgkin's disease, T cell lymphomas, gastric lymphomas and other 
lymphoproliferative disorders, as well as nasopharyngeal carcinoma and gastric 
adenocarcinoma [3, 4]. Identified more recently [5], KSHV has been studied less extensively 
than EBV. KSHV infection is also generally subclinical, however, can cause neoplasms and 
lymphoproliferative diseases including Kaposi’s sarcoma (KS), primary effusion lymphoma 
(PEL), multicentric Castleman's disease (MCD), and KSHV associated inflammatory 
cytokine syndrome (KICS) [3, 5-11].  
 
KSHV associated malignancies  
All KSHV associated diseases (KS, PEL, MCD and KICS) occur more frequently in HIV 
infected individuals, although presentation in HIV uninfected people such as organ 
transplant patients has been documented [13]. Their distribution, therefore, reflects broadly 
the distribution of both KSHV and HIV infections.  
 
• Kaposi’s sarcoma (KS) 
Of all the malignancies caused by KSHV, KS is the most common. The International Agency 
for Research on Cancer (IARC) reported 41,799 new KS cases in 2018 from 185 countries 
[12]. It is among the predominant AIDS-associated cancers and it has a poor prognosis in 
Africa [13].  
 
Prior to antiretroviral therapy (ART), greater than 30% of AIDS patients developed KS in the 
USA, primarily men-who-have-sex-with-men (MSM) [11]. ART has drastically reduced the 
incidence of KS in HIV infected people; in the USA the incidence reduced by 70% with the 
introduction of ART in the 1990s [13]. However, although ART has greatly reduced KS 
16
 incidence worldwide, there are still considerable numbers of KS cases among individuals on 
ART and KS remains a significant cause of mortality [7, 9, 10]. Chronic antigen stimulation, 
inflammation and cytokine dysregulation observed in HIV infected individuals on long-term 
ART may explain the development of KS and other cancers while on ART [13, 14].  
 
The number of individuals living with HIV is increasing worldwide due to the wide use of 
ART. Despite consequent reductions in KS incidence, as people living with chronic HIV age, 
this may lead to increases in the incidence of KS in the future, [13] although evidence for this 
is currently not available. Additionally, in resource-limited settings such as in sub-Saharan 
Africa (sSA), a substantial number of HIV infected people are diagnosed late or do not 
receive ART for various reasons. Furthermore, the available KS chemotherapy is toxic and 
has less favourable efficacy [13]. Thus, mortality from KS remains a major public health 
problem in sSA [15].   
 
KS has been categorised in the literature into four forms based on the clinical manifestation 
and epidemiology: classical, endemic/African, iatrogenic/organ transplant-associated and 
AIDS-associated/epidemic KS. Classic KS occurs in HIV uninfected people, mainly in older 
men from the Mediterranean region and tumours tend to be localised to the lower 
extremities. Endemic KS occurs in HIV uninfected Africans (primarily men, although some 
few cases have been reported among women). Iatrogenic KS occurs in individuals on 
immunosuppressive drugs due to organ transplantation while AIDS-KS occurs in those with 
HIV infection. AIDS-KS is the most common and most aggressive of all KS forms. KSHV has 
been isolated from all four clinical subtypes of KS and all four forms have similar 
histopathologic presentation [13]. 
 
The clinical course of KS is varied. Spontaneous improvement or worsening has been 
observed in some patients after correcting the underlying immunosuppression. For instance, 
immune reconstitution inflammatory syndrome associated with tumour development or 
17
 worsening after ART initiation has been documented [13] and, transplant patients can 
undergo spontaneous regression following changes to immune suppression regimen. 
Likewise, some patients present with indolent patterns while others have aggressive forms 
[16]. Generally, KS manifests as multifocal skin lesions, nodules or macules. These lesions 
are mainly on the lower extremities; possibly due, at least in part to relative hypoxia caused 
by lower skin perfusion pressure [17]. Oedema, ulceration, bleeding, pain and secondary 
infections may be associated with KS lesions. In classic KS these lesions usually are limited 
to the skin and can be indolent; but in more aggressive KS forms there is involvement of a 
wide range of organs and tissues including the oral mucosa and gastrointestinal tract, lungs, 
bones, and lymph nodes. Pulmonary KS is the leading cause of mortality due to KS [16].  
 
The pathogenetic mechanisms leading to KS are not fully understood. Potential mechanisms 
include KSHV interfering with both the innate and adaptive immunity to induce proliferation, 
halt apoptosis, cause angiogenesis, and upregulate certain cytokine production leading to 
oncogenesis in infected endothelial cells. KSHV- transformed endothelial cells have an 
altered morphology and are termed spindle cells. Although the proportion of spindle cells 
expressing lytic genes is only 1-3% in KS, both latent and lytic KSHV proteins seem to play a 
role in KS and other KSHV malignancies. For example, lytic ORF74 encodes a viral G 
protein-coupled receptor (vGPCR) that is vital in causing angiogenesis in KS [13]. Most 
KSHV infected cells in KS lesions exhibit latent infection and latency-associated nuclear 
antigen (LANA) from ORF73 is expressed in all KSHV infected spindle cells. Therefore, 
KSHV LANA-1 staining of spindle cells of biopsies is used for KS diagnosis [13, 16, 17]. 
 
• Primary effusion lymphoma (PEL) 
Like KS, PEL mostly occurs in HIV infected people but much less frequently than KS. It is 
rare, although in Africa it is probably underreported due to diagnostic challenges, including 
difficulties in obtaining specialised hemopathology support. It is an aggressive mature 
monoclonal B cell lymphoma with very poor prognostic outcomes. PEL occurs as body cavity 
18
 effusions but non-cavity effusions have also been observed on rare occasions. It produces 
pleural, peritoneal, and pericardial lymphomatous effusions with pleural effusions being 
predominant. Unlike KS and MCD, PEL tumour cells may contain both KSHV and EBV 
viruses. All PEL cells contain KSHV while only 80% of them also contain EBV. PEL 
manifests as an inflammatory disorder with elevated serum inflammatory cytokines, ferritin 
and IgE antibodies. Long-term remission requires both ART and chemotherapy regimens. 
However, this combination causes long-term remission in only about 40% of patients [13, 16, 
18]. 
 
• KSHV-associated multicentric Castleman's disease (MCD) 
KSHV MCD is a rare B cell lymphoproliferative disease occurring in HIV infected people. 
Unlike other KSHV malignancies, MCD incidence has not decreased with the increased use 
of ART. It is also likely underreported in Africa due to underdiagnosis. It is characterised by 
inflammatory symptoms including fever, night sweats, cachexia and weight loss. In addition, 
patients have lymphadenopathy, splenomegaly and oedema as well as respiratory, 
gastrointestinal, dermatological and neurological symptoms. LANA stained plasmablasts of 
the lymph nodes normally confirm the diagnosis of MCD. It is usually fatal within two years 
following diagnosis if not treated. Furthermore, long-term remission with therapy has not 
been documented. KSHV viral load tends to increase with increased disease manifestation 
and decrease with remission [13, 16, 18].  
 
• KSHV inflammatory cytokine syndrome (KICS) 
This is the newest observed syndrome associated with KSHV. It occurs in HIV infected 
people, normally in those with KSHV malignancies (KS or PEL). It has not been studied 
extensively, and currently, its treatment is limited to specialised centres investigating 
experimental regimens. It is characterised by an MCD-like severe inflammatory syndrome 
without lymph node involvement typical of KSHV MCD. Usually, patients with underlying KS 
or PEL are at a very high risk of mortality if they develop KICS [13, 16, 18]. Understanding 
19
 the biology of KSHV is central to developing interventions for preventing and treating this 
and other KSHV-associated diseases.   
 
KSHV genome and life cycle  
The herpesviruses virion, of which KSHV is a member, have linear double-stranded DNA 
genomes of about 172Kb [19]. The KSHV genome is made of a long unique coding region of 
about 140Kb flanked by terminal repeat sequences [20], which features over 90 documented 
open reading frame (ORF)s [21]. The nomenclature of the KSHV ORFs was based on the 
prototype herpesvirus saimiri (HVS), a non-human primate Rhadinovirus closely related to 
KSHV and the map orientation of the KSHV genome is similar to that of herpesvirus saimiri 
(HVS) [22]. The KSHV genome possesses both conserved ORFs within the herpesviruses 
subfamily and unique KSHV genes. The conserved ORFs were originally named ORF1 to 
ORF75. Of these, 66 are homologs of HVS ORFs [22]. The unique ORFs were originally 
named K1 to 15. More recently additional unique ORFs have been identified and added 
including K4.1, K4.2, K8.1, K10.1, K10.5, K10.7, K11.1, and K14.1. Also, K13 and K8 were 
observed to have homologs in other herpesviruses [21]. The homolog families of genes 
encode mostly viral structural and metabolic proteins as well as DNA replication proteins 
[22]. Unique KSHV genes as well as conserved ORFs encode homologs to human cellular 
proteins [23]. These homologs are responsible for inhibition of apoptosis, cell cycle 
shutdown and evasion of host immunity to support tumorigenesis, pathogenesis and survival 
of the virus [20, 22-24]. KSHV ORFs encoding these cellular homologs include K2 (viral IL6), 
K9 and K10.5 (viral interferon regulatory factors), ORF13 (virus-encoded family of FLICE 
inhibitory protein- vFLIP), ORF16 (Bcl-2 homolog), ORF4 (proteins similar to complement 
binding proteins CD21), ORF14 (NCAM-like adhesion protein), ORF72 (cyclin D homolog), 
ORF74 (IL8 like G protein-coupled receptor- vGPCR), K6 (viral MIP-1), K4 (viral MIP-2), 
K4.1 (viral MIP-3) and ORF72 (D type cyclin homolog) [20, 22, 23].  
 
20
 Like other herpesviruses, KSHV undergoes two stages of its life cycle: the lytic and the latent 
stage [25]. KSHV genes are expressed sequentially within the two transcriptional programs 
(the latent and lytic programs). During primary infection, there is active replication of the 
virus, leading to infection of B cells and epithelial cells, as well as, potentially, a number of 
cells types including, monocytes, macrophages, dendritic cells and endothelial cells.  
Various receptors, such as DC-SIGN, integrin, certain receptor tyrosine kinase of the Eph 
family and heparin sulfate are used for viral attachment and entry into different host cells 
[26]. This is followed by lifelong latency, when the virus resides in specific immune cells, 
expressing only a few proteins. Among infected cells, a small proportion of CD19+ peripheral 
B cells have been shown to serve as a long-term reservoir of KSHV [27]. The latent infection 
is tightly regulated by the host immune response and viral proteins [28].  
 
• Latent Infection 
During latency, the virus exists in infected cells as multiple copies of an extrachromosomal 
circular episome with restricted latent gene expression and without production of progeny 
[28, 29]. The lytic promoter sequences are silent during latency [21]. The active latent 
genome region encodes for the following: ORF73/LANA-1, ORF72/viral cyclin (v-cyc), 
ORF71/v-FLIP and ORFK12/Kaposin and 12 miRNAs. Low levels of K1, vIL6 and K15 
transcripts are also present, while vIRF3 is detected in infected B cells, [24, 29-32].  During 
this phase, KSHV relies on the latently associated nuclear protein (LANA)-1 encoded by 
ORF73 for maintenance of latency as well as genome persistence. Therefore, ORF73 is the 
most frequently expressed latent protein. It is expressed in tumour cells of KSHV associated 
malignancies, making it a suitable diagnostic marker [23]. ORF73/LANA is responsible for 
both latent viral episome DNA replication and segregation to daughter cells during mitosis. 
To achieve this, LANA tethers the KSHV episome onto the host chromatin via histone H1 
during mitosis [29, 33]. LANA also hinders lytic replication by negatively regulating 
transcription of lytic genes to establish latency [31]. Other latent transcripts play significant 
roles as well; these include v-cyc, which promotes cellular proliferation, vFLIP which 
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 enhances cell proliferation and inhibits apoptosis, Kaposin B, which increases cytokine 
expression promoting tumour microenvironment, vIL-6 which inhibits apoptosis to allow cell 
survival, vIRFs which interfere with the host interferon signalling pathway leading to immune 
escape of KSHV, and viral miRNAs, which regulate viral lytic genes and cellular survival 
pathways, [23, 24, 29, 31, 32, 34]. The latency program also plays a significant role in 
tumorigenesis; for instance, over 95% of spindle cells in KS are latently infected, with only 1-
3% of the cells going through lytic replication [31, 35, 36]. Nevertheless, the role of lytic 
replication in tumorigenesis and virus propagation is essential [28]. 
 
• Lytic activation 
During the lytic cycle, the virus enters into another well-ordered program of viral gene 
expression, following a sequence of events including lytic reactivation, lytic DNA replication 
and virion production. Upon reactivation from latency, a full repertoire of lytic viral genes are 
activated in a temporally regulated manner, leading to transcriptional activation of three 
classes of lytic genes: Immediate early (IE), early (E), and late (L) genes [37-40]. The 
Immediate early genes govern the transition of the KSHV genome from latency to the lytic 
phase and are ORF50/RTA, ORF45, K8α, K8.2, K4.2, K4.1, K4, ORF48, ORF29b, K5 and 
ORF70. The major single IE protein, RTA, acts as the essential latent/lytic switch that 
redirects KSHV to enter the lytic replication program required for viral spread and KS 
tumorigenesis [40]. Additionally, IE genes encode for viral proteins directly involved in gene 
transcription, cellular modification and viral replication [28]. Early genes including K8, K5, K2, 
K12, ORF6, ORF57, ORF74, K9, ORF59, K3, ORF37, K1, K8.1A, ORF21, vIL6, PAN RNA, 
vIRF-1, K1, and K15 are required for DNA replication and gene expression [28], as well as 
other individual functions, mentioned previously. The late lytic genes encode for mainly 
structural proteins (glycoprotein-B and K8.1) and capsid protein required for assembly and 
maturation of the virion [28].  
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 KSHV genotypes  
Using variable genes unique to KSHV such as K1 and K15, KSHV has been further 
classified into genotypes. Several research groups [41-44] have identified KSHV genotypes 
and their distribution using samples from described patients with KSHV associated 
malignancies. Using nucleotide sequencing of the K1 variable regions one and two, five 
major genotypes and 15 clades have been identified [42]. The K1 gene has up to 30% 
amino acid variability. Generally, the distribution of these genotypes is as follows: genotype 
A is predominant in western Europe and North America, B in Africa, C in the Middle East and 
Mediterranean Europe, D in Pacific Islands, South Asia, Australia, Taiwan and E in South 
America among indigenous people [41-44]. Variants in the K15 gene are classified as P, M 
and N types [42]. The different genotypes have not been correlated with a specific disease 
or severity. KSHV co-evolved with the human species, as did other herpesviruses that are 
known to co-evolve with their host species. It seems likely to have migrated with the human 
population to different parts of the world from Africa [43, 44]. There has been relatively less 
research on KSHV genotypes in Africa, where the diseases and infection are endemic. 
 
KSHV distribution 
Unlike the other human herpesviruses, which are ubiquitous, KSHV has a distinct 
geographical distribution, which varies within and between regions. The prevalence of KSHV 
is highest in sub-Saharan Africa (generally >30%), intermediate in the Mediterranean region 
(>10%), and low in the USA, northern Europe and Asia (<10%) [45-48]. In the USA and 
northern Europe, KSHV prevalence is elevated in men who have sex with men (MSM) and 
recent immigrants from Africa, compared to the general population. A high prevalence has 
also been reported among indigenous Amerindians in South America [49-51], although the 
reported incidence of KS is low. In sub-Saharan Africa, a prevalence ranging from 20% to 
80% has been reported [15, 52, 53]. In Uganda specifically, other studies have reported a 
KSHV prevalence of 50% to 60% [54-58]. Data from our own studies have reported a KSHV 
prevalence of 69% among women from an urban area, and an increasing prevalence with 
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 age among children, reaching about 15% by age five years [59-61]. Newer data from a rural 
cohort in Uganda shows that participants have amongst the highest prevalence of KSHV 
ever reported (~90%), with the infection occurring mainly in childhood [62]. The reason for 
the distinct global geographical distribution of KSHV is currently unknown. It is, therefore, 
essential to understand risk factors for high KSHV transmission in high prevalence settings 
such as rural Uganda; modifiable risk factors may offer opportunities for reduction of 
transmission and consequent disease. This PhD research aimed at addressing this question.   
 
KSHV transmission 
The primary route of transmission of KSHV is via saliva, especially in KSHV endemic regions 
[27, 63]. In sub-Saharan Africa, infection with KSHV can occur early in life [64], with the peak 
age of acquisition in some studies being between 6-12 years of age [65, 66]. In low 
prevalence areas, adult acquisition is more common, particularly sexual transmission among 
MSM, which might also be due to salivary exchange as well; KSHV can also be acquired via 
blood transfusion [27] however it is unlikely that these transmission modalities have 
significant relevance for the very high transmission rates of KSHV observed in sub-Saharan 
Africa [15, 27]. It is important to note that factors affecting KSHV transmission might differ 
from the ones affecting KSHV pathogenesis. In this PhD thesis, viral shedding in saliva has 
been used to investigate KSHV transmission while viral detection in blood has been used as 
a measure of viral reactivation and subsequent risk of disease. 
 
KSHV risk factors 
KSHV is necessary but not sufficient to cause KS and other associated malignancies. Both 
viral latency and lytic activation appear to play a role in the development of KS [67]. Lytic 
replication is important for viral propagation as well as transmission and critical for KSHV 
induced tumorigenesis [28]. Biomarkers of KSHV reactivation are increasing KSHV antibody 
titres [68, 69], and increasing KSHV viral load in blood. There are a number of factors that 
have been associated with KS development and/or reactivation of KSHV from latency, 
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 including HIV infection and other forms of immunosuppression, as well as oxidative stress, 
inflammatory cytokines, hypoxia, viral co-infections, parasite infections, exposure to 
traditional phytotherapeutics (“oncoweeds”), volcanic soils and other soil types [28].  
 
• Immunosuppression and viral infections 
KSHV reactivation and aggressive forms of KS are seen in individuals with 
immunosuppression. HIV infection acts indirectly through suppression of KSHV-specific T 
cell responses [70] and induction of inflammatory cytokines [71]. Antiretroviral therapy is 
associated with regression of KS and decreasing KSHV detection, and this is accompanied 
by the restoration of numbers and functions of KSHV-specific CD4+ and CD8+ T cells  [40, 
72, 73]. KS development in KSHV infected individuals after solid organ transplant is linked to 
calcineurin inhibitors. This class of drugs prevents organ rejection by immunosuppression 
largely through T cell inhibition. Loss of the KSHV-specific T cell repertoire has been 
demonstrated with calcineurin inhibitors, with recovery and remission of KS after treatment is 
discontinued [74]. The majority of post-transplant KS patients are KSHV seropositive prior to 
transplantation, suggesting that reactivation of the latent virus is responsible for the disease 
[75, 76].   
 
Other viral infections that have been associated with KSHV lytic replication include HSV-1 
[77], HSV-2 [78], HCMV [79], HHV6 [80], HHV7 [81] and Human papillomavirus (HPV) [82]. 
These viruses are relatively ubiquitous in all human populations and, they may play a role in 
reactivation of KSHV where it exists.  
 
• Hypoxia, oxidative stress and reactive oxygen species  
Low tissue oxygen concentration or hypoxia induces accumulation of hypoxia-inducible 
factor (HIF-1α/2α) and has been linked to the initiation and progression of KSHV associated 
cancers. Hypoxia has been shown to stimulate reactivation of KSHV in vitro [83-86] and, has  
also been shown to affect the pathogenesis of other oncogenic viral infections including 
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 Epstein-Barr virus (EBV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human 
papillomavirus (HPV) and Human T cell lymphotropic virus (HTLV)-1 [28].  
  
Reactive oxygen species such as hydrogen peroxide have been shown to mediate KSHV 
reactivation from latency [28]. Hydrogen peroxide induces KSHV lytic replication in KS 
tumours by activating the ERK1/2, JNK and P38 mitogen-activated protein kinase (P38 
MAPK) pathways [87]. Hypoxia and inflammatory cytokines mediate spontaneous KSHV 
reactivation and lytic replication [28].  
 
• “Oncoweeds” and volcanic soils 
KSHV prevalence varies geographically. In most parts of Africa, the incidence of KS mirrors 
the prevalence of KSHV. In The Gambia, a high prevalence of KSHV has been reported but 
a relatively low incidence of KS [46]. Partly based on these observations, environmental 
factors such as ‘oncoweeds’ have been hypothesised to reactivate KSHV. Supporting this 
hypothesis, a number of plant species have been shown to reactivate KSHV in vitro. The 
majority of these plants are from KSHV endemic areas and may be utilized in herbal 
medicine or other traditional practices [88]. KS incidences have been associated with 
volcanic soils. The fine volcanic soils have been shown to damage lower limb lymphatics 
causing Podoconiosis, the damage on lower limb lymphatics may explain the association 
between KS incidence and volcanic soils [89, 90] although data on this are not conclusive.  
 
• Parasites  
Parasite infections including malaria and helminth infections have been hypothesized as 
potential co-factors for KSHV transmission and infection. Malaria is one of the leading cause 
of death due to a single infectious agent worldwide. In 2018 WHO reported 219 million 
malaria cases in 87 countries with 435,000 deaths. The majority (92% of cases and 93% of 
death) of the malaria burden is in Africa. Efforts to eliminate malaria in sub-Saharan Africa 
have not been successful, however, reduction in incidence has been documented. Malaria is 
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 caused by protozoan parasites of the genus Plasmodium which is transmitted by the female 
Anopheles mosquito vector. There are five Plasmodium species that cause malaria in 
humans, including P. falciparum, P. ovale, P. vivax, P. malariae and P knowlesi. Of these, P. 
falciparum is the most common in Africa (responsible for 99.7% of malaria cases) and it is 
associated with severe forms of malaria, causing severe anaemia and cerebral malaria in 
children below the age of five.  
 
Natural immunity to malaria involves mainly antibody responses to the blood stage parasites 
[91, 92]. Cellular and innate responses have also been observed [92, 93]. Protective immune 
response to malaria is multifaceted, partly due to the complex life cycle of the parasites, 
involving numerous immunogens which are genetically diverse [94]. Additionally, immune 
dysfunctions, particularly immunosuppression caused by malaria infection, have been 
observed. Immunosuppression associated with malaria infection has been attributed to 
dendritic cell (DC) dysfunction, upregulation of regulatory T cells [95-97], and T and B cell 
exhaustion [98]. During acute malaria infection, circulating mature DCs significantly reduce 
in number, leading to the accumulation of immature DCs as well as impairment of DC 
function [95, 97]. The ratio of plasmacytoid to myeloid DCs is also affected by a great 
reduction in plasmacytoid DCs [95]. The central role of DCs in antigen presentation can lead 
to impairment of adaptive immune response if they are dysfunctional. Plasmacytoid DCs 
play a major role in innate antiviral immunity by producing type 1 interferons. Therefore, if 
reduced in malaria infection, it could have effects on viral-specific immunity. Expansion of 
regulatory T cells and increased levels of IL-10 have also been documented in malaria 
infection [96]. This immune regulation affects T helper responses causing some form of 
immunosuppression [95, 96]. Additionally, repeated malaria infections have been shown to 
suppress T cell immunity [98]. This immunosuppression caused by malaria infection has 
been shown to affect other herpesvirus coinfections including VZV, HSV-1 and EBV by 
causing reactivation of these viruses [99-101]. Furthermore, It is notable that malaria is 
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 known to affect immune control of EBV, increasing the risk of Burkitt’s lymphoma among 
children living in malaria endemic regions [102, 103].  
 
The survival of parasites is dependent upon their ability to interfere with host immune 
function [104], in turn compromising the host-virus equilibrium in KSHV infection [105]. 
Epidemiological studies from Italy report substantial declines in KSHV seropositivity and KS 
incidence in association with the eradication of mosquitoes and the associated decline of 
malaria [106]. Adaptive immune response dysfunction associated with malaria infection may 
cause KSHV reactivation, increasing viral replication and shedding in saliva, while innate 
immune dysfunctions in malaria may render KSHV uninfected children susceptible to 
infection during acute malaria episodes. We have previously reported an association 
between malaria exposure, malaria parasitaemia and KSHV seropositivity in women and 
children in Uganda [60, 61, 107]. Further investigations of malaria KSHV coinfections are 
reported in this thesis.  
 
We also hypothesise that helminth infections may affect co-infections such as KSHV, due to 
immunomodulation. Soil-transmitted helminths such as hookworm, as well as Schistosoma, 
are common in low-income countries, often affecting the poorest people [108]. These 
parasites have co-evolved with Homo sapiens and have therefore devised means of 
coexistence with the host’s immune system, by provoking immunosuppression [109]. A (Th) 
2 oriented immune response is necessary for helminths clearance. It has been observed that 
developing a (Th) 2 response as opposed to a (Th)1 response, important in virus control, 
interferes with anti-viral immunity. Furthermore, immunoregulation associated with helminth 
infestations also reduces the (Th)1 response important in controlling viral infections [110, 
111]. This association has been demonstrated in mice, where Schistosoma lead to the 
reactivation of herpesviruses in vivo and in vitro [111].  
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 Immune response to KSHV  
KSHV evades host immune responses so as to allow its long-term survival. Latency is one of 
the mechanisms of avoiding viral clearance by immune cells and is achieved by suppression 
of expression of most viral proteins, essentially hiding the virus from recognition. Other 
mechanisms involve the expression of various viral genes which are host cellular homologs 
and interfere with host immune responses. These proteins cause suppression of MHC-1 and 
MHC-11 molecules, impairment of dendritic cells function, down-regulation of co-stimulatory 
molecules, and induction of inhibitory cytokines [105, 112] all of which favour viral survival 
and oncogenesis.  
 
The protective immune response to KSHV is not well documented. Yet it is vital to 
understand these responses to allow the development of interventions for controlling viral 
transmission and disease risk. An effective immune response is required to maintain latency, 
control viral shedding (thereby preventing transmission), and to prevent disease 
pathogenesis. HIV infection greatly increases the risk of developing KS and other KSHV 
associated malignancies.  This is due to the loss of CD4+ T cells in infected individuals, 
suggesting a pivotal role for T cell immunity in the control of KSHV infection. In murine 
models, Murine herpesvirus (MHV)-68, a herpesvirus similar to KSHV, has been shown to 
be controlled by both CD4+ and CD8+ T cell responses [113]. Both CD4+ and CD8+ T cells 
promote the clearance of productive replication during acute MHV68 infection [114, 115]. 
CD8 T cell responses (in mice) persist for life and prevent reactivation of the virus through 
the production of perforins and IFN-.   
 
In humans, CD8 T cell responses have been better studied compared to CD4+ cell 
responses [116]. Although results have been contradictory, the majority of studies suggest 
protective effects of cellular immune responses against KSHV for KSHV-associated 
malignancies [116]. KS tumour regression was correlated with improvement in KSHV cellular 
immune responses [73, 117]. Because KSHV encodes over 86 proteins, the main challenge 
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 in investigating cellular responses is the selection of the antigens to use. However, the 
identification of immunodominant epitopes for both CD4+ and CD8+ KSHV responses has 
not been possible.  
 
The protective effect of humoral responses to KSHV still requires investigation. However, 
high levels of antibody to KSHV have been shown to predict KS development [118], and high 
antibody titres to KSHV are associated with viral reactivation and viral shedding in saliva [68, 
69]. In addition, neutralizing antibodies, but not total antibodies were observed to be lower in 
KS patients compared to controls [119]. This suggests that infection with KSHV may lead to 
the production of high levels of antibodies which play little role in protection from disease 
pathogenesis. This PhD research is aimed at investigating determinants for KSHV 
seropositivity, viral DNA detection in blood and in saliva as well as cellular immune 
responses.   
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 Chapter Two: General Methods 
Study designs, settings and populations 
The work presented in this thesis was nested within three long-standing prospective studies 
at the Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and 
London School of Hygiene & Tropical Medicine (LSHTM) Uganda Research Unit. These are 
the General Population Cohort (GPC), the Lake Victoria Island Intervention Study on Worms 
and Allergy-related diseases (LaVIISWA) and the  Entebbe Mother and Baby Study 
(EMaBS). These three studies provided three different populations with varying prevalence 
of possible risk factors. The GPC is a very rural population, the Lake Victoria island 
communities where LaVIISWA was carried out, are unique due to their high HIV prevalence, 
high S. mansoni infection and very poor health services, while EMaBS, from Entebbe, is a 
relatively urban population with a few people from peri-urban neighbourhoods. Below are the 
brief descriptions of each in turn.  
 
• The General Population Cohort (GPC) 
GPC was established in 1989 by the Medical Research Council in collaboration with the 
Uganda Virus Research Institute with funds from the UK Medical Research Council and UK 
Department for International Development [1]. The GPC is located in southwestern Uganda, 
in Kyamulibwa sub-county of Kalungu district, 40km from the shores of Lake Victoria [2, 3] 
and 16km from the trans-African highway (Figure 1) [4, 5]. The GPC has a population of 
22,000 people scattered across the countryside in 25 adjacent villages [5]. Administrative 
boundaries, as opposed to socio-economic centres, define the village sizes [6]; the smallest 
village has 300 people while the largest has 1500. It is a rural community with semi-
permanent structures built from locally available materials. The area has no tarmac road, 
making accessibility during the rainy season difficult [7]. The community is relatively stable, 
homogeneous and young, with 90% of the people less than 50 years of age. Only about 
13% of the residents attain education beyond primary level. The main occupation is 
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 subsistence farming along with fish trading. Matooke (plantain bananas) and groundnuts are 
the staple food [7].  
43
  
Figure 1: Map showing the location of the General Population Cohort (GPC), from Asiki et al., 2013 
[5].  
44
 The GPC population has various ethnic groups. The major ethnic group are Baganda (75%), 
followed by immigrants from Rwanda (16%) and Burundi (3%), lastly, other minor tribes from 
Uganda and Tanzania make up 6% of the population. The majority of these are Christians; 
28% are Muslims [7].  
 
The GPC was established to examine the trends and determinants of the HIV epidemic in 
rural southwestern Uganda. Originally, annual house-to-house census round surveys were 
carried out to select participants for the medical survey. Other data collected through the 
census round survey included participants’ location, socio-demographic and household data. 
During medical surveys, blood, biophysical and lifestyle data were collected to determine 
disease outcomes and risk factors for selected participants. The process would start with 
community sensitization activities including local council briefings and village meetings. This 
would be followed by participant consenting, interviewing using standard questionnaires and 
phlebotomy at participants’ homes. All people who had lived in the village for at least three 
months or who had the intention of staying were eligible for inclusion. In 2011 at least 84% 
of the residents had ever participated in the surveys [7-9]. The house to house survey 
system was changed to a biennial survey conducted at a central hub in each village starting 
in 2012. The main reasons for the change were to improve on cost-effectiveness, efficient 
data collection, improved population coverage and increased uptake of HIV test results [4]. 
To determine KSHV prevalence in this area, we have tested plasma samples for KSHV IgG 
antibodies, collected at various survey rounds, the latest tested being the 24th (2014/2015) 
and 25th (2016) surveys. Methods and results from round 24 and 25 analysis were published 
[10] and are shown in chapter four of this thesis.  
 
In addition to testing plasma samples collected in the 24th and 25th annual surveys [10], we 
carried out a cross-sectional study to investigate immune correlates and determinates of 
KSHV viral detection in the GPC. Between July 2017 and November 2017, we recruited 975 
KSHV seropositive, HIV seronegative, people aged 2 to 89 years. Participants were 
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 randomly selected from a list of KSHV seropositive, HIV negative people aged 2-89 years, 
ensuring that one participant was selected from each household and representative 
numbers were enrolled from each age group. After participants consented, they were 
counselled and tested for HIV as an eligibility criterion. Only HIV negative people were 
included in the study. Blood (20ml), saliva and stool samples were collected from enrolled 
participants aged 10 years and above. Children below 10 years gave 10ml of blood as well 
as stool and saliva. Stool was tested for helminths using the Kato Katz microscopy methods, 
EDTA blood was used for malaria diagnosis using rapid diagnostic tests (RDT) (ONE STEP 
Malaria HRP-II (P.f) and pLDH (Pan) Antigen Rapid Test) and full blood count using a 
Coulter haematology analyser (Ac.t 5 Diff CP, Beckman Coulter). Peripheral blood 
mononuclear cells (PBMCs) were isolated from an ACD blood tube and stored for ELISpot 
and flow cytometry experiments. Plasma from the ACD tubes was used for ELISA and 
Luminex assays. PBMC and saliva pellets were also used for KSHV viral load quantification 
using PCR. After sample collection, questionnaires (mainly for demographic information) 
were filled and transport refund issued to all invited study participants. More details and 
results from this work are shown in chapters six and seven of this thesis.  
 
• The Lake Victoria Island Intervention Study on Worms and Allergy-related 
diseases (LaVIISWA) 
 LaVIISWA was a two-arm open cluster randomised trial (ISRCTN47196031) of intensive 
versus standard antihelminthic treatment. The trial was carried out in Lake Victoria island 
fishing villages in Koome sub-county, Mukono district, Uganda (Figure 2), between 
September 2012 to August 2016 [11]. Koome islands consists of 27 villages with a 
population of approximately 16,000 people and all the villages participated in the trial. These 
villages are 2-3 hours from Entebbe using a powered canoe. They are well defined and 
geographically separated with a single administrative committee per village; the 
administrative committee is generally located near the lake shores [12]. The trial aimed to 
investigate the effect of helminth treatment on allergy-related outcomes in a Schistosoma 
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 mansoni heavily infected area. Standard treatment comprised of a single dose of 
albendazole (400mg) given twice yearly and a single dose of praziquantel (40mg/Kg) given 
annually, while the intensive treatment was a triple dose of albendazole (400mg) given three 
times annually and a single dose of praziquantel (40mg/Kg), given four times yearly. Twenty-
six villages were randomised to receive either intensive or standard helminth treatment at a 
ratio of 1:1. The remaining village was used for the pilot study. The unit of randomisation 
was the villages as opposed to individuals or households. This was mainly to prevent dilution 
of the treatment effects by neighbours who fail to take the treatment. It was also useful to 
attain community level reduction in transmission. In each village, all households were eligible 
for inclusion in the study, but due to a large number of households, a simple random number 
of 45 households per village was selected to be included in the study. All members of the 
selected households were eligible for inclusion. Two main surveys were carried out, one at 
the beginning (baseline) before the treatment intervention and the second after three years 
of the trial intervention. During these surveys, trial drugs were home delivered.  
Questionnaires were administered to record household features and socio-demographic 
characteristics. A general history and examination were performed, HIV counselling and 
testing was carried out, followed by sample collection (blood, urine and stool) [11-13]. A total 
of 1310 plasma samples collected at baseline before the trial intervention as well as from 
1571 plasma samples, collected after three years of the trial intervention were randomly 
selected and tested for KSHV IgG antibodies to determine KSHV seropositivity in this area 
and then its association with Schistosoma mansoni infection. More details of this analysis 
are shown in chapter five of this thesis. 
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Figure 2: Location of the LaVIISWA area, from Nampijja et al., 2015 [12].  
• The Entebbe Mother and Baby Study (EMaBS) 
The Entebbe Mother and Baby Study (ISRCTN32849447) is a randomised double-blind, 
placebo control trial of anthelminthic treatment during pregnancy. EMaBS was designed to 
investigate the effects of helminth treatment during pregnancy on infant responses to 
vaccines and infectious diseases. Pregnant mothers in their second or third trimester 
attending antenatal care at Entebbe general hospital were recruited between June 2003 and 
August 2005. A total of 2507 pregnant women from Entebbe municipality and Katabi sub-
county (Figure 3) were enrolled in the study. The inclusion criteria were residence in the 
study area (Entebbe and Katabi), planning to deliver from Entebbe general hospital and 
willingness to have an HIV test. Women with haemoglobin below 8g/dL, clinically apparent 
severe liver disease, diarrhoea with blood in the stool, pregnancy abnormalities and/or a 
history of adverse reaction to anthelminthic drugs were excluded from the study. The study 
drugs were a single dose of 400mg of albendazole and 40mg/Kg of praziquantel. After 
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 delivery, the children at age 15 months to five years were also randomised to receive either 
quarterly albendazole or placebo [13-16]. Demographic and clinical details, blood and stool 
samples were obtained from the mothers at enrolment and one month after delivery, and 
from children at ages one, two, three, four, five, six and nine years annually. These samples 
were stored after use, for future studies. Using these plasma samples, we tested for KSHV 
antibody responses to determine the age at KSHV seroconversion and its effect on 
subsequent antibody responses. Results from this analysis were published [17] and are 
shown in chapter three of this thesis.  
 
Figure 3: The Entebbe Mother and Baby Study site area. Figure provided by Professor Alison Elliott 
 
Laboratory methods 
Samples collected from the three populations were tested for various infections and 
immunological parameters. Blood collected in ACD vacutainer tubes was centrifuged at 
1000xg for 5 minutes. Plasma was removed, stored at -80°C and peripheral blood 
mononuclear cells (PBMCs) separated. The remaining blood in the ACD tubes (after plasma 
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 removal) was diluted 1:1 with RPMI (5mL L-glutamine, 5mL pen-strep and 12.5mL HEPES 
buffer in 500mL of RPMI 1640). Ficoll-Paque (15.5mL) was added to a 50ml Leucosep tube 
(ref:227290, Greiner Bio-one) and centrifuged at 1000xg for 1 minute to get the Ficoll below 
the porous filter disc. Diluted blood was transferred into prepared Leucosep tubes and 
centrifuged at 1000xg for 15 minutes without breaks. A white cloudy band of PBMCs layer 
was transferred into a sterile 50mL falcon tube and the volume topped up to 45mL with 
RPMI. These PBMCs were centrifuged at 650xg for 7 minutes. Thereafter the supernatant 
was poured off and the cells re-suspended in 5mL of ACK lysing solution. This was followed 
by a 10 minutes incubation at room temperature and addition of 15mL of RPMI after the 
incubation. Centrifuging at 650xg for 7 minutes followed, and the cells were re-suspended in 
5mL of RPMI for cell counting. Cells were counted using an automated cell counter 
(cellometer Vision Trio Nexcellon bioscience). Two million cells were deducted and 
centrifuged at 13000xg for 10 minutes followed by removing off the supernatant and storage 
of the pellet at -80°C. The remaining viable cells were dissolved in freezing media put in 
cryogenic vials and transferred to -80°C freezer in precooled stratacooler boxes. The 
cryogenic vials containing the cells were then transferred to liquid nitrogen for long-term 
storage after the overnight storage in the freezer. 
 
Study participants were asked to rinse their mouths with 5mL of Listerine mouth wash, 
thereafter spitting Listerine and saliva into a 50mL falcon tube. One mL aliquots of saliva 
were transferred into 1.5 ml tubes, centrifuged at 13,000xg for 10 minutes. The supernatant 
was removed and the pellet stored at -80°C for later use. 
 
Plasma samples were tested for anti-KSHV antibody responses using enzyme-linked 
immunosorbent assay (ELISA) and Luminex assays. Anti-Schistosoma mansoni antibody 
concentrations were also measured using ELISA. KSHV specific IFN- responses were 
determined from PBMCs using enzyme-linked immunospot (ELISpot) assays. PBMCs and 
saliva samples were tested for KSHV viral load using real-time polymerase chain reaction 
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 (PCR) assays. Helminth infections status was ascertained using microscopy and real-time 
PCR assays. KSHV specific assays were developed at the Viral Oncology Section/National 
Cancer Institute, NIH, USA, in collaboration with Denise Whitby and were transferred to the 
MRC/UVRI and LSHTM Uganda Research Unit, where they are well established. Details of 
these assays are shown below. 
 
• KSHV ELISA 
To determine KSHV serostatus, plasma samples from the GPC and LaVIISWA were tested 
for anti-KSHV IgG Antibodies to KSHV-encoded K8.1 and latently associated nuclear 
antigen (LANA)/ORF73 recombinant proteins (obtained from Denise Whitby, Viral Oncology 
Section/National Cancer Institute, NIH, USA) to determine KSHV serostatus following the 
procedure below. DynexImmulon 4 HBX 96 well plates (D17506, Fisher catalogue number: 
NC9939836) were coated with 100l of K8.1 and ORF73 recombinant proteins at a dilution 
of 1:5,000 for each protein. K8.1 protein was diluted in 0.05M carbonate/bicarbonate buffer, 
pH 10 and ORF73 in 1x phosphate buffered saline (PBS). The plates were sealed using 
Nunc plate sealers and incubated in a fridge (4°C) overnight. After the overnight incubation, 
plates were washed three times with 350l of wash solution (1x PBS, 0.05% Tween-20) per 
well, using an automated plate washer (BioTek ELx405). They were then inverted and 
tapped dry on paper towels. A volume of 270uL assay buffer (2.5% bovine serum albumin-
BSA (Sigma Chemical, catalogue number: A-7284) plus 2.5 % normal donor goat serum 
(Equitech-Bio catalogue number SG-0500) and 0.005 % tween 20 as well as 0.005 % Triton 
X-100 in 1x PBS) was added to each plate as a blocking agent, sealed with a plate sealer, 
and incubated for 3 hours at 37°C and stored at -80C. To run the assay, plates were thawed 
and washed three times with 350ul of wash solution prior to adding samples. Plasma 
samples and controls diluted 1:20 for K8.1 and 1:100 for LANA in assay buffer were added 
to each plate in a volume of 100l. Plates were sealed and incubated in a 37°c incubator for 
90 minutes. Each plate contained 88 samples, negative and positive controls (each in 
triplicate) and a blank (assay buffer) in duplicate. After the incubation, plates were washed 
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 five times with wash buffer, tapped dry on paper towels, and 100l of goat anti-human IgG-
Alkaline phosphatase labelled conjugate (KPL catalogue number 4751-1002) at a dilution of 
1:5,000 in assay buffer was added per well. Plates were then sealed and incubated at 37°C 
for 30 minutes. Following the 30 minutes incubation, plates were washed 5 times, tapped dry 
on the paper towel, and 100l of 1-step p-nitrophenyl phosphate (PNPP) substrate solution 
was added per well. They were then developed in the dark at room temperature for 30 
minutes for LANA and 25 minutes for K8.1. Plates were then immediately read using a 
microtiter plate reader (BioTek ELx808) at a wavelength of 405nm. Optical densities (ODs) 
were obtained. The ODs of the blank wells were used for background subtraction for each 
sample and control. The positive and negative controls were used for quality control, to 
determine if a plate has passed. The negative controls were also used to calculate a cut-off 
value for each plate. The cut-off value for each plate was the average background 
subtracted OD of the three negative control triplicates plus a constant value of 0.75 (for 
K8.1) or 0.35 (for LANA). This procedure has been reported previously [18]. 
 
• KSHV Luminex 
The ELISA assay is limited by a narrow dynamic range, a high sample volume and a single 
antigens testing. To overcome these limitations, samples from the GPC and EMaBS were 
tested for anti-KSHV IgG antibody levels using a bead-based multiplex assay. The 
procedure is described below. 
 
Bead coupling  
Eight recombinant KSHV-encoded proteins (OFR73, K8.1, ORF65, ORF38, ORF61, K5, 
K10.5 and ORF19) were coupled to fluorescent magnetic microspores/beads (Megaplex 
Microsphores, Luminex Corp, Austin, USA) individually, using the following procedure. A 
volume of 200uL MagPlex Microspheres, containing 2.5x106 beads,  was resuspended 
(vortexed for 20s and sonicated for 20s) and washed using 100µl of nuclease-free water. 
After removal of the water using a MACSiMAG apparatus, the beads were resuspended in 
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 80µl of activation buffer (0.1M NaH2PO4 in PBS at a PH of 6) and 10µl of 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride (EDC) (10mg EDC in 200µl of nuclease-
free water) and 10µl of N-hydroxysulfosuccinimide (Sulfo-NHS) (10mg Silfo-NHS in 200µl of 
nuclease-free water) for activation. After 20 minutes incubation, the activation buffer was 
removed and the beads resuspended in 250µl of coupling buffer (0.05M MES in PBS) 
followed by removal of the buffer, this step was repeated twice. After washing with coupling 
buffer, the beads were then resuspended in 100µl of coupling buffer followed by addition of 
KSHV proteins (at a concentration of 40µg per 2.5 million beads) to each unique bead set. 
The volume was then adjusted to 500µl using coupling buffer. After a 2hour incubation at 
room temperature in the dark with gentle mixing, the coupled beads were then resuspended 
in 500µl of PBS-TBN (1% BSA, 0.05% Sodium Azide, 0.002% Tween20 in PBS) after 
removal of the previous solution/supernatant. This was followed by resuspension into 1000µl 
of PSB-TBN after removal of the previous 500µl. The 1000µl supernatant was removed and 
coupled beads resuspended into 1000µl of PBS-BN (1% BSA and 0.05% sodium azide in 
PBS). The coupled beads were then counted using a haemocytometer and the bead 
concentration recorded. The coupled beads were then stored at 4oC. 
 
Bead testing  
The coupled beads were then tested using KSHV positive and negative controls before 
running the actual samples, following a similar procedure as the one used to run the actual 
samples but varying the dilution of both the controls and detection antibody.  
 
Assay procedure 
The coupled beads from each ORF were combined to make a multiplexed bead mixture by 
pipetting 2,000 beads per well of each bead set coupled to a particular antigen and topping 
up the volume to make 95µl per well with assay buffer. Using cell culture plates (Costar, 
Corning) that have been prewashed with assay buffer (1% BSA in PBS), 95µl of bead 
mixture were added and 5µl of a prediluted (1/10) sample (plasma) with assay buffer added 
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 to make a final sample dilution of 1/200. The plates were sealed and wrapped in aluminium 
foil followed by agitation for 60 minutes. They were then washed with assay buffer twice 
using a magnetic plate washer. Followed by the addition of 100µl per well of 0.5µg/ml of the 
detection antibody (goat F(abl) 2 anti-human IgG(y) R-PE conjugate), sealed and wrapped in 
aluminium foil and incubated for 30 minutes with gentle shaking.  After incubation, the plates 
were washed twice and 100µl per well of assay buffer added, then Median Fluorescence 
Intensities (MFI) were determined by reading the plate using a Bioplex200 Luminex 
machine. This procedure was followed as reported previously [19]. 
 
• KSHV specific ELISpot 
Stored PBMCs from 40 participants from the GPC were thawed and tested for KSHV 
specific cell-mediated IFN- responses using ELISpot assays. PBMCs stored in liquid 
nitrogen were retrieved and immediately transferred to a water bath pre-warmed to 370C. 
With only a small pellet left, the vials with PBMCs were transferred to a class II safety 
cabinet. Using Pasteur pipettes, cells were transferred to falcon tubes containing 9mL of R-
10 (10% foetal bovine serum (FBS) in RPMI) containing benzonase nuclease. This was 
followed by centrifugation at 350rcf for 5 minutes. After centrifugation, the supernatant was 
poured off and 5ml of AIM-V media added to the cell pellet. Cells were then resuspended 
and counted using a light microscope. Thereafter AIM-V solution was topped up to ensure 
that the cells are resuspended in 100l per 150,000 PBMCs. These cells were then 
temporally stored in the 37oC 5% CO2 incubator as the ELISpot plates were being prepared. 
The MABTECH Human IFN- ELISpot kit (Code: 3420-2APT-10) was used for the assay, 
with a few alterations to the manufacturer's protocol. The 96 well ELISPOT plates coated 
with the IFN- capture antibody from the kit were removed from the fridge and washed 
manually 5 times with 200l of 1xPBS per well. Thereafter, thawed cells which were 
temporally stored in the incubator were added to the plates in a volume of 100l containing 
150,000 cells per well. The plates were covered with the lid and wrapped in aluminium foil 
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 and transferred to a 5% CO2 37oC incubator for resting. The cells were rested for 24 hours. 
To stimulate the cells, overlapping peptides across the KSHV proteome were generated and 
84ORF peptide pools created. Eighty-one of which corresponded to a single ORF and the 
three to ORF64. The peptide pools were supplied by the Viral Oncology Section/National 
Cancer Institute, NIH, USA. Using these peptide pools, working concentrations of 5g/ml 
were prepared in 96 well culture plates using AIM-V media. After the 24 hour resting period, 
100l per well of the peptide pools was added to the cells to stimulate them. Anti-CD3 and a 
pool of peptides from flu, CMV and EBV were added as positive controls in triplicate. Media 
and a non-human antigen, Simian immunodeficiency virus (SIV) peptides were also added 
as negative controls in triplicate. The cells with the stimulants were then incubated at 37oC 
for 46-48 hours. Following the 48-hour stimulation, cells were washed 5 times with 200l of 
PBS per well and 100l of anti-human IFN IgG alkaline phosphatase conjugated (Code: 7-
B6-ALP) added at a dilution of 1/6 in PBS + 0.5% FBS. The plates were incubated at room 
temperature (250C) for 2 hours. After the incubation, the plates were washed 5 times with 
200l of 1xPBS per well and 100l of filtered 5-bromo-4-chromo-3-indolyl-phosphate 
(BCIP)/nitroblue tetrazolium (NBT)-plus substrate (Code: 3650-10) added per well. 
Thereafter plates were incubated at room temperature for 7 minutes and the reaction was 
stopped by washing the plate with running tap water. These plates were dried in the dark 
overnight, thereafter the spots were counted using an ELISPOT reader (AID ELISPOT 
Reader HR model: ELHR010307005). Results from the ELISpot assay are presented in 
chapter seven of this thesis.  
 
• KSHV quantitative real-time polymerase chain reaction (PCR) 
KSHV viral load was quantified from peripheral blood mononuclear cells (PBMCs) and saliva 
collected from 877 KSHV seropositive individuals from the GPC. After PBMC isolation using 
the ficoll density gradient method, two million cells were removed, spun at 13,000rcf for 
10minutes to form cell pellets. The supernatants were poured off and the cell pellets stored 
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 at -80oC. Similarly, 1mL aliquots of saliva were spun at 13,000rcf for 10 minutes to form 
saliva pellets. The saliva supernatants were aliquoted into new storage tubes. Both the 
saliva pellets and supernatants were stored at -80oC until use. The PBMC and saliva pellets 
were retrieved from the -80oC freezer, thawed and genomic DNA extracted using a QIAamp 
blood kit (Qiagen, Valencia, CA), following the manufacturer's instructions. KSHV viral load 
was quantified using real-time PCR. KSHV DNA was detected using primers (K6 forward 
primer K6-10F 5’-CGCCTAATAGCTGCTGCTACGG-3’, K6 reverse primer K6-10R 5’-
TGCATCAGCTGCCTAACCCAG-3’) and a probe (K6 probe p-K6-10 5’-R-
CACCCACCGCCCGTCCAAATTC-Q-3’) previously reported to be specific to the K6 gene 
region [20]. Additionally, the number of cellular equivalents were determined using a 
quantitative assay specific to human endogenous retrovirus 3 (ERV-3), which is present in 
two copies per genomic cell, using these primers (ERV-3 Forward primer PHP10-F 5’-
CATGGGAAGCAAGGGAACTAATG’ ERV-3 Reverse primer PHP10-R 5’-
CCCAGCGAGCAATACAGAATTT-3’) and a probe (ERV-3 Probe PHP-P505 5’-R-
TCTTCCCTCGAACCTGCACCATCAAGTCA-Q-3’). The ERV-3 assay was run on only 
PBMC DNA. To quantify both ERV-3 and KSHV DNA, seven two-fold serial dilutions of K6 
and ERV-3 were made from clone stocks (starting with 1x106 dilution to 1x10-1) to form a 
standard curve on every plate. The clone stocks were prepared and supplied by the Viral 
Oncology Section/National Cancer Institute, NIH, USA. ERV-3 was cloned into Bluescript II 
KS vector (Stratagene, La Jolla, CA, USA) KSHV K6 cloned using PCR Topo II vector, Topo 
TA Cloning kit, Invitrogen, K 4600-40. Primers (500ul each), probes (500ul), nuclease-free 
water (5.5ml) and universal master mix (Applied Biosystems, Foster City CA) (12.5ml) were 
mixed together to form the working solution master mix. Thereafter 10l of the standards, 
sample and controls each, were added to a 96 well PCR plate (ThermoFisher catalogue 
number 7306737) per well, in triplicate, and 40ul of the working solution master mix added to 
each well. This was followed by plate sealing and DNA amplification using an ABI ViiA7 
machine.  All samples were tested in triplicate for both assays and the estimated copy 
number for each individual reaction was averaged. The KSHV viral load was determined in 
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 PBMC DNA by calculating the viral DNA copies per million cells.  Saliva viral copies were 
reported as copies per millilitre.  Any sample that was quantifiable by the ERV-3 assay but 
not positive in all three reactions in the KSHV K6 assay was designated as positive but not 
quantifiable. The lower limit of detection for the ERV-3 assay has been previously 
determined as 10 copies while the KSHV K6 assay has a lower limit of sensitivity of 1 copy. 
This procedure has been reported elsewhere [21-23].   
In order to prevent contamination, qPCR reagents, sample processing, DNA extractions, and 
qPCR setup were conducted in dedicated laboratory areas.  Internal no template controls 
(NTC) were included on each plate, in triplicate, to assess cross-contamination. Assay 
quality controls including NTC, assay controls, and sample triplicate % coefficient of 
variation were used to validate data.  Importantly, the individual dilution parameters of the 
assay standard curve were assessed after each run to ensure performance within expected 
ranges.  Any assay which had failures of assay controls or standard curves were repeated. 
 
• Stool real-time polymerase chain reaction (PCR) 
Multiplex real-time stool PCR was performed on LaVIISWA samples to detect Schistosoma 
mansoni,  Strongyloides stercoralis and Necator americanus, following published protocols 
[24, 25]. A PCR assay was used as this is reportedly more sensitive than microscopy [24, 
25] and Strongyloides stercoralis could not be detected by microscopy. Additionally, the two 
hookworm species could only be identified by PCR. DNA from stool samples was extracted 
using QIAamp DNA mini kits (catalogue number: 51306) following the manufacturer's 
instructions. Primers, probes, magnesium chloride, Hotstart Taq Master mix, bovine serum 
albumin (BSA) and nuclease-free water were mixed together to make a working solution of 
master mix using the following concentrations: magnesium chloride 3.5mM, BSA 0.1mg/ml, 
forward primer S. stercolaris 100nM, reverse primer S. stercolaris 100nM, probe S. 
stercolaris 80nM, forward primer N. amaricanus 200nM, reverse primer N. amaricanus 
200nM, probe N. amaricanus 80nM, forward primer S mansoni 100mM, reverse primer S 
mansoni 100nM, probe S mansoni 80nM, forward primer Phocine Herpes Virus (PhHV) 
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 100nM, reverse primer PhHV 100nM, probe PhHV 80nM, Hotstart Taq Master mix 54.3%, 
nuclease-free water 21%. A volume of 23l of this working solution master mix and 1l of 
PhHV plus either a sample or control DNA volume of 1l were added to each well of the 
FAST MicroAmp 96-well reaction PCR plates. The plates were sealed and loaded into a 
PCR machine (ABI 7500) for amplification using already established protocols. PhHV DNA 
was used as an internal control. Primer and probe sequences used were Necator 
americanus (Na58F 5’-CTGTTTGTCGAACGGTACTTGC-3’, Na158R 5’-
ATAACAGCGTGCACATGTTGC-3’ Na81MGB,  FAM-5’-CTGTACTACGCATTGTATAC-3’-
XS), Schistosoma mansoni (Ssp48F 5’-GGTCTAGATGACTTGATYGAGATGCT-3’, 
Ssp124R 5’-TCCCGAGCGYGTATAATGTCATTA-3’, Ssp78T-RT Texas Red-5’- 
TGGGTTGTGCTCGAGTCGTGGC-3’-BHQ2), Strongyloides stercoralis (Stro18S-1530F 5’-
GAATTCCAAGTAAACGTAAGTCATTAGC-3’, Stro18S-1630R 5’-
TGCCTCTGGATATTGCTCAGTTC-3’, Stro18S-1586T NED-5’-
ACACACCGGCCGTCGCTGC-3’-BHQ2) and  Phocin Herpes Virus (PhHV-267 s5’-
GGGCGAATCACAGATTGAATC -3’, PhHV-337as 5’-GCGGTTCCAAACGTACCAA -3’, 
PhHV-305tq Cy5 -5’-TTTTTATGTGTCCGCCACCATCTGGATC-3’-BHQ2). Samples with 
positive amplifications were noted as positive and the amount of helminths DNA was derived 
from the Ct (cycle threshold) values.  
 
• Kato Katz (stool microscopy) 
A single stool sample was provided by each participant from the GPC and LaVIISWA. This 
stool sample was analysed for helminths (Schistosoma mansoni, Ascaris lumbricoides, 
Tichuris trichiura, Trichostrongylus spp and hookworm) using the Kato Katz method 
following the kit manufacturer's instructions. A small sample of stool was sieved using nylon 
gauze. Using a template an equal amount of stool (41.7mg) was prepared per slide. Glycerol 
was used to clean away the debris material and malachite green was used to stain the 
background for visibility of the eggs. Two slides were prepared and independently examined 
for worm eggs using a light microscope by two laboratory technologists independently. The 
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 number of eggs per gram of stool was recorded. Light, moderate and heavy infections were 
categorised following kit manufacturer's instructions. Details of this procedure have been 
reported elsewhere [26, 27]. Samples from the GPC were kept at 4oC overnight and 
examined the day after, while samples from LaVIISWA were analysed immediately after 
collection. 
 
Ethical approvals 
Work presented in this thesis was approved by the Uganda Virus Research Institute-
Research and Ethics Committee (UVRI-REC) reference numbers: GC/127/16/09/566 and 
GC/127/17/04/317, the Uganda National Council for Science and Technology (UNCST) 
reference numbers: HS2123 and HS1183 and the London School of Hygiene & Tropical 
Medicine (LSHTM) Ethics Committee reference numbers: 11881 and 9917-9. All participants 
aged 18 years and above provided written informed consent for participation in the studies 
and storage of their samples for future use. Children below 18 years were consented for by 
their parents or guardians. In addition, written informed assent was given by participants 
aged 8 to 17 years. Approval letters are presented in Appendix 1.  
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 Results chapters 
 
Results from the PhD research are presented in five chapters (from chapter three to chapter 
seven) of the thesis. The first three chapters focus on risk factors for KSHV seropositivity 
and/or antibody levels. Chapter six shows patterns of KSHV DNA detection and associated 
risk factors. Chapter six also shows the relationship between KSHV antibody levels and viral 
DNA detection. The final result chapter shows IFN- cellular responses to KSHV peptide 
pools.    
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 Chapter Three: Age of infection and KSHV antibody levels 
in Uganda 
 
Preamble 
 
This PhD project focused on understanding factors that may cause high levels of 
transmission of KSHV in Uganda. Transmission of KSHV in endemic areas occurs during 
childhood. The consequences of early infection for the natural history of the virus and the 
risk of KSHV-related disease have not been fully explored. Using samples from an existing 
birth cohort, we determined the age at which children acquired KSHV infection by measuring 
antibody levels to KSHV. We then determined the association between the age of infection 
with KSHV and subsequent KSHV antibody levels. The results showed a very early age of 
infection and that early infection was associated with higher subsequent antibody levels. 
These high antibody levels were sustained over several years and may remain high for life. 
High antibody levels to KSHV have been correlated with KS disease risk. Therefore, these 
results may imply a role of early infection in relation to increased subsequent risk of KS  in 
Africa.   
 
Results from the antibody levels to K8.1 and ORF73 were published in the Pediatric 
Infectious Disease Journal. Antibody levels to other KSHV antigens including K10.5, ORF19, 
ORF61, ORF38, K5 and ORF65 are shown in Chapter Three - additional results. 
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Transmission of Kaposi sarcoma–associated herpesvirus (KSHV) is mainly through salivary exchange and can occur in 
childhood in endemic regions1; KSHV prevalence increases with 
age.2 The impact of age of infection with KSHV on the pathogen-
esis and control of KSHV has not been investigated.
Early infection with Epstein-Barr virus (EBV), another 
gammaherpesvirus closely related to KSHV, is associated with 
higher subsequent viral load.3 High viral capsid antigen antibody 
titers and EBV viral load have been associated with risk of Burkitt 
lymphoma,4 the most common childhood malignancy in equatorial 
Africa, linked to both EBV and malaria.5
High antibody titers to KSHV are an important predictors 
of risk of Kaposi’s sarcoma (KS) disease6; they are also a marker 
of KSHV reactivation.7 This study was designed to determine the 
association between the age at which children from Uganda become 
KSHV seropositive (KSHV seroconversion age) and subsequent 
KSHV-specific immunoglobulin G (IgG) antibody values.
METHODS
Study Population
Samples collected from children enrolled in the Entebbe 
Mother and Baby Study were tested for KSHV IgG antibody 
responses retrospectively. Entebbe Mother and Baby Study was 
initiated as a randomized controlled trial, designed to investigate 
the impact of helminth treatment during pregnancy on childhood 
responses to vaccines and infectious diseases. The trial protocol and 
results have been described elsewhere.8 A total of 2507 pregnant 
women from Entebbe, Uganda, a semiurban area, were recruited 
and their children have been followed from birth. Blood and other 
samples have been collected annually and stored.
Ethical Approval
This study was approved by the Uganda Virus Research 
Institute—Research and Ethics Committee, the Uganda National 
Council for Science and Technology and the London School of 
Hygiene & Tropical Medicine. Informed consent was obtained 
from study participants’ parents or guardians.
KSHV Serologic Testing
Plasma samples collected at 6 years of age (annual 6) were 
tested for KSHV IgG antibodies to identify KSHV seropositive 
children. KSHV seropositivity was defined by seropositivity to 
either ORF73 or K8.1 antigen. Any seropositive child was then 
tested at age 5, and so on retrospectively, until a seronegative speci-
men was identified. To determine if the effect of age at infection on 
subsequent antibody values is sustained for a longer time period, 
we then tested the available plasma samples at age 9 from the 
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children who were seropositive at age 6 for IgG antibody responses 
to KSHV. The estimated age of KSHV seroconversion was defined 
as the midpoint between the last seronegative and the first seroposi-
tive specimen. Because of missing specimens, these samples were 
not always from consecutive years.
An in-house multiplexed bead assay was used to measure 
KSHV-specific IgG antibody responses as previously described.9 
This assay has a wider dynamic range than an enzyme-linked 
immunosorbent assay which is an important advantage when com-
paring antibody values. ORF73 and K8.1 recombinant proteins 
were coupled to fluorescent magnetic beads (Biorad, Hercules, 
CA) according to the manufacturer’s protocol. Coupled beads were 
mixed with plasma samples at a sample dilution of 1/200 and a 
bead concentration of 2000 beads per well in assay/wash buffer (1% 
bovine serum albumin in 1 × phosphate buffered saline), to make 
a total volume of 100 µ per well. The mixture was incubated for an 
hour under gentle agitation and washed with wash buffer thereafter. 
Detection antibody of 100 µ of 0.5µL/mL [goat F(ab′)2 antihuman 
IgG R-phycoerythrin (R-PE) conjugate] was added and incubated 
for 30 minutes under gentle agitation. After washing, 100 µ of assay 
TABLE 1. Association Between Age of KSHV Seroconversion, Sex, Age and KSHV Antibody Levels Among Children 
From Uganda
AI: Antibody Levels at Age 6 yr From 158 Children
 
K8.1 ORF73
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Seroconversion age 0.81 (0.72–0.90) <0.0001 0.81 (0.73–0.91) <0.0001 0.73 (0.64–0.83) <0.0001 0.73 (0.64–0.83) <0.0001
AII: Antibody Levels at Age 6 yr From 100 Children With All Consecutive Samples
 K8.1 ORF73
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Seroconversion age 0.78 (0.69–0.89) <0.0001 0.80 (0.70–0.37) 0.001 0.69 (0.59–0.81) <0.0001 0.68 (0.58–0.80) <0.0001
BI: Antibody Levels at Age 9 yr From 158 Children
 K8.1 ORF73
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Seroconversion age 0.67 (0.57–0.79) <0.0001 0.67 (0.57–0.79) <0.0001 0.75 (0.66–0.85) <0.0001 0.75 (0.66–0.85) <0.0001
BII: Antibody Levels at Age 9 yr From 100 Children With All Consecutive Samples
 K8.1 ORF73
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Crude GMR  
(95% CI) P
Adjusted* GMR 
(95% CI) P
Seroconversion age 0.96 (0.78–1.18) 0.691 0.95 (0.77–1.17) 0.620 1.03 (0.88–1.19) 0.740 1.03 (0.88–1.20) 0.737
CI: Antibody Levels at Ages 1, 2, 3, 4, 5, 6 and 9 yr From 158 Children
 K8.1 ORF73
Crude GMR  
(95% CI) P
Adjusted† GMR 
(95% CI) P
Crude GMR  
(95% CI) P
Adjusted GMR† 
(95% CI) P
Seroconversion age 0.72 (0.66–0.78) <0.0001 0.60 (0.55–0.65) <0.0001 0.71 (0.65–0.77) <0.0001 0.59 (0.53–0.64) <0.0001
Age 0.93 (0.85–0.99) 0.018 1.70 (1.57–1.85) <0.0001 0.82 (0.76–0.88) <0.0001 1.65 (1.53–1.77) <0.0001
CII: Antibody Levels at Ages 1, 2, 3, 4, 5, 6 and 9 yr From 100 Children With All Consecutive Samples
 K8.1 ORF73
Crude GMR  
(95% CI)
P Adjusted† GMR 
(95% CI)
P Crude GMR  
(95% CI)
P Adjusted GMR† 
(95% CI)
P
Seroconversion age 0.80 (0.73–0.87) <0.0001 0.73 (0.67–0.80) <0.0001 0.78 (0.72–0.85) <0.0001 0.68 (0.62–0.75) <0.0001
Age 1.09 (1.02–1.17) 0.008 1.20 (1.12–1.28) <0.0001 1.22 (1.15–1.03) <0.0001 1.29 (1.22–1.37) <0.0001
*Adjusted for sex and seroconversion age.
†Adjusted for age, sex and seroconversion age.
AI and AII show the association between age of KSHV seroconversion, sex and KSHV antibody levels at age 6. BI and BII show the association between age of KSHV seroconver-
sion, sex and KSHV antibody levels at age 9. CI and CII show the association between age of KSHV seroconversion, sex, age and KSHV antibody levels among children at ages 1, 
2, 3, 4, 5, 6 and 9 combined from Uganda. AI and CII show results from 100 children with all 6 consecutive samples plus 58 children missing 1–4 samples. AII and CII show results 
from 100 children with all 6 consecutive samples. BI shows results from 130 children with samples available at age 9. BII shows results from 79 children with available samples at 
age 9, and have all previous consecutive samples. GMR and 95% CI obtained by calculating the log10 exponent of the regression coefficient and the 95% CI, respectively. Regression 
coefficient, 95% CI and P value were obtained using linear regression after log10 transformation of K8.1- and ORF73-specific total IgG MFI. MFI was obtained using the bead assay. 
K8.1 and ORF73 IgG antibody responses were analyzed using separate linear regression models. Seroconversion age is the age at which the children became KSHV seropositive. Age 
is the number of years the children had lived by the time of sample collection.
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buffer was added per well, agitated for 2 minutes and the plate read 
using a Bioplex200 machine (Luminexcorp, Austin, TX) to obtain 
the median fluorescence intensities (MFIs). Each plate contained 3 
negative and 3 positive control wells plus 2 blank wells. The cutoff 
MFI values for OFR73 and K8.1 were 968 and 741, respectively, 
plus the mean values of the negative control per plate.
Statistical Analysis
Data analysis was performed using Stata-13 software 
(STATA 13.0; Statacorp, College Station, TX). Antibody values 
(measured as MFIs) were log
10
 transformed. Linear regression was 
used to examine the relationship between KSHV IgG antibody 
responses at 6 and 9 years of age and seroconversion age while 
adjusting for sex. To investigate the association between serocon-
version age and antibody values (KSHV IgG antibodies) at all time-
points/ages (1, 2, 3, 4, 5, 6 and 9), we used mixed models with ran-
dom effects. Random-effects modeling provided associations that 
were independent of the duration of infection and accounted for 
correlation of results from the same child at different time points. 
Geometric mean ratios (GMRs) and their 95% confidence intervals 
(CIs) were obtained by calculating the log
10
 exponent of the regres-
sion coefficients and their 95% CI, respectively. Antibodies to K8.1 
and ORF73 were analyzed using separate regression models.
RESULTS
Age at KSHV Seroconversion
The number of children who were KSHV seropositive at 6 
years of age was 176/535 (33%), 128/535 (24%) were seropositive 
to K8.1 and 165/535 (31%) were seropositive to ORF73 proteins. 
The number of children with all 6 consecutive samples was 100/176. 
Therefore, 76/176 children had at least 1 missing sample, 39, 11, 5, 
3 and 18 had 1, 2, 3, 4 and 5 missing samples, respectively. The 18 
children with 5 consecutive missing samples were excluded from the 
analysis, leaving a total of 158 children for analysis. Results from 
100 participants with all 6 consecutive samples (Table 1, AII and 
CII) were comparable to those from 158 participants (Table 1, AI 
and CI) at 6 years of age and at all ages combined. At 9 years of 
age, the available samples from the 100 participants were 79 which 
might have reduced the power of the study to detect statistically sig-
nificant differences (Table 1, BII). Among the 158 KSHV seroposi-
tive 6-year-old children analyzed, 43, 50, 23, 14, 18 and 10 children 
were estimated to have seroconverted by ages 6, 5, 4, 3, 2 and 1, 
respectively. The proportions of seroconverters who were boys at the 
different seroconversion age bands were 22/43 (51%), 26/50 (52%), 
14/23 (61%), 8/14 (57%), 10/18 (56%) and 8/10 (80%) at 6, 5, 4, 
3, 2 and 1, respectively. Antibody values increased with age. For 
every annual increase in age, we observed a 71% (P < 0.0001) and 
65% (P < 0.0001) increase in K8.1 and ORF73 IgG antibody values, 
respectively (Table 1, CI). On the other hand median antibody values 
generally decreased with increasing age at primary infection (Fig., 
Supplemental Digital Content 1, http://links.lww.com/INF/C950).
We investigated the association between age at KSHV 
seroconversion and antibody values to K8.1 and ORF73 antigens 
at 6 and 9 years of age using sex-adjusted linear regression mod-
eling. At 6 years of age, antibody values decreased with increas-
ing seroconversion age. For every year of delay in seroconver-
sion age, we observed a 19% decrease in K8.1 antibody values, 
with an adjusted GMR (aGMR) of 0.81, 95% CI (0.73–0.91), P 
= 0.001 (Table 1, AI). In addition, for every year of delay in sero-
conversion age, we observed a 27% decrease in ORF73 antibody 
values, with an aGMR of 0.73, 95% CI (0.64–0.83), P < 0.0001 
(Table 1, AI).
At 9 years of age, both K8.1 and ORF73 antibody values 
decreased with increasing seroconversion age. For every year of 
delay in seroconversion age, we observed a 33% decrease in K8.1 
antibody values, with an aGMR of 0.67, 95% CI (0.57–0.79), P 
> 0.0001 (Table 1, BI). Similarly, for every year of delay in sero-
conversion age, we observed a 25% decrease in ORF73 antibody 
values, with an aGMR of 0.75, 95% CI (0.66–0.85), P < 0.0001 
(Table 1, BI).
To determine the effect of age of infection on antibody titers 
which is independent of duration of infection, we then investigated 
the association between seroconversion age and antibody values at 
all ages/timepoints (1, 2, 3, 4, 5, 6 and 9) to K8.1 and ORF73 using 
random-effects models adjusting for sex and age. Generally, anti-
body values to both K8.1 and ORF73 decreased with increasing 
seroconversion age. For every year of delay in seroconversion, we 
detected a 40% decrease in K8.1 antibody values, aGMR 0.60, 95% 
CI (0.55–0.65), P < 0.0001 (Table 1, CI). Similarly, for every year 
of delay in seroconversion, we observed a 41% reduction in ORF73 
IgG antibody values, aGMR 0.59, 95% CI (0.53–0.64), P < 0.0001 
(Table 1, CI).
DISCUSSION
In KSHV endemic areas, infection can occur early in life, 
but the importance of age of infection to subsequent transmis-
sion and disease risk has not been investigated before. Antibody 
responses to KSHV, and in particular, values of antibodies, have 
been associated with KS development, KSHV reactivation and 
KSHV transmission.6,7. In this study, we have observed very early 
seroconversions and detected a strong association between age of 
KSHV seroconversion and subsequent antibody values to both K8.1 
and ORF73. The earlier these children seroconverted, the higher 
their subsequent antibody values to both K8.1 and ORF73 proteins. 
To our knowledge, this is the first study to look at the effect of age 
of infection with KSHV on subsequent antibody responses. Anti-
body responses are a proxy measure of KSHV reactivation.6 K8.1 
is a glycoprotein expressed during the lytic phase of the virus life 
cycle and ORF73 encodes the latently associated nuclear protein, 
a structural protein expressed during the latent stage of the virus 
life cycle. Measurement of other parameters related to disease and 
transmission risk such as viral load in saliva and in blood in relation 
to KSHV age of infection would be of great interest.
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MACRO- AND MICROVASCULAR PARAMETERS 
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Abstract: Whether individuals who had toxic shock syndrome in childhood 
have differences in macro- and retinal microvascular parameters indica-
tive of increased cardiovascular risk is unknown. We found no evidence 
of adverse macrovascular changes in 22 toxic shock syndrome participants 
compared with 60 control participants. Microvascular comparisons showed 
a reduction in retinal total fractal dimension, which has been associated 
with cardiovascular risk factors in children.
Key Words: toxic shock syndrome, intima-media thickness, arterial stiff-
ness, microcirculation 
Accepted for publication September 4, 2017.
From the *Infection and Immunity Theme, Murdoch Children’s Research Insti-
tute, The Royal Children’s Hospital, Parkville, Victoria, Australia; †Depart-
ment of Paediatrics, University of Melbourne, Parkville, Victoria, Aus-
tralia; ‡Infectious Diseases Unit and Department of General Medicine, The 
Royal Children’s Hospital, Melbourne, Victoria, Australia; §Singapore Eye 
Research Institute, Singapore National Eye Centre, Singapore; ¶Duke-NUS 
Medical School, National University of Singapore, Singapore; ║Department 
of Ophthalmology and Visual Sciences, The Chinese University of Hong 
Kong, Hong Kong; **Heart Research Group, Murdoch Children’s Research 
Institute and Department of Cardiology, The Royal Children’s Hospital, 
Parkville, Victoria, Australia; and ††Department of Paediatrics, Monash 
University, Clayton, Victoria, Australia.
K.Y.H.C. holds an Australian Government Research Training Program scholar-
ship from The University of Melbourne and a Postgraduate Health Research 
Scholarship from Murdoch Children’s Research Institute. D.P.B. holds a 
National Health and Medical Research Council (NHMRC) Senior Research 
Fellowship (APP1064629) and an honorary National Heart Foundation 
Future Leader Fellowship (100369). N.C. is an investigator on NHMRC 
project grant 1064408. Research at Murdoch Children’s Research Institute 
is supported by the Victorian Government’s Operational Infrastructure Sup-
port Program. The Heart Research Group is supported by The RCH1000, 
The Royal Children’s Hospital Foundation and Big W. The sponsors had no 
involvement in the study design, collection, analysis, interpretation and in 
the writing of this article.
D.P.B., M.C., N.C. conceived and designed the experiment. K.Y.H.C., D.P.B., 
N.C. and M.C. participated in the acquisition, analysis and interpretation of 
data. K.Y.H.C. drafted the article. All the authors have read and approved of 
the final article.
The authors have no conflicts of interest to disclose.
Address for correspondence: David Burgner, PhD, Murdoch Children’s Research 
Institute, 50 Flemington Road, Parkville, Victoria 3052, Australia. E-mail: 
david.burgner@mcri.edu.au.
Inflammation is central to the development of atherosclerosis, and pathogenic lesions in arteries are reported from early childhood 
onward.1 Children with acute and chronic inflammatory diseases, 
including Kawasaki disease, inflammatory bowel disease, psoriasis 
and juvenile arthritis may have persistent adverse changes in their vas-
cular structure and function, although the implications for later cardi-
ovascular disease risk are largely unknown.2–4 Toxic shock syndrome 
(TSS) is a rare, acute, life-threatening toxin-mediated illness causing 
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
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fulminant vascular inflammation and dysfunction, often resulting in 
multiorgan failure. It is unknown whether children with TSS have 
changes in either the macro- or microvasculature years after the acute 
illness and are at increased long-term cardiovascular risk.
We aimed to investigate whether participants with past 
TSS have quantitative subclinical changes in macro- and retinal 
microvascular parameters indicative of a possible increased in car-
diovascular risk. The retinal and coronary vasculature share many 
similarities and respond to common metabolic risk factors.5 We 
hypothesized that, compared with control participants, TSS par-
ticipants have a more adverse macrovascular profile [eg, increased 
carotid and aortic intima-media thickness (IMT), increased pulse 
wave velocity (PWV) and decreased carotid artery distensibility 
and compliance] and retinal microvascular profile (eg, wider ven-
ules, narrower arterioles, reduced fractal dimension and increased 
tortuosity).
PATIENTS AND METHODS
We performed a case-control study including participants 
aged 6–30 years who had TSS at least 2 years previously and con-
trol participants of similar age and sex, recruited from The Royal 
Children’s Hospital Melbourne and Monash Medical Centre, Mel-
bourne, Australia. Cases fulfilled the Centers for Disease Control 
and Prevention case definition for either probable or definite TSS.6 
Exclusion criteria were pregnancy, diabetes, known atherosclerotic 
cardiovascular disease, treatment for hypertension and/or hyper-
lipidemia and chronic auto-immune inflammatory conditions. The 
study was approved by the human research ethics committee of 
both hospitals, and written informed consent was obtained from the 
parents or adult participants.
All data were collected at a single visit after a minimum of 6 hours 
of fasting. Demographic data and anthropometric measurements (BC 
418, Tanita, Tokyo, Japan) were obtained. Pubertal status was based on 
self-reported Tanner stage. The mean of 3 blood pressure measurements 
(SphygmoCor XCEL, AtCor Medical, NSW, Australia) was recorded. 
Blood was collected for measurement of high-sensitivity C-reactive pro-
tein (Abbott Architect, IL), glucose, triglycerides, total cholesterol, high 
density lipoprotein and low density lipoprotein cholesterol (Vitros 5600, 
Ortho-Clinical Diagnostics, NJ) during the study visit.
Carotid and Aortic Intima-Media Thickness
Ultrasound images of the carotid artery and the abdominal 
aorta were acquired using Vivid i (General Electronics Healthcare, 
Little Chalfont, UK) with simultaneous electrocardiogram (ECG) 
gating as previously described.7,8 Cine loops of at least 5 cardiac 
cycles focused on the intima-media complex of the posterior wall 
of the right common carotid artery 1 cm proximal to the carotid 
bulb were recorded for offline analysis. Imaging was focused on the 
distal 10–15 mm of the abdominal aorta.
The IMT of the far wall 1 cm from the carotid bulb was 
measured at end diastole using a semiautomated software, Carotid 
Analyzer for Research (Medical imaging applications LLC, Cor-
alville, IA). The “mean IMT” refers to the average IMT in the 
selected area of measurement while the “maximum IMT” to the 
thickest IMT measurement within that segment.8 The mean of these 
“mean IMT” or “maximum IMT” measurements from 5 end-dias-
tolic frames was used in analyses.8
The 5 best-quality frames of the abdominal aorta were 
selected from the recorded cine loops for analysis using the same 
procedure. All IMT measurements were performed by a sin-
gle grader blinded to subject status. The intrarater reliability was 
assessed on 10 masked subjects. Intraclass correlation for carotid 
IMT and aortic IMT was 0.92 [95% confidence interval (CI): 0.69–
0.98] and 0.89 (95% CI: 0.59–0.97), respectively.
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Chapter Three supplementary material  
 
Supplementary Figure 1: The medians and interquartile ranges of both anti-K8.1 and anti-ORF73 
antibodies at ages 6 and 9 for each seroconversion age group/band. Figure 1A and B anti-K8.1 
antibodies at ages 6 and 9 respectively, Figure 1C and D anti-ORF73 antibodies at ages 6 and 9 
respectively, MFI Median Fluorescence Intensity 
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Chapter Three - additional results: Age of infection and antibody 
levels to K10.5, ORF19, ORF61, ORF38, K5, and ORF65 proteins 
 
At age six years, a younger seroconversion age was associated with higher antibody levels 
to ORF65 (Table 1). Antibodies to other antigens were not significantly associated with the 
age of seroconversion at age six years (Table 1). Using random effects longitudinal 
modelling (which determines the association between age of infection and antibody levels 
that is independent of duration of infection), younger seroconversion age was associated 
with antibody levels to all six KSHV antigens at all the six-time points (1, 2, 3, 4, 5, and 6) 
combined (Table 2).  Similar to K8.1 and ORF73, other KSHV antigens may elicit antibody 
levels whose magnitude may be affected by the age at primary infection.  
 
Table 1: Association between the age of KSHV seroconversion, and antibody levels at age 
six years 
 Crude adjustedc 
GMRa (95% CIb) P value GMRa (95% CIb) P value 
K10.5 
Seroconversion  
 
0.96 (0.91, 1.08) 
 
0.843 
 
0.99 (0.91, 1.08) 
 
0.829 
ORF19 
Seroconversion  
 
1.04 (0.98, 1.10) 
 
0.243 
 
1.04 (0.97, 1.10) 
 
0.266 
ORF61 
Seroconversion  
 
1.00 (0.94, 1.06) 
 
0.948 
 
1.00 (0.94, 1.06) 
 
0.917 
ORF38 
Seroconversion  
 
1.03 (0.95, 1.11) 
 
0.502 
 
1.02 (0.95, 1.10) 
 
0.548 
K5 
Seroconversion  
 
1.01 (0.95, 1.07) 
 
0.746 
 
1.01 (0.95, 1.07) 
 
0.773 
ORF65 
Seroconversion  
 
0.87 (0.82, 0.93) 
 
<0.0001 
 
0.88 (0.82, 0.93) 
 
<0.0001 
a: Geometric Mean Ratios, b: Confidence Intervals, c: adjusted for sex. linear regression 
modelling was used for statistical analysis. 
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Table 2: Association between age of KSHV seroconversion, age  and antibody levels at age 
one to six years 
 Crude adjustedc 
GMRa (95% CIb) P value GMR (95% CI) P value 
K10.5 
Seroconversion 
age 
 
0.92 (0.86, 0.99) 
1.12 (1.08, 1.16) 
 
0.022 
<0.0001 
 
0.86 (0.80, 0.93) 
1.22 (1.17, 1.3)  
 
<0.0001 
<0.0001 
ORF19 
Seroconversion 
age 
 
0.94 (0.90, 0.99) 
1.11 (1.08, 1.14) 
 
0.016 
<0.0001 
 
0.89 (0.85, 0.94) 
1.18 (1.14, 1.2) 
 
<0.0001 
<0.0001 
ORF61 
Seroconversion 
age 
 
0.91 (0.87, 0.95) 
1.01 (0.98, 1.03) 
 
<0.0001 
0.611 
 
0.89 (0.85, 0.93) 
1.08 (1.05, 1.11) 
 
<0.0001 
<0.0001 
ORF38 
Seroconversion 
age 
 
0.90 (0.85, 0.95) 
0.97 (0.94, 1.00) 
 
<0.0001 
0.041 
 
0.88 (0.83, 0.94) 
1.05 (1.19, 1.09) 
 
<0.0001 
0.003 
K5 
Seroconversion 
age 
 
0.87 (0.82, 0.91) 
0.91 (0.88, 0.94) 
 
<0.0001 
<0.0001 
 
0.86 (0.86, 0.91) 
1.01 (0.98, 1.05) 
 
<0.0001 
0.417 
ORF65 
Seroconversion 
age 
 
0.83 (0.80, 0.86) 
0.95 (0.93, 0.97) 
 
<0.0001 
<0.0001 
 
0.83 (0.80, 0.86) 
1.01 (0.99, 1.04) 
 
<0.0001 
0.229 
a: Geometric Mean Ratios, b: Confidence Intervals, c: adjusted for sex and age in years. 
Random effects modelling was used for statistical analysis. 
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 Chapter Four: Relationship between anaemia, malaria 
coinfections and KSHV seropositivity in a population-
based study in rural Uganda  
 
Preamble 
 
Work published from our group has shown that malaria and hookworm infections were 
associated with KSHV seropositivity in an urban setting in Uganda. Both malaria and 
hookworm cause anaemia as well as other complications. Additionally, hypoxia, which may 
be caused by anaemia, has been shown to reactivate KSHV in vitro. Furthermore, we had 
observed very high seropositivity of KSHV in rural Uganda. We, therefore, investigated the 
association between haemoglobin levels/anaemia as well as malaria with KSHV 
seropositivity and antibody levels in rural Uganda, where KSHV is highly prevalent. 
 
These results show that both malaria and anaemia independently increase the risk of being 
KSHV seropositive. The KSHV association with malaria is larger and stronger compared to 
that of anaemia. Malaria also partially confounded the association of anaemia with KSHV 
seropositivity, but anaemia did not confound the association of malaria with KSHV 
seropositivity. This implies that both factors may play a role in KSHV infection. The work was 
published in the Journal of Infectious Diseases. 
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Relationship Between Anemia, Malaria 
Coinfection, and Kaposi Sarcoma-
Associated Herpesvirus Seropositivity 
in a Population-Based Study in 
Rural Uganda
Angela Nalwoga,1,2 Stephen Cose,1,2 Stephen Nash,2 Wendell Miley,3  
Gershim Asiki,4 Sylvia Kusemererwa,1 Robert Yarchoan,5  
Nazzarena Labo,3 Denise Whitby,3 and Robert Newton1,6
1Medical Research Council/Uganda Virus Research Institute and London School of 
Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda; 2London 
School of Hygiene and Tropical Medicine, United Kingdom; 3Viral Oncology Section, 
AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National 
Laboratory for Cancer Research, MD; 4African Population and Health Research 
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National Institutes of Health, Bethesda, MD; and 6University of York, United Kingdom
We examined anemia and malaria as risk factors for Kaposi 
sarcoma-associated herpesvirus (KSHV) seropositivity and 
antibody levels in a long-standing rural Ugandan cohort, 
in which KSHV is prevalent. Samples from 4134 children, 
aged 1–17 years, with a sex ratio of 1:1, and 3149 adults aged 
18–103 years, 41% of whom were males, were analyzed. Among 
children, malaria infection was associated with higher KSHV 
prevalence (61% vs 41% prevalence among malaria infected and 
uninfected, respectively); malaria was not assessed in adults. 
Additionally, lower hemoglobin level was associated with an 
increased prevalence of KSHV seropositivity, both in children 
and in adults.
Keywords. Kaposi sarcoma herpesvirus antibodies; rural 
population; anemia; malaria.
 
We recently reported Kaposi sarcoma-associated herpesvirus 
(KSHV) prevalence of 95% among adults in a rural popula-
tion cohort (the General Population Cohort [GPC] in Uganda 
[1]), the highest prevalence of KSHV ever reported, in addition 
to high KSHV antibody levels. We propose that the very high 
prevalence in this population may be driven by frequent KSHV 
reactivation, viral shedding, and transmission rates and that 
the high antibody levels also reflect frequent reactivation. It is 
important, therefore, to study potential cofactors for reactiva-
tion in relation to KSHV prevalence and antibody levels. We 
have previously reported an association between malaria and 
hookworm infections and KSHV seropositivity in an urban 
population in Uganda [2, 3]. Because both malaria and hook-
worm are associated with anemia, we hypothesized that anemia 
may have a role in KSHV transmission via viral reactivation. 
This hypothesis is supported by data from in vitro experiments 
showing reactivation of KSHV in conditions of hypoxia [4]. In 
this study we aimed to confirm the high prevalence of KSHV 
in the GPC in recent years, with higher antiretroviral therapy 
coverage, and determine the role of anemia and malaria coin-
fection as risk factors for KSHV prevalence and antibody levels 
in a highly endemic population.
METHODS
Study Population and Sociodemographic Data Collection
The GPC is located in south-western Uganda, in Kyamulibwa 
subcommunity of Kalungu district, with an altitude of approx-
imately 1200 m above sea level. It is community-based open 
cohort of about 22 000 people in 25 adjacent villages [5]. This 
cross-sectional study analyzed plasma samples collected from 
2 surveys, the adult survey and the children survey. The adults 
were surveyed in 2014/2015 and the children in 2016. Adults 
without hematological parameter data and children without 
either hematological parameter data or malaria parasitemia sta-
tus data were excluded in the laboratory analysis. Children less 
than 1 year of age were excluded from the statistical analysis and 
children less than 2 years were not tested for HIV serostatus, 
due to the potential for maternal IgG to be present, which could 
affect antibody measurement. Socioeconomic scores were gen-
erated for adults using principal component analysis of various 
household indicators during the previous survey.
Ethical Approval
The study was approved by the Research and Ethics Committee 
Uganda Virus Research Institute and the Uganda National 
Council for Science and Technology.
Hematological and Serological Analysis
During these 2 surveys, blood was collected from study partici-
pants and tested immediately after collection for human immu-
nodeficiency virus (HIV); a smaller proportion of samples 
were also tested for malaria parasitemia and hemoglobin levels, 
using point-of-care assays and rapid tests. HIV serostatus was 
determined using rapid diagnostic tests. Malaria parasitemia 
was measured in children only, using malaria Rapid Diagnostic 
Tests (One Step Malaria HRP-II [Pf] and pLDH [Pan] Antigen 
Rapid Test). Hemoglobin levels in g/dL were obtained from a 
Hemocue 201 analyzer.
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Stored plasma samples for both children and adults were 
retrieved and tested for KSHV antibodies using an in-house 
enzyme-linked immunosorbent assay (ELISA), as previously 
described [6]. Samples from the 2 surveys were tested separately 
after simple randomization onto ELISA plates. Antibodies to 
both K8.1 and ORF73 proteins were measured as optical den-
sity. Each ELISA plate contained 3 negative and positive con-
trol wells; negative controls were used to calculate a cutoff value 
for every plate as previously described [2, 7]. Seropositivity was 
defined as reactivity to either K8.1 or ORF73 proteins.
Statistical Analysis
Statistical analysis was carried out using STATA13 (Statacorp, 
College Station, TX). Children’s and adults’ results were ana-
lyzed separately. Hemoglobin levels were mean centered for 
easier interpretation. Anemia was defined using hemoglobin 
levels in g/dL after altitude adjustment following World Health 
Organization (WHO) guidelines [8]. A constant value 0.5 was 
subtracted from hemoglobin levels for altitude adjustment, the 
results were then categorized into normal and anemic using the 
following cutoff values: 11.0 for pregnant females and children 
below 5 years, 11.5 for children 5 to 11 years, 12.0 for children 
12 to 14 years and other females 15 years and above, and 13.0 
for males 15 years and above. These WHO hemoglobin refer-
ence ranges used to define anemia may not be representative 
of African populations, as previously reported [9, 10], because 
they are based on western population data. We therefore ana-
lyzed hemoglobin both as a continuous variable and as catego-
rized into normal and anemic using separate regression models.
Linear regression with bootstrapped confidence intervals 
(CI) was used for antibody levels analysis, because they were 
severely skewed. Logistic regression was used for seropreva-
lence analysis; furthermore, we adjusted for clustering at the 
village level using survey commands. We assessed interaction 
between age and hemoglobin levels, as well as between age and 
anemia, in relation to anti-K8.1 antibody levels, anti-ORF73 
antibody levels, and KSHV prevalence based on a priori suspi-
cions of interaction, using likelihood ratio tests.
RESULTS
The characteristics of the individuals analyzed are shown in 
Supplementary Table 1. We analyzed results from 3149 adults 
and 4134 children. This analysis included children aged 1 
to 17  years and adults aged 18 to 103  years (Supplementary 
Table 1).
Risk Factors for KSHV Prevalence and Antibody Levels Among Adults
KSHV prevalence was 91% in all adults (2871/3149) 
(Supplementary Figure  1). Every 1  g/dL decrease in hemo-
globin values was associated with increased odds of being 
KSHV seropositive (odds ratio [OR]  =  0.86; 95% CI, 0.77–
0.96; P = .006) and anemic individuals were more likely to be 
KSHV seropositive compared to people with normal hemoglo-
bin values, but this association was not statistically significant 
(OR = 1.25; 95% CI, 0.87–1.79; P = .229; Table 1).
We then analyzed antibody levels to K8.1 and ORF73 pro-
teins as continuous variables without categorizing participants 
as seropositive or seronegative. Anemic adults had higher anti-
bodies to ORF73 protein compared to individuals with normal 
hemoglobin values (regression coefficient 0.28; 95% CI, 0.16–
0.39; P <  .0001). Similarly, every 1 g/dL decrease in hemoglo-
bin was associated with an increase in ORF73 antibody optical 
densities (Table  1). The association between hemoglobin and 
antibodies to ORF73 protein was strongest among older people 
(Table  1). Conversely, anti-K8.1 antibody levels were not sig-
nificantly associated with either hemoglobin levels or anemia 
(Table 1). This may be due to the relative abundance of LANA 
compared to late lytic proteins such as K8.1, even during KS 
disease [11].
Compared to HIV-negative adults, HIV-positive adults had 
lower antibodies to KSHV, especially those with CD4 counts 
of 500 cell/μL or less (Table 1). This may be due to B-cell dys-
function caused by HIV infection, and consequent decreased 
antibody responses [12, 13]. On the other hand, HIV-positive 
adults with CD4 counts above 500 cells/μL, compared to HIV-
negative adults, were more likely to be KSHV seropositive 
(Table 1), which may be due to antiretroviral treatment.
Risk Factors for KSHV Prevalence and Antibody Levels Among Children
We then investigated associations between KSHV prevalence 
and antibody levels and risk factors among children. Overall, 
KSHV prevalence was 51% (2117/4134) in the children, the 
prevalence increased with age, rising from 31% among 1–5 year 
olds, to 53% among 6–12 year olds, to 73% among 13–17 year 
olds (Supplementary Figure 1). We first adjusted for HIV status, 
age, and sex, then malaria parasitemia and anemia/hemoglobin 
levels were added in the full models. In the first analysis, hemo-
globin levels, malaria parasitemia, and age were strongly associ-
ated with KSHV prevalence (Table 2). Every 1 g/dL decrease in 
hemoglobin levels increased the odds of being KSHV seroposi-
tive by 11% (P < .0001) and the odds of being KSHV positive if 
anemic compared to normal hemoglobin levels was 1.42 (95% 
CI, 1.18–1.71; P < .0001). The odds of being KSHV seropositive, 
if malaria infected, compared to uninfected was 2.22 (95% CI, 
1.84–2.69; P < .0001) and every annual increase in age was asso-
ciated with a 17% increased risk of being KSHV seropositive 
(Table 2).
After adjusting for malaria parasitemia, the risk of being 
KSHV seropositive for every 1  g/dL decrease in hemoglobin 
reduced to 7% (P =  .005). Similarly, the odds of being KSHV 
seropositive in comparing anemic children to children with 
normal hemoglobin levels reduced to 1.23 (95% CI, 1.01–1.49; 
P  =  .037). After adjusting for hemoglobin levels, the odds 
of being KSHV seropositive comparing children with and 
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without malaria parasitemia changed little (OR = 2.13; 95% CI, 
1.75–2.58; P  <  .0001) (Table  2). Every annual increase in age 
remained strongly associated with increased KSHV prevalence 
risk, OR = 1.18 (P < .0001) even after adjusting for malaria par-
asitemia and hemoglobin (Table 2).
We then finally investigated associations between the same 
risk factors and KSHV antibody levels (optical density) as 
continuous variables without categorizing participants as 
seropositive or seronegative. Only malaria parasitemia was as-
sociated with both anti-K8.1 and anti-ORF73 antibody levels in 
the fully multivariate analysis (Table 2).
Discussion
We observed a significant association between hemoglobin lev-
els and KSHV prevalence among children and adults, where 
people with low levels of hemoglobin were more likely to be 
Table 1. Risk Factors for KSHV Prevalence and Antibody Levels Among Adults Aged 18 to 103 Years
Risk Factors for KSHV Prevalence
Risk Factor KSHV Prevalence Adjusted a OR (95% CI) P Value
Age 1.01 (1.003–1.02) .010
Sex
Males 94% (1218/1297) 1
Females 89% (1653/1852) 0.61 (0.46–0.80) .001
HIV and CD4 count status
(−) CD4 count unknown 92% (2615/2841) 1
(+) CD4 count > 500 cells/μL 70% (32/46) 0.16 (0.10–0.26) <.0001
(+) CD4 count ≤ 500 cells/μL 90% (76/84) 0.61 (0.16–2.36) .451
(+) CD4 count unknown 83% (146/175) 0.53 (0.29–0.96) .039
Hemoglobin levelsb 0.86 (0.77–0.96) .006
Anemiac
Normal 91% (2153/2370) 1
Anemic 92% (718/779) 1.25 (0.87–1.79) .229
Risk Factors for Anti-K8.1 and Anti-ORF73 Antibody Levels
Risk Factor K8.1 ORF73
Adjusteda Coef. (95% CI) P Value Adjusteda Coef. (95% CI) P Value
Age 0.004 (0.001–0.007) .015 0.01 (0.007–0.013) <.0001
Sex
Males Ref
Females −0.25 (−0.35 to −0.14) <.0001 −0.24 (−0.34 to −0.14) <.0001
HIV and CD4 count status
 (−) CD4 count unknown Ref Ref
(+) CD4 count > 500 cells/μL −0.77 (−1.21 to −0.33) .001 −0.71 (−1.15 to −0.29) .001
(+) CD4 count ≤ 500 cells/μL −0.33 (−0.64 to −0.02) .036 −0.48 (−0.79 to −0.17) .003
(+) CD4 count unknown −0.28 (−0.51 to −0.06) .014 −0.38 (−0.59 to −0.16) .001
Hemoglobin levelsb −0.03 (−0.06 to 0.01) .119
Anemiac
Normal Ref
Anemic 0.007 (−0.11 to 0.13) .910 0.28 (0.16–0.39) <.0001
Age Group Specific Association Between Anti-ORF73 Antibody Levels and Hemoglobin Levels
Age Group, years Adjusteda Coef. (95% CI) P Value Interaction P Value
Hemoglobin levelsb 18–24 −0.09 (−0.16 to 0.02) .009
25–44 −0.08 (−0.12 to 0.03) .001
45–103 −0.17 (−0.21 to 0.12) <.0001 .007
Anti-K8.1 and anti-ORF73 antibody levels (measured as optical density) were obtained from enzyme-linked immunosorbent assay. KSHV seropositivity was defined as reactivity to either 
K8.1 or ORF73 antigens. Logistic regression, allowing for the survey design, was used for statistical analysis of risk factors for KSHV prevalence. Linear regression with bootstrapped con-
fidence intervals was used for statistical analysis of risk factors for antibody levels. Age group specific associations between ORF73 antibody levels and hemoglobin levels were reported 
due to interaction between age and hemoglobin levels. 
Abbreviations: Coef., regression coefficient; CI, confidence interval; KSHV, Kaposi sarcoma-associated herpesvirus; OR, odds ratio.
aAdjusted for age, sex, HIV status, and household socioeconomic status. 
bHemoglobin levels were mean (13.7 g/dL) centered. 
cHemoglobin levels were altitude adjusted and categorized into normal and anemic following World Health Organization guidelines. 
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KSHV seropositive. As a categorical variable, anemia was asso-
ciated with KSHV prevalence among children. Reduction in he-
moglobin has been shown to cause hypoxia/low tissue oxygen, 
while hypoxia has been shown to reactivate KSHV in vitro [4]. 
We therefore hypothesize that a low hemoglobin level leads to 
reactivation of KSHV through hypoxia. Increased reactivation 
may help spread the virus during initial infection. Alternately, 
hypoxia may enhance initial infection of cells, possibly through 
upregulation of the replication and transcription activator [14]. 
In this cross-sectional study, we did not directly measure KSHV 
reactivation or KSHV viral load in blood or plasma, although 
antibody levels may be viewed as a surrogate marker for fre-
quent reactivation. The connection between KSHV reactiva-
tion, hypoxia, and anemia requires further investigation.
We showed that children infected with malaria are more likely 
to be KSHV seropositive. Additionally, the effect of anemia and/
Table 2. Risk Factors for KSHV Prevalence and Antibody Levels Among Children Aged 1 to 17 years
Risk Factors for KSHV Prevalence
Adjusteda Adjustedb
Risk Factor (n) KSHV Prevalence OR (95% CI) P Value OR (95% CI) P Value
Hemoglobin levels 
(3199)c
0.89 (0.84–0.93) <.0001 0.93 (0.88–0.98) .005
Anemiad
Normal 44% (1143/2584) 1
Anemic 48% (294/615) 1.42 (1.18–1.71) <.0001 1.23 (1.01–1.49) .037
Malaria
Negative 41% (1088/2630) 1 1
Positive 61% (348/569) 2.22 (1.84–2.69) <.0001 2.13 (1.75–2.58) <.0001
Age (4134) 1.17 (1.15–1.18) <.0001 1.18 (1.15–1.21) <.0001
Sex
Boys 52% (1076/2061) 1 1
Girls 50% (1041/2073) 0.93 (0.82–1.07) .27 0.94 (0.82–1.07) .33
HIV
Negative 53% (2030/3812) 1 1
Positive 40% (19/48) 0.49 (0.25–0.96) .04 0.55 (0.30–1.03) .06
Risk Factors for Antibody Levels
K8.1 ORF73
Adjusteda Adjustedb Adjusteda Adjustedb
Risk factor (n) Coef. (95% CI) P value Coef. (95% CI) P value Coef. (95% CI) P value Coef. (95% CI) P value
Malaria
Negative (2630) ref ref ref ref
Positive (569) 0.27 (0.18–0.38) <.0001 0.26 (0.16–0.37) <.0001 0.30 (0.21–0.38) <.0001 0.26 (0.18–0.34) <.0001
Age (4134) 0.08 (0.07–0.09) <.0001 0.1 (0.08–0.11) <.0001 0.06 (0.05–0.07) <.0001 0.05 (0.04–0.06) <.0001
Hemoglobin levels 
(3199)c
−0.04 (−0.06 to −0.01) .003 −0.02 (−0.05 to 0.01) .2 −0.03 (−0.06 to −0.01) .001 −0.02 (−0.04 to 0.005) .13
Anemiad
Normal ref ref ref ref
Anemic 0.04 (−0.05 to 0.13) .414 −0.02 (−0.12 to 0.07) .649 0.12 (0.05–0.19) .001 0.07 (−0.01 to 0.14) .073
Sex
Boys (2061) ref ref ref ref
Girls (2073) −0.05 (−0.11 to 0.02) .17 −0.01 (−0.09 to 0.06) .75 0.01 (−0.04 to 0.07) .63 −0.01 (−0.07 to 0.05) .66
HIV
Negative (3808) ref ref ref ref
Positive (270) −0.24 (−0.56 to 0.07) .13 −0.12 (−0.48 to 0.24) .5 0.20 (−0.17 to 0.57) .29 0.29 (−0.13 to 0.72) .18
Logistic regression, allowing for survey design, was used for statistical analysis of risk factors and KSHV prevalence. Linear regression with bootstrapped confidence interval used in the 
analysis of risk factors for KSHV antibody levels. ORF73 and K8.1 antibody levels (measured as optical density) were obtained from enzyme-linked immunosorbent assay. KSHV prevalence 
defined as antibody reactivity to either K8.1 or ORF73 antigens. HIV status obtained using rapid diagnostic tests. Malaria parasitemia determined using rapid diagnostic tests. 
Abbreviations: Coef., regression coefficient; CI, confidence interval; KSHV, Kaposi sarcoma-associated herpesvirus; OR, odds ratio.
aAdjusted for age, sex, and HIV status.
 bAdjusted for age, sex, HIV status, hemoglobin, and malaria parasitemia. 
cHemoglobin levels were mean (13.0 g/dL) centered.
dHemoglobin levels were altitude adjusted and categorized into normal and anemic following World Health Organization guidelines. 
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or hemoglobin levels on KSHV prevalence and antibody lev-
els reduced to about 50% after adjusting for malaria infection. 
Malaria causes anemia, and in part the anemia effect in children 
could be explained (confounded) by malaria infection. The con-
sistent association between malaria infection and KSHV prev-
alence suggests malaria may be driving KSHV transmission in 
malaria endemic areas. This might imply that exposure to malaria 
significantly impacts on KSHV reactivation, which might also 
have long-lasting effects. The mechanism through which malaria 
may reactivate KSHV requires further investigation.
Findings from this study suggest malaria infection as a risk 
factor for KSHV prevalence. Malaria-associated anemia is one 
mechanism that likely contributes to this association but can-
not entirely explain it. In KSHV and malaria endemic areas, a 
number of other parasite coinfections such as helminths, which 
cause anemia and/or immunomodulation are common. The 
role of multiple parasitic infections and KSHV transmission 
and pathogenesis warrants further careful study.
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Supplementary Figure 1: KSHV prevalence and 95% confidence intervals across ages 1 to 103 years 
among individuals from the General Population Cohort in south-western Uganda. KSHV Seropositivity 
defined as antibody reactivity to either K8.1 or ORF73 antigens. Anti-K8.1 and anti-ORF antibodies 
detected using ELISA 
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 Supplementary Table 1: General Population Cohort characteristics from the calendar years 
2014 to 2016 
Children (25th survey, carried out in 2016) 
Age groups (years) 
1 – 5 
6 – 12 
13 – 17 
 
28% (1148/4134) 
49% (2040/4134) 
23% (946/4134) 
Sex  
Males 
 
50% (2061/4134) 
Haemoglobin levels, mean (range) 13.0 (3.7, 21.8) g/dL 
Anaemiaa 
Normal 
Anaemic 
 
81% (2584/3199) 
19% (615/3199) 
HIV prevalence 1% (48/3860) 
Malaria parasitaemia 18% (569/3199) 
Adults (24th survey, carried out in 2014 and 2015) 
Age groups 
18 – 24 
24 - 44 
45 - 103 
 
21% (666/3149) 
40% (1265/3149) 
39% (1218/3149) 
Sex 
Males 
 
41% (1297/3149) 
Haemoglobin levels, mean (range) 13.7 (2.8, 21.1) g/dL 
Anaemiaa 
Normal 
Anaemic 
 
75% (2370/3149) 
25% (779/3149) 
HIV prevalence 9.7% (305/3146) 
Proportions were determined using survey commands. ahaemoglobin levels were altitude adjusted 
and categorised into normal and anaemic following 2011 WHO guidelines. 
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 Chapter Four - additional results: KSHV seropositivity in children 
including those aged below one year 
 
All the seropositivity and antibody data shown in this thesis excluded children below one 
year of age. This was because in those below one-year maternal IgG antibodies were likely 
to be present, confounding the data (Figure 1). 
 
 
Figure 1: KSHV seropositivity and 95% confidence intervals among individuals from the General 
Population Cohort (GPC) including those below one year of age. Seropositivity determined from IgG 
antibody to K8.1 and ORF73 measurement using ELISA. Data analysis was done in STATA adjusting 
for survey design.  
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Chapter Five: Kaposi’s sarcoma-associated herpesvirus 
prevalence and parasite infections in Ugandan fishing 
communities on Lake Victoria islands  
 
Preamble 
 
KSHV prevalence varies even within small geographical areas. Lake Victoria fishing villages 
have a high prevalence of both HIV and Schistosoma mansoni infection. The prevalence of 
KSHV and its associated risk factors in these areas have not been determined before. 
Previously, in vitro studies showed reactivation of KSHV by S. mansoni. We aimed to 
determine the prevalence of KSHV in the Lake Victoria island communities of Uganda. We 
also aimed to determine the effect of S. mansoni and other parasitic infections, including 
malaria, on KSHV seropositivity and antibody levels. Using a well-established community-
based cohort we planned to ascertain the effect of intensive vs. standard anti-helminthic 
treatment on KSHV antibody levels.  
 
S. masoni infection was associated with KSHV seropositivity at both baseline and after three 
years of anti-helminthic treatment. Among other parasitic infections, malaria was associated 
with KSHV seropositivity after three years of anti-helminthic treatment. We did not observe 
any effect of intensive vs. standard anti-helminthic treatment on KSHV antibody levels. 
These data have been submitted to PLOS Neglected Tropical Diseases. 
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 Kaposi’s sarcoma-associated herpesvirus prevalence is associated 
with helminth infections in Ugandan fishing communities on Lake 
Victoria islands  
 
Angela Nalwoga1,2, Emily L Webb2, Belinda Chihota2, Wendell Miley3, Bridgious Walusimbi1, 
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Abstract 
 
We investigated the impact of helminths and malaria infection on Kaposi’s sarcoma 
associated herpesvirus (KSHV) seroprevalence, using samples and data collected from a 
cluster-randomised trial of intensive versus standard anthelminthic treatment. The trial was 
carried out among fishing communities on Lake Victoria islands in Uganda. Plasma samples 
from 1571 participants in a household survey, collected after three years of the trial 
intervention, were tested for KSHV IgG antibody responses using ELISA. Infection by 
helminths (S. mansoni, N. americanus, T. trichiura and S. stercoralis) was diagnosed using 
real time PCR, urine circulating cathodic antigen (CCA) and stool microscopy (Kato-Katz 
method) while malaria infection was diagnosed using microscopy. We analysed the 
relationship between helminth and malaria infections and KSHV seropositivity using 
regression modelling, allowing for survey design.  
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Around half of the participants were male (48%) and the median age was 24 years. The 
most prevalent helminth infection was S. mansoni (34% by microscopy 86% by CCA and 
50% by PCR). KSHV seropositivity was 56% among those 1-12 years and >80% in those 
13+ years; malaria parasitaemia prevalence was 4%. Among the infections tested, S. 
mansoni (by microscopy, adjusted Odds Ratio (aOR=1.43 (1.04 -1.95), p=0.028) and 
malaria parasitaemia (aOR=3.49 (1.08 – 11.28), p=0.038) were positively associated with 
KSHV seroprevalence. Additionally, KSHV seropositive participants had higher S. mansoni-
specific IgE and IgG antibody concentrations in plasma.  
 
Schistosoma species skew the immune response towards Th2 and regulatory responses, 
which could impact on an individual’s susceptibility to KSHV and its reactivation if co-
infected with both organisms.  
 
Keywords: Kaposi's sarcoma associated herpesvirus (KSHV), Schistosoma mansoni, 
malaria parasitaemia, Lake Victoria islands, Uganda  
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Author summary 
Kaposi's sarcoma associated herpesvirus (KSHV) the causative agent of Kaposi's sarcoma 
cancer varies geographically. KSHV infections tend to spread the highest in sub-Saharan 
Africa with Uganda having the highest occurrence of the infection reported. Infection with 
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 KSHV is lifelong with an intermittent revival of the virus leading to viral spread. In this study, 
we show that infection with Schistosoma mansoni and malaria parasites is associated with 
being infected or exposed to KSHV. These parasite infections interfere with the proper 
functioning of the immune system to control viral infections. This might lead to the revival of 
KSHV in infected people or make uninfected children susceptible to infection, hence 
increasing the spread of KSHV in sub Saharan Africa.   
Introduction 
 
The prevalence of Kaposi's sarcoma associated herpesvirus (KSHV), also known as human 
herpesvirus 8 (HHV8), varies geographically, unlike that of other herpesviruses which are 
ubiquitous [1-3]. Uganda has a high prevalence of KSHV [4, 5] and a high incidence of 
Kaposi’s sarcoma (KS) [6, 7]. The incidence of KS rises dramatically among 
immunocompromised individuals [8-10]; immunosuppression has been implicated in the 
reactivation of KSHV and the progression of KS [9, 11].  
 
Co-infection with helminths has been shown to modulate immune responses to other 
infections and vaccines [12-14]. Chronic infection with Schistosoma is characterised by the 
production of IL4, IL5 and IL13 cytokines, typical of a T helper (Th) type 2  response and 
IL10, a regulatory cytokine [15, 16]. The skewed immune response to a Th2 and regulatory 
response may impair the T helper  (Th) 1 response, vital for control of viral infections  [17-
19]. The impact of Schistosoma co-infection on herpesviruses and other viruses has been 
demonstrated in animal models where Schistosoma mansoni infection led to IL4-mediated 
reactivation of murine herpesvirus 68 and M2 macrophage polarization [17, 18].  
 
Our group has documented associations between KSHV antibodies and parasite infections 
including P. falciparum and helminths (hookworm and Mansonella perstans) in rural [4] and 
peri-urban [20-22] populations in Uganda. Lake Victoria island communities in East Africa 
are characterised by poor sanitation and a high prevalence of infectious diseases, including 
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 schistosomiasis [23-26]. No study to date has documented the burden of KSHV or KS in 
these unique communities. Therefore, this study aimed to determine the seropositivity of 
KSHV in the Lake Victoria island communities of Koome sub-county, Uganda and the 
association between KSHV seropositivity and parasite co-infections. 
 
Methods 
 
Study population, participant selection and ethical approval 
 
This cross-sectional study used samples from an open cluster-randomised trial of intensive 
versus standard anthelminthic treatment, the Lake Victoria Island Intervention Study on 
Worms and Allergy-related diseases (LaVIISWA) (ISRCTN47196031) [29]. The study was 
carried out in the Lake Victoria island communities of Koome sub-county, Mukono district, 
Uganda. Twenty-six island villages were included in the trial. These 26 villages were 
randomised to receive either standard or intensive anthelminthic treatment, with 13 villages 
in each trial arm [29, 30]. After three years of the intervention, a household survey was 
conducted, which involved selecting a random sample of 70 households per village and 
inviting all residents of selected households to participate. Data on socio-demographic 
characteristics were collected, clinical examinations were performed, and blood and stool 
samples were taken. A total of 1571 plasma samples from the survey were selected 
randomly for this analysis. Ethical approvals were obtained from the Uganda Virus Research 
Institute Research and Ethics Committee (reference number: GC/127/17/04/317), the 
Uganda National Council for Science and Technology (reference number: HS1183) and the 
London School of Hygiene & Tropical Medicine Research and Ethics committee (reference 
number: 9917-9). Written informed consent was obtained from all adults aged 18 years and 
above. Children below 18 years were consented into the study by their parents or guardians; 
we also sought, in addition to parental consent, written assent from children aged between 
8-17 years. 
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Serology  
 
IgG antibodies to K8.1 and ORF73 antigens were measured using ELISA to determine 
KSHV seroprevalence, as previously described [30]. Each plate contained three negative 
and positive controls. The negative controls were used to determine the cut-off value. 
Seropositivity was defined as reactivity to either K8.1 or ORF73 antigens or both. IgE, IgG 
(all subclasses) and IgG4 antibody concentrations to Schistosoma mansoni Egg Antigen 
(SEA) and Schistosoma mansoni adult Worm Antigen (SWA) were measured using ELISA. 
Antigen concentrations of 8 g/mL (SWA) and 2.4 g/mL (SEA) plus sample dilutions of 1/20 
(IgE), 1/200 (IgG4) and 1/3000 (IgG) were used, as previously reported [14, 31, 32]. 
 
Diagnostic testing and socio demographic data collection 
 
Duplicate slides were made from each stool sample and analysed independently by two 
technicians for helminth infection and intensity using the Kato-Katz (KK) method [33]. An 
aliquot of the stool was stored in 70% ethanol and later used to detect helminths by real time 
PCR. The multiplex real time PCR assay was used to detect Necator americanus, 
Strongyloides stercoralis and Schistosoma mansoni as previously described [34, 35]. S. 
mansoni antigens were also tested in urine using the Circulating Cathodic Antigen (CCA) 
kits (Rapid Medical Diagnostics, Pretoria, South Africa) [29]. Mansonella perstans infection 
was detected using the modified Knott’s method [36] and thick blood films were made for 
malaria parasitaemia detection using microscopy. Questionnaires were administered for 
demographic data collection while HIV infection status was determined using rapid HIV 
diagnostic kits following the Uganda national HIV testing algorithm.  
 
Statistical analysis 
 
Statistical analysis was carried out using STATA version 13 (Statacorp, College Station, 
Texas USA). Logistic regression (allowing for the survey design) was used to determine 
associations between risk factors and KSHV seroprevalence.  A p value of less than 5% was 
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 considered statistically significant. Multivariable models included age (grouped), sex, HIV 
status, S. mansoni, hookworm and malaria parasite infection. Participants not tested for HIV 
were also included in the analysis. Observational analyses took into account clustering 
within villages and village-level weights to allow for the different village sizes. [37]. For 
assessing the effect of intensive versus standard treatment, the analysis was done at the 
cluster level. The proportion of KSHV seropositive participants was calculated for each 
village, and the mean of these taken for the two trial arms. The risk ratio (RR) was then 
calculated by dividing the mean KSHV prevalence in the intensive arm by that in the 
standard arm, and a Taylor approximation was used to calculate a 95% confidence interval 
for this RR. The p-value was generated from a t-test comparing the village-level prevalences 
between the two arms. A similar approach was used to assess the effect of intensive versus 
standard treatment on KSHV antibody levels. 
 
Results 
 
Participants Characteristics 
 
A total of 1571 individuals from 26 villages were analysed. The median age was 24 years 
with an interquartile range (IQR) of 9 to 33 years. The overall proportion of males was 48%. 
Details of the socio-demographic characteristics of the study population are shown in Table 
1. Around a quarter of participants (342/1571, 26%), mainly children, were not tested for 
HIV. There were 201 HIV seropositive individuals among 1229 tested (17% prevalence), 
with 103 participants confirmed to be on antiretroviral therapy (ART). Malaria infection 
prevalence was low, at 4% overall, and 8% in children aged 1 to 12 years. Among the 
helminth infections tested, Schistosoma mansoni was the most prevalent, as expected, due 
to the close proximity of the study sites to the waters of Lake Victoria. The prevalence was 
86% by CCA, 50% by PCR and 34% by microscopy (Table 1). Hookworm prevalence was 
2% by microscopy and 8% by PCR. The prevalence of other helminths was 6% for 
Strongyloides stercoralis (using PCR), 9% for Trichuris trichiura (using KK), 0.04% for 
93
 Ascaris lumbricoides (using KK) and 0.9% for Mansonella perstans (Table 1). The majority 
of the infected individuals had light to moderate helminth infections; 8% had a heavy S. 
mansoni infection based on KK (Table 1).  
 
Table 1: Characteristics of the study population 
Factor n=1571 
Age, median and interquartile range 24 (9 – 33) 
Age group, years 
1-12  
13-30 
31-44 
45-72 
 
31% (492/1571) 
39% (596/1571) 
22% (353/1571) 
9% (130/1571) 
Sex (males) 48% (801/1571) 
HIV prevalence  
Overall  
Participants aged 1-12 years 
Participants aged 13-72 years  
 
17% (201/1229) 
2% (6/270) 
21% (195/959) 
ART status 
(+) treated 
(+) untreated 
(+) no treatment status 
 
57% (103/201) 
6% (13/201) 
37% (85/201) 
Malaria infection  
Overall 
Children (1-12 years) 
 
4% (60/1554) 
8% (34/491) 
Schistosoma mansoni prevalence  
KK 
PCR 
CCA 
Schistosoma mansoni intensity KK 
Uninfected  
Light infection 
Moderate 
Heavy 
 
34% (440/1355) 
50% (673/1353) 
86% (1225/1430) 
 
66% (915/1355) 
16% (216/1355) 
10% (119/1355) 
8% (105/1355) 
Necator americanus prevalence PCR 
Hookworm prevalence KK 
8% (120/1353) 
2% (30/1355) 
Strongyloides stercoralis prevalence 
PCR 
6% (98/1353) 
Trichuris trichiura prevalence KK 9% (135/1355) 
Ascaris lumbricoides prevalence KK 0.04% (8/1355) 
Mansonella perstans prevalence  0.9% (14/1567) 
Proportions were weighted to allow for the survey design. Helminths infection status and were 
determined from a single stool sample using Kato-Katz (KK) method or PCR (polymerase chain 
reaction) method or both. Rapid tests were used for HIV screening and microscopy was used for 
malaria diagnosis.  
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 KSHV seropositivity  
 
Overall KSHV seropositivity was 75%. The prevalence increased steeply with age (overall 
p<0.0001), rising from 56% in the 1-12-year age group to 84% in the 13-30-year age group, 
and plateaued thereafter (Figure 1). 
 
 
Figure 1: KSHV seropositivity and 95% confidence intervals (CI) across ages 1 to 72 years. KSHV 
Seropositivity defined as reactivity to either ORF73 or K8.1 proteins. KSHV antibodies were detected 
using ELISA.  Seropositivity and 95% CI were obtained in STATA, allowing for the survey design. 
 
Associations between KSHV seropositivity and risk factors 
 
We investigated associations of KSHV seropositivity with parasite infections and other 
factors. Overall, KSHV prevalence was higher in males compared to females (adjusted Odds 
Ratio (aOR)=1.72 (1.29, 2.30), p=0.001) (Table 2). HIV seropositive individuals on ART were 
less likely to be KSHV seropositive compared to HIV seronegative individuals (Table 2).  
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Table 2: Association between KSHV seropositivity and risk factors  
Factor KSHV prevalence Crude ORa (95% 
CIb) 
P value Adjustedc OR 
(95% CI) 
P value 
Age group (years) 
1-12 
13-30 
31-44 
45-72 
 
56% (289/492) 
84% (511/596) 
81% (294/353) 
89% (113/130) 
 
1 
4.35 (2.80,6.74) 
3.44 (2.28, 5.19) 
6.65 (3.00,14.77) 
 
 
 
 
<0.0001 
 
1 
4.84 (2.92, 8.02) 
4.13 (2.40, 7.10) 
7.74 (3.47, 17.27) 
 
 
 
 
<0.0001 
Sex 
Female 
Male 
 
71% (561/770) 
80% (646/801) 
 
1 
1.68 (1.26, 2.25) 
 
 
0.001 
 
1 
1.72 (1.29, 2.30) 
 
 
0.001 
HIV status 
Negative 
(+) treated 
(+) untreated 
(+) no treatment 
status 
Not tested 
 
79% (813/1028) 
70% (71/103) 
76% (10/13) 
85% (73/85) 
 
67% (240/342) 
 
1 
0.64 (0.47, 0.87) 
0.88 (0.22, 3.50) 
1.60 (0.82, 3.11) 
 
0.55 (0.31, 1.00) 
 
 
 
 
 
 
0.002 
 
1 
0.46 (0.30, 0.71) 
0.55 (0.14, 2.16) 
1.22 (0.57, 2.26) 
 
1.05 (0.56, 1.95) 
 
 
 
 
 
 
0.002 
S. mansoni 
Uninfected 
Infected 
 
73% (676/915) 
80% (359/440) 
 
1 
1.55 (1.13, 2.11) 
 
 
0.008 
 
1 
1.43 (1.04, 1.95) 
 
 
0.028 
N. americanus 
Uninfected 
Infected 
 
74% (927/1233) 
86% (106/120) 
 
1 
2.15 (1.18, 3.94) 
 
 
0.015 
 
1 
1.55 (0.86, 2.80) 
 
 
0.136 
T. trichiura 
Uninfected 
Infected 
 
75% (924/1220) 
79% (111/135) 
 
1 
1.25 (0.66, 2.39) 
 
 
0.480 
 
1 
1.60 (0.83, 3.08) 
 
 
0.150 
S. stercoralis 
Uninfected 
Infected 
 
74% (949/1255) 
85% (84/98) 
 
1 
1.82 (0.72, 4.62) 
 
 
0.198 
 
1 
1.03 (0.41, 2.61) 
 
 
0.947 
Malaria  
Negative 
Positive 
 
75% (1142/1494) 
84% (50/60) 
 
1 
1.76 (0.81, 3.82) 
 
 
0.144 
 
1 
3.49 (1.08, 11.28) 
 
 
0.038 
Seropositivity defined as reactivity to either ORF73 or K8.1 proteins. KSHV antibodies were detected 
using ELISA. Rapid tests were used to determine HIV status. Statistical analysis was performed using 
logistic regression, allowing for the survey design. Schistosoma mansoni and Trichuris trichiura 
infections were determined from a single stool sample using the Kato-Katz method. Necator 
americanus and Strongyloides stercoralis infections determined using PCR (polymerase chain 
reaction) method. aOR: odds ratios. bCI: Confidence Intervals. c adjusted for age, sex, HIV status, S. 
mansoni, N. americanus and malaria parasitaemia.  
 
Although hookworm infection was positively associated with KSHV seropositivity in the 
unadjusted analysis (OR=2.15 (1.18, 3.94), p=0.015), this association was lost after 
adjusting for age group, sex, HIV serostatus, S. mansoni infection status and malaria 
infection status (Table 2). Helminth infections including Trichuris trichiura and Strongyloides 
stercoralis showed no association with KSHV seropositivity (Table 2). Other helminth 
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 infections such as Ascaris lumbricoides and Mansonella perstans were not analysed using 
regression modelling due to the small numbers of infected participants. 
 
Individuals with S. mansoni based on microscopy (aOR=1.43 (1.04, 1.95), p=0.028) or 
malaria parasite (aOR=3.49 (1.08, 11.28), p=0.038) infections were more likely to be KSHV 
seropositive (Table 2). The seropositivity of KSHV among individuals heavily infected with S. 
mansoni was 82% compared to 80% among lightly or moderately infected individuals, and 
73% among uninfected individuals, although evidence for an increasing prevalence with 
increasing intensity was borderline after adjusting for possible confounders (P value for 
trend=0.068) (Table 3). We did not observe significant associations between S. mansoni 
detected by CCA or PCR and KSHV seropositivity (Supplementary Table 1). There was no 
effect of intensive versus standard anthelminthic treatment on either KSHV seropositivity or 
antibody levels (Table 4).  
 
Table 3: Associations between KSHV seropositivity and S. mansoni infection intensity  
Risk factor  KSHV 
seropositivity  
Univariate Age, sex, HIV, N. americanus and 
malaria adjusted 
 OR (95% CI) P value  OR (95% CI) P value 
S. mansoni 
intensity 
Uninfected 
Light  
Moderate 
Heavy 
 
 
73% (676/915) 
80% (173/216) 
80% (99/119) 
82% (87/105) 
 
 
1 
1.53 (1.14, 2.05) 
1.48 (0.94, 2.33) 
1.68 (0.71, 3.98) 
 
 
 
 
0.049 
trend 
 
 
1 
1.38 (0.98, 1.93) 
1.29 (0.79, 2.11) 
1.74 (0.69, 4.36) 
 
 
 
 
0.068 
trend 
KSHV Seropositivity defined reactivity to either ORF73 or K8.1 proteins. KSHV antibodies detected 
using ELISA. OR: odds ratios. Schistosoma mansoni was determined from a single stool sample 
using the Kato-Katz method. Statistical analysis was performed using logistic regression, allowing for 
the survey design.  
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 Table 4:  Effect of anti-helminthic treatment on KSHV seropositivity and antibody levels  
  KSHV seroprevalence K8.1 ORF73 
 KSHV 
seroprevalence 
Crude 
RRa (95% 
CIb) 
P 
value 
Adjusted 
RR (95% 
CI) 
P 
value 
Crude 
diffc 
(95% CI) 
P 
value 
Adjusted diff 
(95% CI) 
P 
value 
Crude diff   
(95% CI) 
P 
value 
Adjusted diff  
(95% CI) 
P 
value 
Trial arm 
Standard 
Intensive 
 
78% (550/710) 
77% (657/861) 
 
1 
0.99  
(0.92, 
1.05) 
 
 
0.690 
 
1 
1.00  
(0.93, 
1.07) 
 
 
0.925 
 
Ref 
0.03  
(-0.09, 
0.15) 
 
 
0.644 
 
Ref 
-0.06  
(-0.18, 0.67) 
 
 
0.352 
 
Ref 
0.06  
(-0.06, 
0.15) 
 
 
0.312 
 
Ref 
-0.08 
(-0.22, 0.06) 
 
 
0.228 
KSHV Seropositivity defined as reactivity to either ORF73 or K8.1 proteins. KSHV antibodies were detected using ELISA. aRR: risk ratio. bCI: Confidence 
Interval. cDiff: difference.  Adjusted for sex, age group and HIV status. 
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 Associations between KSHV seropositivity and Schistosoma mansoni antibody 
concentrations 
 
IgE (n=364), IgG (n=372) and IgG4 (n=370) antibody concentrations against S. mansoni egg 
and adult worm antigens were measured in a subset of individuals with sufficient plasma for 
the analysis. Participants whose samples were used for this analysis were on average older 
than participants whose samples were not used; other participant characteristics were 
comparable (Supplementary Table 2). After adjusting for age group, sex and HIV status, 
increased levels of IgE to SWA (aOR=55.03 (3.14, 963.65), p=0.008) and SEA (aOR=8.20 
(1.53, 44.05), p=0.016) as well as IgG to SWA (aOR=4.22 (0.98, 18.18) p=0.053) and SEA 
(aOR=2.57 (1.17, 5.68), p=0.02) were associated with an increased risk of being KSHV 
seropositive (Table 5).  
 
Table 5: Associations between KSHV seropositivity and Schistosoma mansoni antibody 
concentrations  
Antibody type  Univariate Age, sex and HIV adjusted 
OR (95% CI) P 
value 
OR (95% CI) P value 
IgE to SEA  (n=364) 7.57 (1.54, 37.20) 0.015 8.20 (1.53, 44.05) 0.016 
IgE to SWA (n=364) 83.03 (4.69, 1470.38) 0.004 55.03 (3.14, 963.65) 0.008 
IgG to SEA (n=372) 3.03 (1.19, 7.77) 0.023 2.57 (1.17, 5.68) 0.021 
IgG to SWA (n=372) 6.99 (1.24, 39.49) 0.029 4.22 (0.98, 18.18) 0.053 
IgG4 to SEA (n=370) 1.30 (1.03, 1.62) 0.026 1.23 (0.96, 11.58) 0.097 
IgG4 to SWA (n=370) 1.37 (0.96, 1.97) 0.080 1.18(0.82, 1.71) 0.362 
KSHV Seropositivity defined reactivity to either ORF73 or K8.1 proteins. KSHV and Schistosoma 
mansoni antibodies detected using ELISA, measured in ng/mL and converted to g/mL. OR: odds 
ratios per unit increase in antibody level. Statistical analysis was performed using logistic regression, 
allowing for the survey design. SEA: Schistosoma mansoni Egg Antigen; SWA: Schistosoma mansoni 
Worm antigen. Ig: Immunoglobuline 
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 Discussion  
 
KSHV prevalence can vary, even between geographically proximate areas [3]. We have 
previously reported a high KSHV prevalence of >95% in adults in the General Population 
Cohort in rural southwestern Uganda [5] But a lower prevalence of 61% amongst mothers in 
a peri-urban cohort [38]. This study shows high seropositivity of KSHV (>80% in 13+-year-
olds) amongst Lake Victoria island communities with seropositive participants as young as 
one year. Additionally, we show that males were more likely to be KSHV seropositive 
compared to females. These findings are similar to those documented in other studies 
carried out in sub-Saharan Africa [4, 5, 39].  
 
HIV prevalence in the studied communities was very high (17%). We observed a lower risk 
of being KSHV seropositive among individuals treated for HIV compared to HIV negative 
individuals. ART has been shown to lead to tumour regression among AIDS-KS patients [40-
42]. This tumour regression has mainly been attributed to the reduction in the HIV load and 
the reconstitution of immune function [43]. Results from the current study, however, show an 
association between HIV treatment and lower KSHV prevalence. Additionally, others have 
shown a decline in KSHV viral load following HAART initiation [44, 45]. Since our study was 
cross-sectional however the interpretation of these data is difficult and the finding should be 
treated with caution. 
 
The high untreated HIV prevalence coupled with other factors including parasite infections 
may contribute to the high prevalence of KSHV in this area. The burden of S. mansoni in 
these island communities is very high. Here we show that being infected with S. mansoni is 
associated with an increased risk of being KSHV seropositive. These results suggest a role 
for S. mansoni in KSHV transmission, which requires further investigation. Others have 
reported no association between S. mansoni and KSHV infections, possibly due to the low 
prevalence of KSHV or S. mansoni in the study areas [46, 47]. In vitro reactivation of the 
model gammaherpesvirus, MHV68 by S. mansoni was demonstrated by Reese et al., 
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 mediated through IL4 production [18]. Our human data are consistent with this model, as we 
observed an association with S. mansoni and KSHV seroprevalence. We also show that 
increasing IgE and IgG but not IgG4 antibodies to S. mansoni are associated with an 
increased risk of being KSHV seropositive. This would then suggest that S. mansoni, 
through IL-4 upregulation, may reactivate KSHV latently infected cells, or render KSHV 
uninfected individuals susceptible to infection, both of which can lead to increased 
transmission of the virus.  
 
The association between S. mansoni and KSHV seropositivity was only observed if S. 
mansoni was detected using microscopy (KK) but not PCR or CCA, in this study. This might 
be attributed to the specificity and sensitivity of the three tests. KK might have detected only 
heavier infections compared to PCR, whereas CCA had very few negative samples for 
comparison. We did not see any effect of intensive versus standard anthelminthic treatment 
on KSHV seroprevalence, not surprisingly as such an intervention could only possibly affect 
incident but not the prevalent infection.  
 
We also found malaria parasitemia to be associated with KSHV seroprevalence, consistent 
with our previous findings [4, 21], and these data reinforce the need to investigate the 
mechanism through which malaria infection impacts on KSHV and its subsequent role in 
KSHV transmission. Infection with Plasmodium falciparum, the main cause of malaria 
disease in Africa, induces inflammation which is normally regulated through induction of 
regulatory T cells and production of IL10 and TGF- Increased IL10 levels, a cytokine 
mainly produced by regulatory cells, has been reported in disseminated KS [48]. Plasmodia 
have also been shown to cause macrophage and dendritic cell dysfunction [49]. The 
immunosuppression caused by P. falciparum infection has also been shown to lead to the 
reactivation of some herpesviruses such as EBV, HSV-1 and VZV [50-54]. We, therefore, 
hypothesize that the immune dysregulation caused by malaria infection contributes to 
frequent reactivation of KSHV from latency. Since KSHV is transmitted by salivary exchange 
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 [3, 55, 56], studies examining parasite co-infections and KSHV viral load in saliva are 
warranted.  
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 Chapter Five supplementary material  
 
Supplementary Table 1: Association between KSHV seropositivity and S. mansoni infection 
detected using PCR and CCA method. 
Risk factor  KSHV 
seroprevalence 
Crude Age, sex, HIV,   
N. americanus and malaria 
adjusted  
OR (95% CI) P 
value 
OR (95% CI) P value 
S. mansoni 
(CCA) 
Uninfected 
Infected 
 
 
80% (160/205) 
76% (955/1225) 
 
 
1 
0.82 (0.50, 1.33) 
 
 
 
0.402 
 
 
1 
0.87 (0.46, 1.65) 
 
 
 
0.654 
S.mansoni 
(PCR) 
Uninfected 
Infected 
 
 
73% (501/680) 
77% (532/673) 
 
 
1 
1.25 (0.97, 1.63) 
 
 
 
0.083 
 
 
1 
1.16 (0.84, 1.62) 
 
 
 
0.351 
KSHV seropositivity defined reactivity to either ORF73 or K8.1 proteins. KSHV antibodies detected 
using ELISA. OR: odds ratios. PCR (polymerase chain reaction), CCA (circulating cathodic antigen). 
Statistical analysis was performed using logistic regression, allowing for the survey design. 
 
Supplementary Table 2: Infection status and study characteristics of participants tested for 
Schistosoma mansoni antibody responses compared to those not tested. 
 Tested 
(n=372) 
Not tested 
(n=1199) 
P value 
Age groups 
1-12 
13-30 
31-44 
45-72 
 
14% 
52% 
23% 
11% 
 
36% 
35% 
22% 
8% 
 
 
 
 
<0.0001 
Sex 
Male 
 
44% 
 
49% 
 
0.053 
HIV prevalence 17% 17% 0.914 
Malaria parasitaemia 4% 4% 0.515 
Schistosoma mansoni KK 16% 17% 0.858 
P value obtained from a Chi2 test, allowing for the survey design. 
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 Chapter Five - additional results: KSHV seropositivity and 
associated risk factors at baseline, before anti-helminthic treatment 
 
KSHV prevalence was high, at 70% among children aged 1-12 years and 93% among those 
aged 31 to 44 years (Figure 1), even prior to helminths treatment.  HIV prevalence was 13%, 
while malaria parasitaemia was 14%. S. mansoni was the most prevalent helminth/parasite 
at 52% by Kato Katz (KK) and 72% by circulating cathodic antigen (CCA) (Table 1).  Similar 
to what we observed after three years of helminths treatment, infection with S. mansoni 
(ascertained by KK) was associated with an increased KSHV prevalence (Table 2) and 
increased S. mansoni intensity was associated with an increased risk of being KSHV 
seropositive (Table 3). S. mansoni infection (detected by CCA) was not associated with 
KSHV seropositivity (Table 4).  
 
Additional results Figure 1: KSHV seropositivity at baseline. KSHV seropositivity and 95% 
confidence intervals (CI) across ages 1 to 74 years. KSHV Seropositivity defined as reactivity to 
either ORF73 or K8.1 proteins. KSHV antibodies were detected using ELISA.  Seropositivity and 95% 
CI were obtained in STATA, allowing for the survey design. 
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 Additional results Table 1: Characteristics of the study population at baseline 
Factor N=1310 
Age, median and interquartile range 25 (3 – 33) 
Age group, years 
1-12  
13-30 
31-44 
45-74 
 
29% (362/1308) 
40% (546/1308) 
24% (319/1308) 
7% (130/1308) 
Sex (males) 56% (744/1310) 
HIV prevalence  
Overall  
Participants aged 1-12 years 
Participants aged 13-74 years  
 
13% (145/1150) 
0.04% (1/288) 
17% (144/862) 
Malaria infection  
Overall 
Children (1-12 years) 
 
7% (92/1307) 
14% (51/361) 
Schistosoma mansoni prevalence  
KK 
CCA 
Schistosoma mansoni intensity KK 
Uninfected  
Light infection 
Moderate 
Heavy 
 
52% (606/1137) 
72% (414/569) 
 
48% (531/1137) 
20% (238/1137) 
15% (183/1137) 
16% (185/1137) 
Necator americanus prevalence PCR 
Hookworm prevalence KK 
26% (295/1136) 
7% (82/1137) 
Strongyloides stercoralis prevalence 
PCR 
14% (176/1136) 
Trichuris trichiura prevalence KK 11% (148/1137) 
Ascaris lumbricoides prevalence KK 0.1% (15/1137) 
Mansonella perstans prevalence  3% (37/1296) 
Proportions were weighted to allow for the survey design. Helminths infection status and were 
determined from a single stool sample using Kato-Katz (KK) method or PCR (polymerase chain 
reaction) method or both. Rapid tests were used for HIV screening and microscopy was used for 
malaria diagnosis.  
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 Additional results Table 2: Association between KSHV seropositivity and risk factors at 
baseline 
Factor KSHV 
prevalence 
Crude ORa (95% 
CIb) 
P value Adjustedc OR 
(95% CI) 
P value 
Age group (years) 
1-12 
13-30 
31-44 
45-74 
 
66% (236/362) 
90% (490/546) 
93% (290/319) 
90% (74/81) 
 
1 
4.65 (2.88,7.52) 
6.50 (3.16, 13.36) 
4.21 (1.41,12.57) 
 
 
 
 
<0.0001 
 
1 
5.14 (2.92, 9.05) 
7.59 (3.31, 17.40) 
6.29 (2.54, 15.58) 
 
 
 
 
<0.0001 
Sex 
Female 
Male 
 
81% (450/566) 
86% (641/744) 
 
1 
1.41 (1.03, 1.94) 
 
 
0.035 
 
1 
1.01 (0.63, 1.59) 
 
 
0.980 
HIV status 
Negative 
Positive 
 
84% (846/1005) 
89% (126/145) 
 
1 
0.65 (0.79, 3.45) 
 
 
0.170 
 
1 
0.72 (0.36, 1.47) 
 
 
0.357 
S. mansoni 
Uninfected 
Infected 
 
77% (410/531) 
89% (533/606) 
 
1 
2.25 (1.45, 3.50) 
 
 
0.001 
 
1 
1.86 (1.16, 2.99) 
 
 
0.012 
N. americanus 
Uninfected 
Infected 
 
82% (684/841) 
86% (258/295) 
 
1 
1.32 (0.92, 1.90) 
 
 
0.125 
 
1 
1.21 (0.68, 2.15) 
 
 
0.499 
T. trichiura 
Uninfected 
Infected 
 
83% (816/989) 
86% (127/148) 
 
1 
1.28 (0.62, 2.67) 
 
 
0.491 
  
S. stercoralis 
Uninfected 
Infected 
 
82% (786/960) 
89% (156/176) 
 
1 
1.77 (1.08, 2.89) 
 
 
0.025 
 
1 
0.92 (0.59, 1.44) 
 
 
0.708 
Malaria  
Negative 
Positive 
 
84% 
(1016/1215) 
80% (72/92) 
 
1 
1.80 (0.51, 1.25) 
 
 
0.310 
 
1 
1.27 (0.69, 2.33) 
 
 
0.428 
Seropositivity defined as reactivity to either ORF73 or K8.1 proteins. KSHV antibodies were detected 
using ELISA. Rapid tests were used to determine HIV status. Statistical analysis was performed using 
logistic regression, allowing for the survey design. Schistosoma mansoni and Trichuris trichiura 
infections were determined from a single stool sample using the Kato-Katz method. Necator 
americanus and Strongyloides stercoralis infections determined using PCR (polymerase chain 
reaction) method. aOR: odds ratios. bCI: Confidence Intervals. c adjusted for age, sex, HIV status, S. 
mansoni, N. americanus and malaria parasitaemia.  
 
Additional results Table 3: Associations between KSHV seropositivity and S. mansoni 
infection intensity at baseline 
Risk factor  KSHV 
seropositivity  
Univariate Age, sex, HIV, N. americanus and 
malaria adjusted 
 OR (95% CI) P value  OR (95% CI) P value 
S. mansoni 
intensity 
Uninfected 
Light  
Moderate 
Heavy 
 
 
77% (410/531) 
87% (203/238) 
91% (163/183) 
88% (167/185) 
 
 
1 
1.91 (0.93, 3.92) 
3.00 (1.42, 6.37) 
2.20 (1.27, 3.81) 
 
 
 
 
<0.0001 
trend 
 
 
1 
1.56 (0.79, 3.08) 
2.76 (1.17, 6.52) 
1.66 (0.84, 3.26) 
 
 
 
 
0.013 
trend 
KSHV Seropositivity defined reactivity to either ORF73 or K8.1 proteins. KSHV antibodies detected 
using ELISA. OR: odds ratios. Schistosoma mansoni was determined from a single stool sample 
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 using the Kato-Katz method. Statistical analysis was performed using logistic regression, allowing for 
the survey design.  
 
Additional results Table 4: Association between KSHV seropositivity and S. mansoni 
infection detected using CCA method  
Risk factor  KSHV 
seropositivity 
Crude Age, sex, HIV,   
N. americanus and malaria 
adjusted  
OR (95% CI) P 
value 
OR (95% CI) P value 
S. mansoni 
(CCA) 
Uninfected 
Infected 
 
85% (132/155) 
84% (344/414) 
 
1 
0.92 (0.56, 1.51) 
 
 
0.722 
 
1 
0.78 (0.38, 1.59) 
 
 
0.401 
KSHV seropositivity defined reactivity to either ORF73 or K8.1 proteins. KSHV antibodies detected 
using ELISA. OR: odds ratios. CCA (circulating cathodic antigen). Statistical analysis was performed 
using logistic regression, allowing for the survey design. 
 
114
 Chapter Six: Risk factors for Kaposi's sarcoma-associated 
herpesvirus (KSHV) DNA in blood and in saliva in rural 
Uganda 
 
Preamble 
 
Increased antibody levels are proxy measures of KSHV reactivation; viral detection in the 
blood is a more direct measure. Viral detection in the blood increases with KS disease 
progression and reduces with tumour regression. In this Chapter, we investigate the pattern 
of KSHV viral detection and levels of DNA in the blood and in saliva across a wide range of 
ages. This was carried out among apparently healthy individuals from rural Uganda where 
KSHV is highly prevalent. Similar data from comparable populations has not been published 
before. The following observations were made from this analysis: 
(1) levels of KSHV DNA in blood did not correlate with levels of DNA in saliva 
(2) viral detection in saliva is more frequent than viral detection in blood 
(3) the frequency of individuals with detectable virus in blood and in saliva was 
highest among children  
(4) increasing levels of KSHV DNA in the blood is associated with malaria 
parasitaemia.  
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Abstract 
Detectable KSHV DNA in blood and increased antibody titres may indicate KSHV 
reactivation, while transmission of KSHV occurs via viral shedding in saliva. We investigated 
risk factors for KSHV DNA detection by real-time PCR, in blood and viral shedding in saliva, 
in 878 people aged 3 to 89 years of both sexes in a rural Ugandan population cohort. 
Helminths were detected using microscopy and malaria parasitaemia was identified using 
rapid diagnostic tests. Regression modelling was used for statistical analysis. 
 
KSHV viral load in blood did not correlate with viral load in saliva, suggesting separate 
immunological control within each compartment. The proportion of individuals with 
detectable virus in blood was 23% among children aged 3-5 years, 22% among 6-12 years 
old, thereafter reducing with increasing age. The proportion of individuals with detectable 
virus in saliva increased from 30% in 3-5-year-old children to 45% in those aged 6-12 and 
decreasing subsequently with increasing age. Overall, 29% of males shed in saliva 
compared to 19% of females  (p = 0.008). Together, these data suggest that young males 
may be responsible for much of the onward transmission of KSHV. Individuals with a current 
malaria infection had higher levels of viral DNA in the blood (p = 0.031) compared to malaria 
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 uninfected individuals. This suggests that malaria may lead to KSHV reactivation, thereby 
increasing transmission and pathogenicity of the virus.  
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Author summary  
 
Kapos’s Sarcoma Herpesvirus (KSHV) is endemic in sub-Saharan Africa, though factors 
favouring its high transmission in the region are not well understood. Viral shedding in the 
saliva is associated with the transmission of the virus while viral detection in the blood is 
associated with reactivation and disease pathogenesis. Here we determine factors 
associated with both viral shedding in saliva and viral detection in blood in a KSHV endemic 
population. Our data show that children, particularly boys, may be a major source of viral 
transmission and malaria parasite infections could play a role in viral reactivation and 
susceptibility to infection. 
 
Introduction 
 
Kaposi's sarcoma-associated herpesvirus (KSHV) causes Kaposi’s sarcoma (KS), 
multicentric Castleman disease (MCD) and primary effusion lymphoma (PEL) (1-6). 
Prevalence of KSHV and incidence of KS both vary geographically, (7-9) and are endemic in 
sub-Saharan Africa (10, 11)  
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 Salivary exchange is the main route of transmission of KSHV, normally occurring in early 
childhood and increasing with age (12-15). In a rural population cohort in Uganda (the 
General Population Cohort – GPC), for instance, we have reported KSHV infections in 
children as young as one year (11, 16). In addition to viral shedding in saliva, viral DNA 
detection in blood and increased antibody titres to lytic antigens are markers of frequent 
KSHV reactivation (13). KSHV-associated oncogenesis and progression of diseases, as well 
as virus transmission, are all thought to be related to virus reactivation (17).  
 
Viral DNA detection in blood has been associated with KS disease risk and progression (18-
21). Additionally, treatment of AIDS-KS patients with cART has been shown to reduce KSHV 
load in blood to undetectable levels (18, 22). Determinants of KSHV DNA detection in blood 
among KSHV seropositive people in the general population is not well understood. Viral load 
in plasma and PBMCs has been reported mainly in high-risk groups such as HIV infected 
individuals and patients with KSHV related diseases (18, 23-27). A few studies have 
reported KSHV viral load in blood donors (adults) in non-endemic areas (28-30) and a study 
reported plasma viral load in a population-based HIV survey in an endemic area (31).  
 
Environmental factors may contribute to high KSHV transmission in endemic areas. We 
have previously shown that KSHV seropositivity is associated with malaria parasitaemia 
(16), higher malaria antibody titres (32) and helminth infections (33, 34). We and others have 
reported that KSHV shedding in the saliva is more common in males compared to females 
(35, 36), but no study has investigated KSHV viral load in both blood and saliva in the same 
individuals within a population-based study in a KSHV endemic area. 
 
This study investigated KSHV viral DNA detection in PBMCs and saliva in KSHV 
seropositive individuals aged 3 to 89 years from the General Population Cohort (GPC) – a 
longstanding cohort in rural south-western Uganda. We also determined the risk factors 
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 associated with viral DNA detection and levels in PBMCs and in saliva and the relationship 
between viral DNA detection in PBMCs and saliva and KSHV antibody levels in plasma. 
 
Methods 
 
Study population and ethical approvals 
This work was carried out within the General Population Cohort (GPC). The GPC is a 
community-based cohort of 22,000 people in 25 adjacent villages in south-western Uganda. 
It was established in 1989 to carry out HIV research; participants from the GPC have been 
followed ever since. Between July 2017 and November 2017, we nested a cross-sectional 
study within the GPC enrolling 975 KSHV seropositive (tested previously (32)), HIV negative 
individuals aged three to eighty-nine years. Participants were selected randomly after 
stratification for age, sex and household. Blood, stool and saliva samples were collected 
from these individuals. Peripheral blood mononuclear cells (PBMCs) and plasma were 
obtained from blood for immunological and virological analyses. Stool samples were used 
for helminth diagnosis while saliva was used for KSHV viral DNA detection and 
quantification. Socio-demographic data were collected using standard questionnaires. This 
study was approved by the UVRI-Research and Ethics Committee (REC) (reference 
number: GC/127/16/09/566), the Uganda National Council for Science and Technology 
(UNCST) (reference number: HS2123) and LSHTM Ethics Committee (reference number: 
11881). Written informed consent was obtained from all adults aged 18 years and above. 
Parents or guardians consented for children below 18 years, additionally, children aged 8-17 
years provided written assent. 
 
Laboratory procedures   
KSHV DNA was quantified in PBMCs and saliva from 878 KSHV seropositive individuals. A 
pellet of about two million PBMCs and saliva pellets were processed for DNA extraction. 
Study participants were instructed to rinse with 5mL of Listerine mouthwash, emptying it, as 
well as saliva in a falcon tube. Aliquots (of 1mL each) of saliva were spun at 13,000rcf for 10 
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 minutes to form saliva pellets. Thereafter the supernatant was removed and the saliva pellet 
stored at -80oC. Genomic DNA was extracted from PBMCs and saliva pellets using a 
QIAamp blood kit (Qiagen, Valencia, CA), following the manufacturer's instructions. KSHV 
DNA was quantified using real-time PCR, following procedures previously reported (13, 37, 
38). KSHV DNA was detected using primers and a probe specific to the K6 gene region (39). 
Additionally, the number of cellular equivalents in PBMCs were determined using a 
quantitative assay specific to human endogenous retrovirus 3 (ERV-3) (39), which is present 
in two copies per genomic cell. Raw copies were reported for saliva KSHV DNA. Samples 
were amplified in triplicate; the samples that were positive in one or two reactions in the 
KSHV K6 assay were designated as qualitative positives.  
 
Using an in house Luminex assay and ELISA, previously reported (40-42), plasma samples 
were tested for IgG antibody levels to the KSHV K8.1 (lytic) and ORF73 (latent) antigens. 
The ELISA was used to confirm serostatus while the Luminex assay was used to determine 
antibody levels, due to its wider dynamic range. Malaria parasitemia was diagnosed using 
rapid diagnostic tests (RDT) (ONE STEP Malaria HRP-II (P.f) and pLDH (Pan) Antigen 
Rapid Test). A single stool sample was provided by each participant. This was analysed for 
helminths (Schistosoma mansoni, Ascaris lumbricoides, Tichuris trichiura, Trichostrongylus 
spp and hookworm) using the Kato Katz microscopy method following the manufacturer’s 
instructions. Details of this procedure have been reported elsewhere (43, 44). 
 
Statistical analysis 
Statistical analysis was carried out using STATA version 13 (StataCorp, College Station, 
Texas USA). Graphs were drawn using STATA and GraphPad Prism version 6. Qualitative 
positive samples were given a constant value of 0.04 for saliva and 0.5 for PBMCs, which 
were below the values of the lowest qualified samples for quantitative analysis. Viral load 
levels were log10 transformed. First, risk factors associated with viral DNA detection (as a 
categorical outcome variable) in saliva and blood, separately, were obtained using logistic 
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 regression modelling.  Thereafter, risk factors associated with increasing levels of viral DNA 
(as a continuous outcome variable) in saliva and in blood, separately, were determined 
using linear regression modelling. Likelihood ratio tests were used to select the best fit 
models.  
 
Results  
 
Study participants’ characteristics 
We tested 878 individuals for KSHV viral DNA; 49% (410/834) were males, while 3% 
(27/840), 11% (95/840), 13% (110/840), 8% (67/840), 17% (139/840), 14% (121/840), 14% 
(118/840), 9% (74/840) and 11% (89/840) were aged 3-5, 6-12, 13-18, 19-25, 26-35, 36-45, 
46-55, 56-65 and 66-89 years respectively. The proportion of individuals with malaria 
parasitaemia was 4% (34/834) overall and 11% (13/120) among children 3-12 years. 
Previously we have reported an annual malaria prevalence of 18% in the same population 
(16). The lower prevalence of malaria infection in this study might be attributed to sample 
collection during the dry season. The prevalence of helminths was as follows: Hookworm 
was the most prevalent at 15% (104/686), followed by Schistosoma mansoni and Ascaris 
lumbricoides at 1% (8/686) each and Trichuris trichiura at 0.1% (1/686). We may have 
slightly underestimated the true prevalence of helminths, because a single, rather than triple 
sample test, was used.   
  
Blood and saliva KSHV DNA detection and levels of viral DNA 
We did not observe a correlation between KSHV DNA copy numbers in PBMCs and DNA 
copy numbers in saliva (Figure 1). The proportion of individuals with detectable viral DNA in 
saliva was higher than the proportion of people with the detectable viral DNA in PBMCs 
(Figure 2a and 2b). Children had the highest proportion of detectable viral DNA in PBMCs 
(Figure 2a) and in saliva (Figure 2b), decreasing with increasing age in adults. The trend 
was similar for females and males, with males having higher proportions of detectable viral 
DNA in saliva.  
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Figure1: KSHV viral load in saliva and in peripheral blood mononuclear cells (PBMCs). KSHV viral 
loads were measured using real time PCR.  
 
 
 
Figure 2: Proportion of individuals with detectable KSHV in peripheral blood mononuclear cells 
(PBMCs) (2a) and saliva (2b). KSHV viral loads were measured using real time PCR. 
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 Associations between risk factors and KSHV DNA in PBMCs 
The proportion of individuals with detectable viral DNA in PBMCs decreased with increasing 
age; this trend was significant even after adjusting for sex and parasite infections (Table 1). 
Individuals infected with malaria parasites had higher levels of KSHV DNA in blood 
compared to malaria uninfected individuals (adjusted regression coefficient 0.79 (0.07,1.50), 
p=0.031) (Table 2). We observe no statistically significant associations with other measured 
risk factors including age, sex, hookworm and S. mansoni infections (Table 2).  
 
Table 1: Risk factors for the presence of detectable KSHV DNA in blood (categorically) 
 
% detectable viral 
DNA in blood 
ORa (95% CI) P value Adjustedb OR (95% 
CI) 
P value 
Age group 
3-12 
13-25 
26-50 
50+ 
 
23% (27/120) 
15% (26/177) 
7% (20/307) 
8% (18/227) 
 
1 
0.59 (0.33, 1.08) 
0.24 (0.13, 0.45) 
0.30 (0.16, 0.57) 
 
 
 
 
<0.0001 
 
1 
0.63 (0.33, 1.17) 
0.29 (0.15, 0.57) 
0.34 (0.16, 0.72) 
 
 
 
 
0.0014 
Sex 
Female 
Male 
 
10% (41/419) 
12% (49/406) 
 
1 
1.27 (0.82, 1.96) 
 
 
0.294 
 
1 
0.89 (0.55, 1.45) 
 
 
0.638 
Malaria 
parasiatemia 
Negative 
Positive 
 
 
10% (83/791) 
21% (7/34) 
 
 
1 
2.21 (0.93, 5.24) 
 
 
 
0.071 
 
 
1 
1.59 (0.64, 3.95) 
 
 
 
0.321 
S. mansoni 
Negative 
Positive 
 
11% (77/672) 
43% (3/7) 
 
1 
5.80 (1.27, 26.38) 
 
 
0.023 
 
1 
11.04 (2.16, 56.97) 
 
 
0.004 
Hookworm 
Negative 
Positive 
 
13% (74/576) 
6% (6/103) 
 
1 
0.42 (0.18, 0.99) 
 
 
0.048 
 
1 
0.41 (0.16, 1.04) 
 
 
0.061 
a OR: odds ratio, b adjusted for age, sex, malaria parasitaemia, S. mansoni and hookworm infection 
status. Logistic regression was used for statistical analysis. Malaria parasitaemia was determined 
using rapid diagnostic tests (RDTs). Helminth status was determined from a single stool sample using 
the Kato-Katz method.  
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 Table 2: Risk factors associated with increasing levels of KSHV DNA in blood (continuously) 
 
Coefa. (95% CI) P value Adjustedb Coef. 
(95% CI) 
P value 
Age group 
3-12 
13-25 
26-50 
50+ 
 
Ref 
-0.39 (-0.86, 0.07) 
0.19 (-0.31, 0.69) 
-0.32 (-0.83, 0.19) 
 
 
 
 
0.084 
 
Ref 
-0.35 (-0.84, 0.15) 
0.26 (-0.30, 0.83) 
-0.06 (-0.70, 0.57) 
 
 
 
 
0.160 
Sex 
Female 
Male 
 
Ref 
0.10 (-0.27, 0.47) 
 
 
0.594 
 
ref 
0.21 (-0.19, 0.61) 
 
 
0.292 
Malaria 
parasitaemia 
Negative 
Positive 
 
 
Ref 
0.71 (0.05, 1.38) 
 
 
 
0.036 
 
 
Ref 
0.79 (0.07, 1.50) 
 
 
 
0.031 
S. mansoni 
Negative 
Positive 
 
Ref 
0.17 (-0.87, 1.21) 
 
 
0.750 
 
Ref 
-0.15 (-1.30,  1.00) 
 
 
0.797 
Hookworm 
Negative 
Positive 
 
Ref 
0.30 (-0.45, 1.05) 
 
 
0.79 
 
Ref 
0.37 (-0.46, 1.21) 
 
 
0.372 
a Coef: linear regression coefficient, b adjusted for age, sex, malaria parasitaemia, S. mansoni and 
hookworm infection status. Linear regression modelling was performed on log10 transformed KSHV 
DNA levels for statistical analysis. Malaria parasitaemia was determined using rapid diagnostic tests 
(RDTs). Helminth status was determined from a single stool sample using the Kato Katz method.  
 
Associations between risk factors and KSHV DNA in saliva 
 
Overall, males had a higher risk of shedding viral DNA compared to females; adjusted Odds 
Ratio 1.63 (1.14, 2.34), p=0.008 (Table 3). Similar to PBMCs, the proportion of shedders in 
saliva diminished with increasing age, even after adjusting for sex and parasite infections 
p=0.0001 (Table 3). Additionally, compared to females, males had higher levels of KSHV 
DNA in saliva (adjusted regression coefficient 0.46 (0.05,0.87), p=0.027) (Table 4).  
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 Table 3: Risk factors for the presence of detectable KSHV DNA in saliva (categorically) 
 
% detectable viral 
DNA in saliva 
ORa (95% CI) P value Adjustedb OR 
(95% CI) 
P value 
Age group 
3-12 
13-25 
26-50 
50+ 
 
42% (50/120) 
31% (55/175) 
18% (56/310) 
17% (39/231) 
 
1 
0.64 (0.40, 1.40) 
0.31 (0.19, 0.49) 
0.28 (0.18, 0.47) 
 
 
 
 
<0.0001 
 
 
0.61 (0.37, 1.02) 
0.38 (0.24, 0.63) 
0.30 (0.18, 0.54) 
 
 
 
 
0.0001 
Sex 
Female 
Male 
 
19% (79/423) 
29% (119/407) 
 
1 
1.80 (1.30, 2.49) 
 
 
<0.0001 
 
1 
1.63 (1.14, 2.34) 
 
 
0.008 
Malaria 
parasitaemia 
Negative 
Positive 
 
 
24% (188/796) 
29% (10/34) 
 
 
1 
1.35 (0.63, 2.87) 
 
 
 
0.439 
 
 
1 
0.98 (0.44, 2.16) 
 
 
 
0.952 
S. mansoni 
Negative 
positive 
 
26% (174/675) 
43% (3/70) 
 
1 
2.16 (0.48, 9.74) 
 
 
0.317 
 
1 
2.43 (0.51, 11.52) 
 
 
0.265 
Hookworm 
Negative 
Positive 
 
27% (158/578) 
18% (19/104) 
 
1 
0.59 (0.35, 1.009) 
 
 
0.054 
 
1 
0.66 (0.38, 1.14) 
 
 
0.136 
a OR: odds ratio, b adjusted for age, sex, malaria parasitaemia, S. mansoni and hookworm infection 
status. Logistic regression was used for statistical analysis. Malaria parasitaemia was determined 
using rapid diagnostic tests (RDTs). Helminth status was determined from a single stool sample using 
the Kato Katz method.  
 
Table 4: Risk factors associated with levels of KSHV DNA in saliva (continuously)  
 
Coef.a (95% CI) P value Adjustedb Coef. (95% CI) P value 
Age group 
3-12 
13-25 
26-50 
50+ 
 
Ref 
-0.50 (-1.02, 0.21) 
-0.31 (-0.82, 0.21) 
0.78 (-1.35, -0.21) 
 
 
 
 
0.049 
 
Ref 
-0.61 (-0.13, -0.09) 
-0.26 (-0.80, 0.28) 
-0.76 (-1.40, -0.11) 
 
 
 
 
0.048 
Sex 
Female 
Male 
 
Ref 
0.51 (0.12, 0.89) 
 
 
0.010 
 
Ref 
0.46 (0.05, 0.87) 
 
 
0.027 
Malaria 
parasitaemia 
Negative 
Positive 
 
 
Ref 
0.20 (-0.67, 1.07) 
 
 
 
0.651 
 
 
Ref 
0.05 (-0.82, 0.92) 
 
 
 
0.909 
S. mansoni 
Negative 
positive 
 
Ref 
-0.58 (-2.12, 0.96) 
 
 
0.460 
 
Ref 
-0.38 (-1.94, 1.18) 
 
 
0.635 
Hookworm 
Negative 
Positive 
 
Ref 
-0.36 (-0.96, 0.32) 
 
 
0.326 
 
Ref 
-0.37 (-1.03, 0.29) 
 
 
0.270 
a Coef: linear regression coefficient, b adjusted for age, sex, malaria parasitaemia, S. mansoni and 
hookworm infection status. Linear regression modelling was performed on log10 transformed KSHV 
DNA levels for statistical analysis. Malaria parasitaemia was determined using rapid diagnostic tests 
(RDTs). Helminth status was determined from a single stool sample using the Kato Katz method.  
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 KSHV DNA detection and antibody levels 
 
Individuals with detectable viral DNA in PBMCs (Figure 3a) and in saliva (Figure 3b) had 
higher IgG antibodies to the K8.1 antigen (p<0.0001), as previously reported (13). There was 
no difference in IgG antibodies to ORF73 antigen between individuals with or without 
detectable viral DNA in the blood (Figure 3c) or in saliva (Figure 3d). 
 
Figure 3: IgG antibody levels to K8.1 (a & b) and ORF73 ( c & d) protein among individuals with and 
without detectable KSHV in the blood (a & c) and in saliva (b & d). Antibodies were measured using 
the Luminex assay. These antibodies were log10 transformed. P values were obtained from a ttest 
after log10 transformation of the data. The box show all values within the 25th and 75th quatiles 
(interquatile range). The line in the box represent the median. The whiskers are +/- 2 to the 
interquatile range. The dots represent outliers.  
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 Discussion 
 
This is the first population-based study to report on presence and levels of KSHV viral DNA 
in blood and saliva in apparently healthy people across the life-course. The proportion of 
individuals with detectable viral DNA in saliva was higher than the proportion of individuals 
with detectable viral DNA in blood, consistent with previous reports (22, 45-47). We have 
previously reported KSHV and EBV DNA shedding in the saliva of children and their mothers 
in Uganda and noted that EBV DNA was shed more frequently and at higher levels than 
KSHV (38).  
 
In this study, we observed no correlation between levels of KSHV DNA in blood and in 
saliva. Detection of KSHV DNA in blood and in saliva may reflect reactivation of the virus or 
an initial infection that manifests with lytic replication. Viral shedding in saliva leads to the 
transmission of the virus (13), while viral load in blood has been implicated in disease risk 
and progression (18, 23). The lack of a correlation between blood and saliva viral DNA 
suggests that the mechanisms for reactivation of the virus in blood and in saliva may be 
different. This may imply that distinct immune control measures are required to prevent viral 
reactivation in different compartments. Studies of immune correlates of KSHV DNA 
detection in saliva and PBMC are therefore warranted. 
 
The proportion of KSHV DNA detected in blood and saliva was highest in children, 
compared to adults. Previous studies have reported a high risk of KSHV seropositivity in 
children born to KSHV seropositive mothers (13, 35, 48). However, seropositivity in children 
whose mothers were seronegative has also been reported (48, 49). Our current study 
suggests that siblings or playmates may also be a major source of transmission to 
uninfected children.  
 
High viral load among children could be associated with co-infections that are very prevalent 
in childhood such as malaria; we also observed the highest prevalence of malaria 
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 parasitaemia in the same age group. We showed that participants with malaria parasitaemia 
have higher levels of KSHV DNA in blood compared to those uninfected with malaria. This is 
the first study to relate malaria parasitaemia directly with KSHV load in blood. We have 
previously reported associations between malaria (parasitaemia and antibodies) and KSHV 
seropositivity (16, 32-34). Results from the current study support the potential role of malaria 
in KSHV pathogenesis. The mechanisms for the association between malaria and KSHV 
viral load could include immunomodulation and dysfunction associated with repeated 
malaria infections (50, 51).  
 
In the present study, males (both men and boys) were more likely to shed KSHV DNA in 
saliva and had higher levels of viral DNA compared to females. This is consistent with 
previous studies by us and others (31, 36, 38). Sex differences in immune control of KSHV 
infection might contribute to the higher risk of KS in men (52, 53). These findings warrant 
further study. 
 
We have previously reported that high KSHV K8.1 antibody titres are associated with and 
predictive of KS risk (54). In the current study, we have observed that people with detectable 
viral DNA in both blood and saliva have higher IgG antibody levels for K8.1 but not ORF73, 
compared to individuals without the detectable viral DNA. This association confirms our 
previous hypothesis (54) that increased lytic antibody levels reflect more frequent KSHV 
reactivation. 
 
In summary, our data are consistent with high rates of KSHV transmission in rural Uganda. 
This might be partly attributed to parasite co-infections such as malaria which interfere with 
immune control, or make uninfected children susceptible to infections. Studies investigating 
the mechanism through which malaria affects KSHV are required. Additionally, 
characterisation of protective immune responses to KSHV is needed to inform vaccine 
development and to develop strategies to lower KSHV transmission in endemic areas.  
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 Chapter Seven: IFN- cellular responses to the KSHV 
proteome in individuals from rural Uganda 
 
Preamble 
 
Cellular immune responses to KSHV have been poorly studied and published reports rarely 
replicate previous findings. In the current study, we used 82 peptide pools spanning the 
entire KSHV proteome to determine cellular immune responses and how they relate to viral 
detection in PBMCs. Our data show no immune dominance and a robust response among 
adults who control the virus in the blood. These results require a bigger sample size for 
confirmation. Therefore we will test more samples before submitting the manuscript for 
publication. 
 
 
139
140
141
 Kaposi's sarcoma-associated herpesvirus (KSHV) specific IFN- 
cellular immune responses in relation to age and viral DNA 
detection in healthy individuals from rural Uganda 
 
Angela Nalwoga1,2, Romin Roshan3, Marjorie Nakibuule1, Vickie Marshall3, Wendell Miley3, 
Nazzarena Labo3, Stephen Cose1,2, Robert Newton1,4* Denise Whitby3*. 
 
*contributed equally 
 
1. MRC/UVRI and LSHTM Uganda Research Unit, Entebbe; Uganda 
2. London School of Hygiene & Tropical Medicine, London; United Kingdom 
3. Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical 
Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD; 
United States of America 
4. University of York, York; United Kingdom 
 
Abstract 
 
Little is known about the cellular immune response to KSHV among apparently healthy 
KSHV seropositive individuals from endemic areas. We investigated IFN- responses to the 
entire KSHV proteome in individuals from a rural Ugandan population cohort. An ex-vivo 
IFN- ELISpot assay was carried out on PBMCs from 34 individuals, using 82 KSHV ORFs. 
KSHV viral load in PBMC was determined using real-time PCR. 
 
Cellular immune responses to KSHV were heterogenous showing no shared 
immunodominance. The responses were most intense in young adults (27-44 years old), 
lower in older people and very low in children. Among young adults, those without robust 
cellular immune responses had detectable viral DNA in their blood, whereas those with a 
good response had no evidence of viral DNA in blood. 
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Although the sample size in the current study was small, these findings suggest that cellular 
immune responses decline with age and robust IFN- responses correlate with a lack of 
detectable KSHV viral load in blood.  
 
Keywords: Kaposi’s sarcoma herpesvirus, cellular responses, Uganda 
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 Introduction 
 
The adaptive immune response to KSHV is central in protection from KSHV associated 
malignancies (Kaposi’s sarcoma-KS, Multicentric Castleman’s disease-MCD and primary 
effusion lymphoma-PEL) [1, 2]. This is shown by the substantial increase in the risk of 
developing KS and other KSHV malignancies in immunocompromised individuals due to HIV 
or immunosuppressive drugs [3, 4]. Furthermore, the pivotal role of T cells in controlling 
latent herpesviruses, including EBV, CMV and HSV, has been documented [5, 6], although 
similar evidence for KSHV is still lacking. 
 
During the adaptive immune response, CD4+ T cells help B cells and CD8+ T cells to 
function efficiently; cytotoxic CD8+ T cells kill virally-infected cells and B cells produce 
antibodies which neutralise and opsonise viruses, as well as activating complement to lyse 
extracellular virus. A protective role of antibody responses in KSHV pathogenesis and 
disease progression has not been observed [4], and few studies have investigated CD4+ T 
cells in relation to KSHV and its associated malignancies [2]. Conversely,  several studies 
have reported a predominant role of cytotoxic CD8 T cells in the control of Classic, 
Iatrogenic and AIDS-related KS [1, 2, 7, 8]. Only two studies have reported cellular 
responses to KSHV in sub-Saharan Africa [9, 10].  
 
A higher frequency of T cells (mainly CD8+) has been reported in KS patients who achieve 
complete remission compared to cases with unresolved KS [11-13]. In comparison to KS 
patients, higher T cell responses and frequency in asymptomatic individuals have been 
reported [14]. Treatment with highly active antiretroviral therapy (HAART) of AIDS-KS 
patients has been associated with an improved T cell response, correlating with KS 
regression [15, 16].  
 
KSHV encodes over 80 proteins [17]. This has made the search for a T cell 
immunodominant peptide extremely difficult. Previous studies have each used different 
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 peptides, making each study unique, but difficult to compare between studies. A systematic 
approach of using the entire KSHV proteome to investigate KSHV antibody responses in 
Americans revealed additional immunogenic KSHV proteins than had previously been 
reported [18]. Using a similar approach, the same authors investigated T cell responses to 
the entire KSHV proteome among Americans [19]. This study confirms T cell immune 
variability and the lack of an immune dominant peptide in that population.  
 
As noted above, all of the T cell studies have been done among patients with some form of 
KSHV associated malignancy and, in individuals from countries where KSHV is not endemic. 
T cells studies in healthy individuals from endemic countries are still lacking. Due to the high 
transmission of KSHV and the high burden of KS in endemic areas, understanding T cell 
responses in these populations is paramount in the development of a KSHV vaccine for 
these key populations. Vaccination would halt transmission and prevent KSHV-associated 
cancers.   
 
We undertook the same systematic approach to investigate T cell responses to the entire 
KSHV proteome in a rural cohort in Uganda, where KSHV is endemic. We focused on age-
specific responses among KSHV seropositive individuals with and without KSHV DNA in 
PBMCs.  
 
Methods 
 
Study population  
The General Population Cohort (GPC) is a community-based cohort of 22,000 people in 25 
adjacent villages [20, 21]. Located in southwestern Uganda, the GPC is a typical Ugandan 
rural community. Previously, we have documented high seropositivity of KSHV in the GPC 
[22, 23]. For this study, we recruited individuals who were KSHV seropositive, but HIV 
seronegative from the GPC in 2017, to investigate determinants of KSHV viral detection. 
Only one individual was recruited per household. Blood samples were processed to isolate 
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 PBMCs (stored in liquid nitrogen for later immunological assays) and plasma (stored at -80 
°C for later use). Cell pellets containing two million PBMCs were stored at -80°C for later 
DNA extraction. KSHV-specific IFN- responses were determined in 34 participants aged six 
to 87 years. Purposive sampling was used ensuring that participants with and without 
detectable viral DNA in blood from each age group were selected. Details of the 
characteristics of the participants selected are shown in Supplementary Table 1. 
 
KSHV ELISPOT assay 
Overlapping 15mer peptides were synthesised to span the entire KSHV proteome, and 
peptides divided into pools representing each open reading frame (ORF) [19]. Using these 
peptide pools, working concentrations of 5g/ml/peptide were prepared in 96 well culture 
plates using AIM-V media. The MABTECH Human IFN- ELISpot kit (Code: 3420-2APT-10) 
was used for the assay, with a few alterations to the manufacturer's protocol. The ELISPOT 
plates with the capture antibody from the kit were washed 5 times with 200l of 1xPBS per 
well. Afterwards, thawed cells were added to the plates in a volume of 100l containing 
150,000 cells per well. The plates were covered with the lid and wrapped in aluminium foil 
and transferred to a 5% CO2 37°C incubator for a 24 hour resting period. To stimulate them, 
100l per well of the peptide pools were added to the cells. Anti-CD3 and a pool of peptides 
from flu, CMV and EBV were added as positive controls in triplicate. Media and a non-
human antigen (Simian immunodeficiency virus (SIV) peptides) were also added as negative 
controls in triplicate. The plates were then incubated at 37°C for 46-48 hours. Following 
stimulation, cells were washed 5 times with 200l of PBS per well and 100l of anti-human 
IFN IgG conjugated to alkaline phosphatase (Code: 7-B6-ALP) was added at a dilution of 
1/6 in PBS + 0.5% FBS. The plates were incubated at room temperature (25°C) for 2 hours. 
After the incubation, the plates were washed 5 times with 200l of 1xPBS per well and 100l 
of filtered 5-bromo-4-chromo-3-indolyl-phosphate (BCIP)/nitroblue tetrazolium (NBT)-plus 
substrate (Code: 3650-10) added per well. The plates were then incubated at room 
146
 temperature for 7 minutes and the reaction stopped by washing the plate with running tap 
water. The plates were dried in the dark overnight, subsequently, the spots were counted 
using an ELISPOT reader (AID ELISPOT Reader HR model: ELHR010307005). This 
protocol has been reported elsewhere [19]. 
 
KSHV ELISA and PCR 
Plasma samples from the same individuals were tested for KSHV IgG antibodies to K8.1 and 
ORF73 antigens to confirm seropositivity using methods previously reported [24, 25]. DNA 
extracted from 2 million PBMC pellets was tested for KSHV load using real-time PCR as 
previously reported [26-28].  
 
Statistical analysis 
Graphical representation was done using GraphPad Prism 8.0.1 (145). Spot Forming Cells 
(SFC) per million PBMC were calculated from the number of spots counted by the ELISpot 
reader and the number of PBMCs plated using Microsoft Office Excel (version 15.23). A cut-
off of 60 SFC derived from the mean SFC of the SIV negative control and its standard 
deviation was applied. Therefore, individuals with SFC below 60 were considered non-
responders.  
 
Ethical approvals 
This study was approved by the UVRI-Research and Ethics Committee (REC) (reference 
number: GC/127/16/09/566), the Uganda National Council for Science and Technology 
(UNCST) (reference number: HS2123) and the LSHTM Ethics Committee (reference 
number: 11881). Written informed consent was obtained from all adults aged 18 years and 
above. Children below 18 years were consented into the study by their parents or guardian; 
we also sought, in addition to parental consent, written assent from children aged between 
8-17 years. 
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 Results 
 
KSHV specific IFN responses  
IFN responses to 84 peptide pools were determined in PBMC from 34 individuals. SFCs per 
million PBMCs to peptide pools raged from 0 to 3873, while those to CEF (a cocktail of 
peptides from CMV, influenza and EBV) ranged from 0 to 392. All the samples responded to 
anti-CD3 while about half of the samples responded to CEF. Responses to CEF were 
independent of responses to KSHV peptides (Figure 1).  
 
There was no consistent pattern in response to peptide pools. Of the 84 peptide pools used, 
no reaction was observed to 26 (K12, ORF16, ORF19, ORF22, ORF23, ORF25, ORF26, 
ORF29a, ORF29b, ORF31, ORF35, ORF47, ORF48, ORF49, ORF53, ORF54, ORF56, 
ORF57, ORF60, ORF62, ORF64/1, ORF64/3, ORF70, ORF72, ORF74 and ORF75) in any 
individual, reactions to 35 were observed (K2, K4, K5, K6, K7, K9, K10, K14, K15, ORF2, 
ORF10, ORF11, ORF17, ORF18, ORF28, 0RF32, ORF33, ORF34, ORF36, ORF38, 
ORF39, ORF40, ORF43, ORF45, ORF46, ORF52, ORF55, ORF58, ORF59, ORF63, 
ORF64/2, ORF65, ORF66, ORF67 and ORF69) in one individual, while reactions to 23 were 
observed (K1, K3, K8, K11, K13/ORF71, ORF4, ORF6, ORF7, ORF8, ORF9, ORF20, 
ORF21, ORF24, ORF27, ORF30, ORF37, ORF41, ORF42, ORF44, ORF50, ORF61, 
ORF68 and ORF73) in more than one individual.  
 
In regards to the participants selected, the majority (65%; 22/34) responded to at least one 
peptide pool. The individual who responded to the largest number of peptide pools belonged 
to the 27-44 age group and had the highest response overall as well. This individual 
responded to 27 peptide pools with the highest response of 3873 SFCs to K4 (Figure 1). In 
the 6-13 and 51-87 age groups, the individuals who responded to the maximum number of 
peptide pools reacted to 3 and 18 peptide pools respectively. The maximum number of 
people reacting to a single peptide pool (K11) was six (18%). Responses varied according to 
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 age. Children aged 6 to 13 years had the lowest responses, ranging from 67-947 SFC, 
compared to young adults aged 27 to 44 years (60-3873SFCs) and older individuals aged 
51-87 years (60-2140SFC). Additionally, only 40% (6/15) of children responded to at least 
one single peptide pool while 87% (13/15) of older individuals and 50% (2/4) of young adults 
responded to at least one peptide pool.  
 
Generally, individuals responded to various KSHV peptide pools, without any 
immunodominance. The intensity and robustness of responses were highest in young adults 
(27-44 years), lower in older people (51-87) and very low in children (6-13 years). Among 
young adults, those without detectable virus had more robust responses compared to those 
with the virus in the blood (Figure 1). 
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Figure 1: A heat map summarizing KSHV specific IFN- responses to 84 peptide pools in 34 
individuals aged six to eighty-seven. The ELISpot assay was used to determine the responses. Spot 
forming cells (SFCs) per million PBMCs were recorded for each reaction. The intensity of the blue 
colour correlates with the number of SFCs per million PBMCs. The Y-axis labels show the study 
participant's identification numbers and the age band for each participant. The X-axis label shows the 
84 peptide pools used in the analysis.  (+) individuals with detectable KSHV DNA in blood. (-) 
individuals without detectable KSHV DNA in blood. GraphPad Prism version 8 was used to draw the 
heat map.   
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 Discussion and conclusion  
 
This is the first study to demonstrate KSHV cellular responses to the entire proteome among 
healthy individuals, of a wide age range, and from an endemic area. Interestingly, the 
responses we have observed in a KSHV-endemic population confirm the observations 
reported in US healthy donors and patients with KSHV related disease [19, 29], namely that 
there is a complete lack of immune dominance. Additionally, we have shown that the 
presence of a robust cellular response among young adults is associated with viral control, 
data that has not previously been demonstrated.  We further showed that young adults have 
the highest and most robust cellular responses compared to children and older individuals 
and that older people compared to children have more robust and higher cellular immune 
response. We have previously reported that children have the highest rates of detection of 
KSHV DNA in PBMC. Taken together with the current study, we speculate that these 
observations are consistent with (presumably) recently infected participants failing to mount 
effective cellular immune responses favouring KSHV reactivation. 
 
Previous studies [1, 2] have focused on only a few KSHV antigens to investigate cellular 
responses, with the exception of one study [19] which was carried out among Americans. 
Some of these studies showed that cellular responses are skewed to the latent, early lytic 
and late lytic antigens. In the current study, we confirm the previous findings in a population 
with high KSHV prevalence showing heterogenous responses across the whole proteome 
without any immune dominance. 
 
Several studies have correlated KS regression and remission with improved T cell 
responses [11, 13, 14, 30, 31]. It has therefore been hypothesized that improving the T cell 
response in these patients provides immunity to both KS and KSHV, leading to tumour 
regression. Our study confirms the role of the cellular response in the control of KSHV 
reactivation. It is the first study to show KSHV control attributed to cellular responses in 
healthy individuals from an endemic area.  
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Young children and older individuals are at risk of KS in endemic areas [32], and infection 
with KSHV occurs in childhood [27, 33].  Children may be at risk of developing KS due to the 
immaturity of their developing immune system, and older people are likely more susceptible 
due to their ageing immune system (immunosenescence) and chronic inflammation [34].  
Consistent with these hypotheses, it is not surprising then that our study showed that cellular 
responses to KSHV are weaker in these age groups, compared to young adults whom we 
show have a robust T cell response. 
 
In summary cellular immune response to KSHV is likely paramount in the control of 
reactivation of the virus. KSHV does not illicit an immunodominant response. This has now 
been shown in two geographically distinct locations.  This has major implications for vaccine 
design.  Vaccine efforts may need to concentrate on multiple epitope vaccines, or attenuated 
whole virus, to induce effective protective immunity. Additionally, therapeutic provoking a 
specific immune response (shown to be protective) in individuals at a high risk of developing 
KS and other KSHV-associated malignancies is another possibility. Vaccination and 
therapeutic prevention would drastically reduce KS and other KSHV-associated 
malignancies which have a very poor prognosis in developing countries. 
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 Chapter Seven supplementary material  
Supplementary Table 1: Study participants’ characteristics  
 
 
 
KSHV T cell responses 
(ELISpot) n=34 
The proportion 
with detectable 
KSHV in 
PBMCa 
Sex 
Male 
Female 
 
Age group 
1-13 
27-44 
51-87 
 
61% (11/18) 
56% (9/16) 
 
 
53% (8/15) 
50% (2/4) 
67% (10/15) 
aPBMC: peripheral blood mononuclear cells. KSHV viral load measured using real time polymerase 
chain reaction (PCR).  
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 Chapter Eight: General discussion 
 
Research aims, hypotheses and summary of findings  
 
The prevalence of KSHV varies geographically [1, 2]. Sub-Saharan Africa bears the highest 
burden of the associated disease (KS) as well as of the infection (KSHV) [3, 4]. Currently, 
KSHV cannot be eradicated and, long-term remission has been achieved only in some KS 
cases [5]. KSHV infection is necessary, but not sufficient for oncogenesis and important co-
factors, such as immunosuppression, have been identified [6]. In addition, the prognosis for 
those diagnosed with KS is very poor in sub-Saharan Africa [5]. To prevent disease, it is 
essential to control KSHV transmission and to identify people at risk of developing KS 
among those already infected. This PhD study had the following aims:  
(1) To document the burden of KSHV in recent years in rural Uganda and Lake 
Victoria island fishing communities 
(2) To use two markers of KSHV reactivation (increased antibody levels and viral 
load) to identify biological and other risk factors associated with KSHV 
reactivation 
(3) To assess factors associated with transmission (using viral shedding in saliva as 
a proxy marker) in Uganda, where KSHV is endemic  
(4) To investigate cellular immune responses to KSHV and its relationship to viral 
reactivation or control.  
 
We hypothesized the following: 
(1)  That there would be urban-rural differences in prevalence, with higher 
prevalence in rural areas due to increased parasite burden and other KSHV risk 
factors  
(2) That in the Lake Victoria Island communities, KSHV prevalence would be high 
due to the high parasite and HIV burden [9] 
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 (3) That, based on previous findings [10-12], malaria, anaemia, and helminths would 
be associated with KSHV-specific antibody levels, as well as viral DNA detection 
in blood and saliva 
(4) That malaria and helminths affect KSHV reactivation through anaemia, which 
leads to hypoxia 
(5) That age of infection with KSHV affects viral control (based on findings relating to 
EBV infection) [13, 14] 
(6) That KSHV DNA shedding in saliva and viral DNA detection in the blood would 
be high in both children and older people since these age groups are at higher 
risk of KS [15]  
(7) That, similar to CMV [16], KSHV has cellular immune dominance that may be 
population specific 
(8) That robust cellular, as well as antibody responses, would be associated with 
KSHV control in blood.   
 
The following observations were made from three populations: the peri-urban population 
(EMaBS), Lake Victoria fishing villages (LaVIISWA) and rural Uganda population (GPC). 
KSHV was highly prevalent both in rural Uganda and Lake Victoria fishing villages, higher 
than the prevalence previously reported in a peri-urban population of Entebbe (EMaBS) [10-
12]. In rural Uganda and Lake Victoria fishing villages, KSHV antibody levels and 
seropositivity generally increased with increasing age and KSHV seropositivity was higher in 
males compared to females. In the EMaBS, younger primary age of infection was associated 
with higher antibody levels in later years. These higher antibody levels were likely 
maintained because they were still high several years after seroconversion.  
 
Schistosoma mansoni infection (which is highly prevalent in areas around water bodies with 
snails) was associated with KSHV seropositivity in fishing villages of Lake Victoria. Increase 
in IgE and IgG antibody concentrations to S. mansoni was associated with an increased risk 
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 of being KSHV seropositive in island individuals. HIV treatment was associated with lower 
KSHV prevalence in the same communities.  
 
In the GPC, malaria parasite infection was a risk factor for KSHV seropositivity and people 
infected with malaria tended to have higher KSHV antibody levels. The malaria association 
with KSHV seropositivity was also observed in LaVIISWA. Furthermore, malaria parasite-
infected individuals had higher levels of KSHV DNA in PBMCs compared to malaria 
uninfected individuals. Lower haemoglobin levels (independent of malaria parasite infection) 
were associated with higher KSHV seropositivity and KSHV-specific antibody levels. Among 
seropositive individuals from rural Uganda, the proportion of individuals with detectable viral 
DNA in PBMCs and in saliva was highest in children and decreased as individuals got older. 
KSHV viral load was detected more often and at higher levels in saliva compared to blood in 
rural Uganda. Furthermore, levels of viral DNA in PBMCs did not correlate with those in 
saliva. IgG antibody levels to K8.1 recombinant protein were higher in individuals with 
detectable KSHV DNA in blood and in saliva. Male individuals were more likely to shed 
KSHV in saliva and had higher levels of viral DNA in saliva compared to females. In relation 
to the IFN- cellular response to 82 KSHV peptide pools, there was heterogeneity of 
response and no immune dominant phenotype was observed. Viral control (measured by 
viral DNA in PBMCs by PCR) was associated with age group-specific robust cellular 
response. Although cellular responses to KSHV increased as children became adults, these 
responses seemed to reduce in old age.  
  
Discussion and conclusions  
 
KSHV transmission in endemic areas may be affected by social behaviours leading to 
salivary exchange as well as factors affecting the immune system. Here we have focused on 
factors that may affect the immune system because KSHV activation has been shown to be 
sensitive to immune dysfunction [17]. Effects on adaptive immunity may increase the 
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 reactivation of the virus, affecting viral control. This could lead to pathogenesis and 
increased transmission. Factors which affect innate immunity may also render uninfected 
individuals susceptible to infection, by preventing primary control of the infection.  
 
We observed an increased risk of KSHV seropositivity if individuals were infected with 
malaria parasites. Although malaria parasite infection causes polyclonal non-specific B cell 
activation [18, 19], which could lead to increased antibody responses and explain the 
associations with antibody levels, we also observed increased levels of viral DNA in blood if 
infected with malaria (as measured by the presence of parasitaemia). Infection with malaria 
parasites has been shown to cause immune dysfunction of both the adaptive and the innate 
immune systems. Dendritic cell frequency and function are impaired by malaria infection as 
well as T and B cell function [20-22].  
 
Similarly, we observed an increased risk of seropsitivity in people infected with S. mansoni. 
The adaptive immune effects of S. mansoni may affect KSHV reactivation. S. mansoni 
skews the immune response to a (Th) 2 type response characterized by the production of 
IgE antibody, eosinophilia and production of cytokines such as IL4 and IL5. It is also known 
to induce IL10 production, which is an immunomodulating cytokine. The (Th) 2 and 
regulatory immune responses elicited by S. mansoni may affect chronic herpesvirus control, 
as has been shown in an animal model [23]. Furthermore, we observed an increased risk of 
KSHV seropositivity with increasing IgE to S. mansoni adult worm antigen (SWA) and S. 
mansoni egg antigen (SEA) and IgG to SWA. We observed no association with S. mansoni 
IgG4 antibody levels with KSHV seropositivity.  The (Th) 2 immune response to S. mansoni, 
characterised by IgE, IL4 and IL5 production has been linked to protection from S mansoni 
reinfection, while IgG4 production has been linked to susceptibility to reinfection [24]. This 
protective immunity tends to increase with age and requires repeated exposure to develop. 
The rationale is that the repeated exposure to antigens, for example from dead worms due 
to age or treatment, leads to immune boosting, leading to higher, and therefore protective, 
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 levels of immunity [24]. Therefore, increased IgG and IgE antibody responses to S. mansoni 
could be used as a measure of repeated exposure to the parasite. The association of higher 
S. mansoni antibody concentration with KSHV seropositivity may be due to repeated 
exposure to the parasite, leading to interference with KSHV immunity and increasing KSHV 
antibody levels. Furthermore, the lack of association with S. mansoni IgG4 antibody 
concentrations may imply that the effect of S. mansoni on KSHV is through specific immune 
responses.  
 
The disparity in KSHV prevalence between rural and urban areas also requires further 
investigation. A number of factors including environmental, behavioural and biological 
factors may explain this. For example, being chronically infected with infections such as 
malaria and helminths may affect KSHV transmission; these infections may be more 
common in rural areas than urbanized areas due to higher socioeconomic status, higher 
education levels and easier access to medical care in urban centres. Another example is 
local plant derivatives (“oncoweeds”) that reactivate KSHV [25] that may be more common 
and frequently used in rural areas compared to urban areas. Behavioural factors affecting 
salivary exchange (for example children are more likely to share food on the same plate) 
may be more common in rural places compared to urbanized areas. Education levels are 
lower in Ugandan villages than in urban areas, and higher parental education has been 
associated with less risk of being KSHV seropositive in children [11, 12]. This association 
might be attributed to a number of factors including social behaviour, health care access, 
parasite infections among others.  
 
Males tended to have higher KSHV prevalence and higher viral load in saliva, compared to 
females. This result has also been shown previously [26, 27]. Males are also at a higher risk 
of KS compared to females, especially among HIV negative persons [28, 29]. Others have 
also shown a higher KSHV load in blood in males compared to females [30]. Sex differences 
have been observed in other infections and disorders [31]. The general observation is that 
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 there is a higher risk of infectious diseases (such as Mycobacteria tuberculosis, malaria and 
West Nile virus) in males compared to females, whereas there is a higher risk of 
autoimmune disease (such as Addison’s disease and systemic lupus erythematosus) in 
females compared to males [31]. The risk of Burkitt’s lymphoma is also higher in boys 
compared to girls [32-34]. These differences have been attributed to the higher 
responsiveness of immune cells in females compared to males, which protects females from 
infectious diseases, but also then predisposes females to autoimmune diseases. Some of 
the possible mechanisms responsible for sex differences in immunity include genetics, 
steroid hormones [31], and environmental exposures that are gender specific, although the 
precise mechanisms for sex-related immune differences are still to be elucidated. In relation 
to KSHV, the knockdown of androgen receptor expression in cultured human endothelial 
cells was associated with dysregulation of KSHV infection [35]. These findings require 
further investigations. 
 
The effect of age of infection on disease outcomes may vary depending on the underlying 
mechanism. For example, in western countries, EBV infection in adulthood is associated 
with infectious mononucleosis [14], whereas early infection with EBV in Africa is associated 
with a higher viral load and risk for Burkitt's lymphoma [13]. Similarly, we observed that early 
infection with KSHV was associated with higher subsequent antibody levels, which were 
maintained for several years. Increased antibody titres to KSHV have been associated with 
the risk of KS [36]. In addition, the fact that children have more detectable KSHV DNA in 
both saliva and in blood compared to adults implies that children fail to control KSHV 
effectively. Uganda is a high disease burden setting. Multiple infections (and vaccines) in 
childhood may mean that “resources” for the immune system are prioritized to acute 
infections and vaccines, leading loss of control of chronic viruses such as KSHV. These two 
scenarios are not mutually exclusive, and may, in fact, have a cumulative effect. Further 
work on assessing immune exhaustion in children would be an obvious approach to take in 
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 assessing the impact of multiple infections and vaccines, and susceptibility to KSHV 
infection.  
 
Prevention of viral shedding in the saliva is paramount for blocking transmission, while 
deterrence of viral reactivation in the blood may prevent oncogenesis. We observed no 
correlation between levels of KSHV DNA in saliva and in blood. This is contrary to EBV, in 
which EBV DNA detection in blood has been correlated to that in saliva, with an increased 
risk of detecting EBV in blood if it was present in saliva [37]. Oral replication of 
herpesviruses seems to be a paramount source of the virus [38]. The lack of correlation 
between oral and blood KSHV DNA levels is intriguing and requires further investigation. 
Perhaps, after primary infection, the virus spreads from the oral cavity to other parts of the 
body, establishing infections at different sites. Thereafter, the virus is controlled by different 
mechanisms at different sites – mucosal immunity in the oral cavity versus systemic 
immunity in other parts of the body. It is therefore important to investigate KSHV immunity in 
saliva to understand factors that affect viral shedding in saliva. 
 
The lack of KSHV cellular immune dominance was reported previously [39, 40]. However, 
the limitations of previous studies are that they either used very few peptide pools or were 
not from KSHV endemic areas. Here we used peptide pools spanning the entire KSHV 
genome and observed a similar lack of immune dominance. Some immunodominance has 
been observed in other herpesviruses including EBV and HCMV [16, 41]. In KSHV, we have 
observed very low cell-mediated responses during early infection. The higher cellular 
immune responses in adults may result from recurrent antigen expression during 
reactivation. These responses may be HLA haplotype-specific as they tend to vary in 
different individuals. It would, therefore, be interesting to investigate HLA haplotypes in 
relation to KSHV epitopes.  We also observed age group-specific (young adults) correlation 
of cellular-mediated immune responses with lack of detectable KSHV DNA in blood. This is 
suggestive that robust cellular immune responses are associated with reduced viral 
165
 reactivation. This result requires confirmation with an increased number of participants. 
Therefore, we have planned to test more samples for KSHV IFN- cellular responses. These 
responses seemed to be lost as people get older, probably due to a number of factors 
including immunosenescence and chronic inflammation seen in older people. It is not 
surprising given the wide range of complications which become apparent in older people 
[31]. This reduction in cellular responses as people get older may explain why KS and other 
KSHV malignancies are more common in older people.  
 
In the current study, we have observed lower KSHV prevalence in those on HIV treatment 
and/or had CD4 counts above 500cells/l, but this should be interpreted with caution. One 
might expect higher KSHV prevalence in HIV infected people due to their 
immunosuppressed state, although this was not what we observed. The immunosuppression 
could lead to the reactivation of KSHV in those already infected, leading to increased 
antibody levels, that could easily be detected by the serology assay. Similarly, the 
immunosuppression could render the few KSHV uninfected individuals susceptible to KSHV 
infection. Since most KSHV infections occur in childhood prior to horizontal HIV acquisition, 
reactivation is more likely to occur. One of the limitations of this finding was that we could 
not ascertain the exact treatment regimens or in some cases, whether the study participants 
were treated or not (we, therefore, used CD4 counts in those cases). Secondly, there was a 
significant number of individuals who were not tested for HIV. Therefore, although these 
data are intriguing, we cannot make definitive conclusions. Nevertheless, ART is well known 
for the rapid KS tumour resolution and prevention of oncogenesis when initiated. This is 
attained through recovery of immune function and suppression of both HIV viremia and 
KSHV blood viral load [42]. Furthermore, prevention of KSHV acquisition by ART in children 
has been observed [43], and the in vitro inhibitory effects of HIV protease inhibitors on KSHV 
replication have been documented [44]. These factors may suggest a possible effect of ART 
on KSHV, preventing acquisition (viral establishment) or reactivation of the virus.  
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Strengths and limitations  
 
The particular strengths of this thesis were the large sample size, and different cohorts, 
allowing definitive epidemiological association between KSHV and various risk factors.  In 
addition, we were able to assess KSHV prevalence and associated risk factors in 
population-based studies with a wide age range in various populations rather than relying on 
small high-risk populations of hospital patients.   
 
Nevertheless, there were a few limitations in the current studies. The KSHV cellular immune 
response study (shown in chapter seven) used a small sample size, making definitive 
conclusions about the data difficult. However, the data are intriguing and testing more 
samples will confirm, or not, our initial observations. With the exceptions of the retrospective 
study, which determined the age of infection with KSHV, the rest of the studies were cross-
sectional. This prevented confirmation of causation and makes cohort studies with 
appropriate follow up, necessary to confirm these findings. All the cross-sectional studies 
had minimal missing data, although the retrospective study (shown in chapter three), had  
some missing data. However, results from a sample of fewer participants with all 
consecutive data were analysed separately and the conclusions did not differ from the ones 
with missing data. Additionally, data were missing completely at random, suggesting there 
was at least no bias.    
 
Recommendations and future proposed work 
 
The incidence of KS is highest in resource-limited countries of Africa. Ultimately, with limited 
resources to manage cancer in Africa, prevention of KSHV transmission to uninfected 
individuals, and prevention of cancer development in already infected individuals would 
provide the the best strategies to improve public health. Prevention of transmission and 
disease progression can be achieved using two approaches. The first approach is to 
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 understand factors affecting viral shedding in saliva because the reduction of viral shedding 
in saliva will prevent transmission to uninfected individuals. The second approach is to 
understand factors favouring viral control to prevent cancer development. To understand 
factors affecting viral shedding in saliva more, we plan to measure KSHV-specific IgA in oral 
fluids in those individuals from rural Uganda in whom we already have salivary viral load 
data, to ascertain the role of local immunity on viral control at mucosal sites. In order to 
understand factors that favour viral control in blood, we will test more samples for KSHV 
cellular responses to confirm (or not) the current ELISPOT findings. It is possible that if 
these immune responses could be provoked in high-risk KSHV-infected individuals (perhaps 
with a therapeutic vaccine), that this may impact on KSHV viral load and subsequent risk of 
KS. 
 
In this current PhD research, we have observed a number of associations from cross-
sectional studies which require confirmation of causation through cohort studies. Therefore, 
in further postdoctoral work, we plan to recruit 6-month-old children from the GPC and follow 
them for three years to look at the effect of malaria parasitaemia, as well as malaria 
treatment on KSHV acquisition and reactivation. We will also investigate immune 
mechanisms for any associations.   
 
Other achievements 
 
During this PhD, I contributed to work on other projects including studies on KSHV, 
Norovirus and Tuberculosis [45-48]. I also trained to perform KSHV specific assays which 
were developed at Viral Oncology Section at NIH and I was responsible for transfer and 
establishment of these assays at the MRC/UVRI and LSHTM Uganda Research Unit. 
Additionally, I facilitated the transfer of equipment required for the assays to the MRC Unit, 
as well as installation, validation and maintenance. I also took a leadership role in 
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 establishing a field immunology laboratory in Kyamulibwa for sample processing in the field 
including PBMC isolation.   
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Observational / Interventions Research Ethics Committee
 
 
 
Ms Angela Nalwoga 
LSHTM
30 November 2016 
Dear Angela,
Study Title: Determinants and Immune correlates of KSHV suppression and transmission in Uganda 
LSHTM Ethics Ref: 11881 
Thank you for responding to the Observational Committee’s request for further information on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation
as revised, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Protocol / Proposal KSHV_study_protocol 08/07/2016 01
Protocol / Proposal KSHV_Questionnaire_emabs 08/07/2016 01
Protocol / Proposal KSHV_Questionnaire_GPC 08/07/2016 01
Information Sheet EngV1_EMaBS_assent 08/08/2016 1
Information Sheet EngV1_EMaBS_consent 08/08/2016 1
Information Sheet EngV1_EMaBS_storage 08/08/2016 1
Information Sheet EngV1_GPC_assent 08/08/2016 1
Information Sheet EngV1_GPC_consent_adults 08/08/2016 1
Information Sheet EngV1_GPC_consent_for_children 08/08/2016 1
Information Sheet EngV1_GPC_storage 08/08/2016 1
Investigator CV CV_for_Angela_Nalwoga_130616 05/09/2016 01
Investigator CV CV for Robert Newton 05/09/2016 01
Investigator CV Denise Whitby CV 05/09/2016 01
Investigator CV Steve_cose_Academic CV 05/09/2016 01
Local Approval UVRI_REC_approval 14/09/2016 01
Local Approval KSHV AN Initial UNCST Approval 25/10/2016 1
Information Sheet EngV1.2_EMaBS_assent 20/11/2016 1.2
Information Sheet EngV1.2_EMaBS_consent 20/11/2016 1.2
Information Sheet EngV1.2_EMaBS_consent_for_children 20/11/2016 1.2
Information Sheet EngV1.2_EMaBS_storage_children_assent 20/11/2016 1.2
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Information Sheet EngV1.2_EMaBS_storage_consent_for_children 20/11/2016 1.2
Information Sheet EngV1.2_EMaBS_storage_mother_consent 20/11/2016 1.2
Information Sheet EngV1.2_GPC_assent 20/11/2016 1.2
Information Sheet EngV1.2_GPC_consent_adults 20/11/2016 1.2
Information Sheet EngV1.2_GPC_consent_for_children 20/11/2016 1.2
Information Sheet EngV1.2_GPC_storage__consent_assent 20/11/2016 1.2
Information Sheet EngV1.2_GPC_storage_consent_for_children 20/11/2016 1.2
Protocol / Proposal KSHV_study_protocol_V1.2 20/11/2016 1.2
Covering Letter response_to_LSHTM_ethics_21nov16 21/11/2016 1
 
After ethical review
The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the Committee for review
using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.  
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project
by submitting a Serious Adverse Event form. 
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk
Additional information is available at: www.lshtm.ac.uk/ethics
Yours sincerely,
Professor John DH Porter
Chair
ethics@lshtm.ac.uk
http://www.lshtm.ac.uk/ethics/ 
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Observational / Interventions Research Ethics Committee
Prof Alison Elliott      
Professor of Tropical Medicine 
Department of Clinical Research (CRD) 
LSHTM
28 April 2017 
Dear Prof  Alison 
Study Title: Lake Victoria Island Intervention Study on Worms and Allergy‑related diseases 
LSHTM Ethics Ref:  9917 ‑ 9 
Thank you for your application for the above amendment to the existing ethically approved study and submitting revised documentation.  The amendment application has been considered by
the Interventions Committee.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above amendment to research on the basis described in the application form, protocol and supporting
documentation as revised, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval for the amendment having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Other 2. Protocol_LaVIISWA version 10, changes highlighted 12/03/2017 10
Other 3. LaVIISWA_Appendix K_protocol amendment Jan 2017_final 12/03/2017 2
 
After ethical review
The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the Committee for review
using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.  
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project
by submitting a Serious Adverse Event form. 
An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study. 
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk
Additional information is available at: www.lshtm.ac.uk/ethics
Yours sincerely,
Professor John DH Porter
Chair
ethics@lshtm.ac.uk
http://www.lshtm.ac.uk/ethics/ 
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